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Preface
This thesis is the result of a fortunate coincidence in 1995, when the author, then a medical stu-
dent in search of a neurological research project, met Baziel van Engelen. He suggested to pick 
up the Nijmegen research on hereditary focal neuropathies, and she was intrigued by this pe-
culiar group of patients that had a rather painful variety manifesting as a plexopathy. That was 
her first acquaintance with neuralgic amyotrophy in one of its many facets. The subsequent 
interaction of patients and personalities led to a long-lasting cooperation, and the gradual but 
steady development of interests. Slowly over the years the focus shifted from the hereditary 
recurrent peripheral neuropathies to ever more questions on the subject of idiopathic plex-
opathies. Ten years later, the thesis now before you is one of the results, but certainly not the 
endpoint, of this search for the ‘secrets of the plexopath’. This plexophiliac is most indebted to 
all those - patients, colleagues, friends - who made this possible!
The general aim of this study was to improve the awareness and knowledge of neuralgic amyo-
trophy (NA) syndromes, or idiopathic plexopathies. First of course in the author and her co-
workers, but also in her fellow neurologists, other health care professionals, and last but not 
least in the patients suffering from these disorders. More specifically, the aims were to obtain 
a more accurate impression of the true incidence and impact on daily life of these disorders, to 
gain insight in the variety of clinical expressions in different patients, to set up the stage for 
further research into the underlying pathophysiological mechanisms, and to try and take a few 
steps on the road to a therapy for neuralgic amyotrophy.
Part I of this thesis provides a general introduction on plexopathies, and introduces neuralgic 
amyotrophy from a historical perspective. The rationale for this thesis is provided, by outlin-
ing the questions that arose when patients started telling their stories to us.
Part II presents an analysis of the different syndromes within the clinical spectrum of neural-
gic amyotrophy. It starts where it all started, with the natural history of hereditary neuralgic 
amyotrophy. Ten years on, both hereditary and idiopathic neuralgic amyotrophy are revisited 
in a description of the clinical phenotype from a large cohort of patients. Subsequently, the 
phenotype of neuralgic amyotrophy in children, and its differences with respect to adults is 
described. Finally the focus is on the lumbosacral plexus variant of neuralgic amyotrophy.
In Part III, the long route to an underlying pathophysiology and treatment is explored. It starts 
with the histological findings in HNA patients. Then the focus is shifted towards underlying 
mechanisms, in a review of the current knowledge on the immunological aspects of NA attacks. 
Moving back to a clinical perspective, a subsequent chapter of ‘practice-based medicine’ de-
scribes the neuralgic amyotrophy consultation, including an overview of the best current 
pharmacological, paramedical and rehabilitation treatments.
Part IV provides a general discussion and summary of this thesis in English, including some 
thoughts on further research in neuralgic amyotrophy.
Part V is for readers who prefer Dutch. It summarizes the thesis, and provides two additional 
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To many neurologists, and other physicians likewise, plexopathies are know as ‘dif-
ficult’ disorders. This is most likely due to their relatively rare occurrence and the 
complex anatomical features of these structures. Probably few people will recall the 
exact course of nerve roots to peripheral nerves in the brachial and lumbosacral 
plexuses, but many will remember that was complicated - and leave it at that.
However, in daily practice there are a few rules-of-thumb that can help clinicians 
to diagnose plexopathies and their aetiology without having to go through com-
plex anatomical schemes or heavy neurological textbooks. It is precisely the intri-
cate anatomy that sets plexopathies apart clinically from ‘simpler’ radiculopathies 
or mononeuropathies. If the signs and symptoms are that of a peripheral nervous 
system lesion, but cannot be attributed to a lesion of a single root or nerve, logic 
dictates that the lesion is either in the plexus, or the patient suffers from a condi-
tion that does not respect Occam’s Razor1 (for example when multiple simultane-
ous radiculopathies exist). Furthermore, once the anatomical origin of the patients’ 
symptoms has been localized to the plexus, the list of possible aetiologies is rela-
tively limited, and many causes will already be likely or unlikely from the clinical 
context or medical history.
In this introduction a short overview of the anatomy of the brachial and lumbosac-
ral plexus and the causes and differential diagnosis of both plexopathies are pro-
vided.
1.   A rule in science and philosophy stating that entities should not be multiplied needlessly. This rule is interpreted to mean that the
simplest of two or more competing theories is preferable and that an explanation for unknown phenomena should first be attempted 
in terms of what is already known.
Anatomy review
In mammals, birds and some lower animals (e.g. crocodiles, some agile coral reef 
fish) the peripheral nerves to the upper and lower extremities are organized in 
nerve plexuses. The word ‘plexus’ is derived from the Latin ‘plectere’, which means 
‘to plait; the interweaving of three or more strands or strips’. Oddly apt in the con-
text of the subject of this thesis, ‘plectere’ also means to punish or suffer.
The brachial plexus is made up of the ventral rami of the cervical C5 to T1 roots, also 
receiving a contribution from the C4 or T2 root in some people. This braid of nerves 
(figure 1) runs from the neck to the armpit, hanging suspended behind the clavi-
cle (figure 2). It contains an estimated 100.000 axons. The motor and sensory nerve 
fibres in it are accompanied by autonomic nerve fibres that supply the vasomotor 
control of the arm and hand . An important contribution in this respect is formed 
by branches of the cervical sympathetic chain that run with the T1 ventral root.
The lumbosacral plexus (see figure 3) consists of the interwoven nerves bundles 
coming from the L3 to S3 nerve roots, with small additions from the L2 and S4 nerve 
roots as well. Actually, the plexus consists of two separate parts, the lumbar and the 
sacral plexuses, that are connected by the so-called lumbosacral trunk. The lumbar 
part of the plexus mainly lies embedded between and in the paraspinal quadratus 
lumborum and psoas muscles, making it vulnerable to local trauma or compres-
sion. On the other hand, the sacral plexus lies in the pelvis, with the lumbosacral 
trunk crossing the pelvic brim, making it vulnerable to intrapelvic pathology.
Interestingly, nothing is known or published on why nature and evolution have 
chosen this particular arrangement of nerves in vertebrate species that bear weight 
or exercise force with their limbs. We do know that plexuses form whenever there is 
no intervening bony structure that prevents embryonic spinal nerves from fusing 
outside the spinal column (D. Arnold, personal communication). One could specu-
late that the arrangement of nerves into a plexus makes them more resistant to me-
chanical stretch and displacement occurring when moving the limb. This would be 
by supplying extra attachments for the nerve elements within a compound struc-
ture instead of single strands that only experience and withstand force in one direc-
tion, analogous to woven textile versus single pieces of thread. The more degrees 
of freedom are available in the joints between trunk and extremities, the more it 
seems necessary to dissipate and be able to withstand stretch forces in all those di-
rections, instead of just in the one, longitudinal direction a single nerve can provide. 
One can imagine it provides an evolutionary advantage when limb nerves stay in-
tact as the creature moves about in it’s natural environment. Taking it one step fur-
ther, one could also state that human beings with their upright posture and rigid 
vertebropelvic junction have probably made the lumbosacral plexus redundant.
Figure 1. The braided structure of the brachial plexus (after Kerr, 1918).
general introduction on plexopathies
1 1
general introduction on plexopathies
20 21
Figure 2. Schematic of the brachial plexus position in vivo.
 
Differential diagnosis of plexopathies
As stated above, the most important aspect in the differential diagnosis is establish-
ing the existence of a plexus lesion, by demonstrating symptoms that cannot be 
explained by a lesion of a single nerve root or peripheral nerve. However, there are 
some disorders that can mimic this clinical picture. 
In the shoulder and arm, cervical radiculopathies typically present with posture-de-
pendent radiating pain and sensory disturbances in the corresponding dermatome. 
As they are usually caused by nerve root compression due to degenerative spinal col-
umn disease, they occur most frequently at the levels that suffer the largest amount 
of mechanical strain during life. The estimated incidence of these radiculopathies 
is highest at the C7 level (150/106/year), and decreases exponentially towards more 
cranial levels (C6: 40/106/year, C5: 4/106/year). When they present in an acute fashion, 
it is likely that the cause is a disk rupture with herniation, which usually occurs at a 
single level at a time. If there is a progressive degenerative spondylosis with forami-
nal stenosis patients can suffer from radiculopathies at multiple levels simultane-
ously, and will usually present with gradually progressive symptoms. 
A true mononeuritis multiplex, that is a peripheral nervous system vasculitis, can 
give rise to multiple, progressive focal nerve lesions in the arms. As the chance of 
being affected by such a vasculitic process is highest in the longest axons, patients 
usually also suffer from focal neuropathies in the legs, and will often progress to 
a polyneuropathy-like distribution of their symptoms. Multiple focal paresis in 
the arm can also be found in multifocal motor neuropathy, a patchy, painless, and 
pure motor inflammatory peripheral nervous system disorder with a predilection 
for the forearm. Sometimes a carpal tunnel syndrome can present atypically, with 
pain and paraesthesias radiating up the arm to the shoulder region. Rarely, a bra-
chial plexopathy-like distribution is seen in a focal subtype of motor neuron disease 
called brachial amyotrophic diplegia.
In the back and lower extremity, a lumbar spinal stenosis can also cause compres-
sive lesions of multiple nerve roots, which causes pain, sensory symptoms and 
sometimes paresis in a plexus-like distribution. Usually, the additional symptoms 
of lower back pain and provocation of symptoms by certain activities (e.g. walking) 
give a clue to this diagnosis. Another mimic of a lumbosacral plexopathy can be 
lower-limb motor neuron disease, either idiopathic as in ALS, or infectious in en-
demic areas as in poliomyelitis anterior acuta. A previously undiscovered tethered 
spinal cord can also present with patchy paresis and sensory symptoms in the legs. 
A vasculitic mononeuritis multiplex typically presents with symptoms (also) in the 
lower legs, and can easily resemble a plexus lesion. 
Of course non-neurological disorders, such as inflammatory or degenerative shoul-
der, elbow, sacro-iliac or hip joint disease also present with pain and limitations 
of upper or lower extremity movements. ‘Shoulder complaints’ for example, are 
very common in the general population, with an estimated incidence of around 
1500/106/year. Careful examination will usually reveal the arthrogenic cause, and 
sensory symptoms or a real paresis are typically not seen with these disorders. It can 
be difficult to rule a paresis out clinically, however, for example in cases with a bi-
ceps or supraspinatus tendon rupture that results in an inability to convey muscu-
lar contraction strength to the joint, or when movements result in a pain increase 
that prevents any further attempts at motion. Similarly, hip joint pathology can 
also induce pain with an almost radiating-like quality and movement limitations 
in a fashion that cannot be explained by a single nerve or root paresis. Correctly 
identifying these as non-neurological symptoms will also require an adequate in-
dex of suspicion and appropriate testing from the examiner.
Finally, patients with a type I or idiopathic complex regional pain syndrome also 
present with pain, patchy ‘paresis’ or rather a loss of function, sensory and auto-
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nomic disturbances in any extremity. Clinically the symptoms in these patients 
usually do not follow any known anatomical tracts or boundaries. In many cases, 
ancillary investigations will be required to exclude known neurological or arthro-
genic causes for the symptoms encountered.
Causes of plexopathies
Brachial plexopathy
When the clinical diagnosis of a brachial plexopathy has been made, the etiological 
possibilities are usually limited. Many plexopathies are either caused by direct trauma 
(e.g. in a motor vehicle accident) or iatrogenic damage, e.g. after radiation or surgery. 
The lower brachial plexus lesion seen in patients with a Pancoast tumour has a dis-
tinct, ominous course, with progressive pain and sensory disturbances, and eventu-
ally paresis, spreading from the T2 and T1 segments to more proximal sites as the 
tumour grows. A similar typical lower plexus distribution pattern, of a more benign 
but still disabling nature, can be seen in true neurogenic thoracic outlet syndrome, 
in which the lower trunk of the plexus containing the C8 and T1 root extensions gets 
compressed by a fibrous band extending from an elongated C7 transverse process to 
the first rib. Typically the sensory disturbances are in the medial forearm and ulnar 
side of the hand, while motor symptoms prevail, with atrophy that is more severe in 
the thenar than hypothenar muscles.
When no cause is apparent and the plexopathy had a rapid painful onset, the cause is 
most likely neuralgic amyotrophy. Rarely, a similar picture but with usually progres-
sive symptoms can be found with certain infectious causes, such as neuroborreliosis or 
HIV. In painless idiopathic brachial plexopathies with only limited paresis and sensory 
symptoms it can sometimes take weeks to months before the patient notes anything 
is wrong. In such a case it can be difficult to exclude other insidious causes such as a 
nerve or nerve sheath tumour of the plexus. Even without additional investigations 
clinical follow-up will then usually tell them apart, by showing the disorder is really 
progressive, as would be expected in case of a neoplasm, or slowly improving as it will 
in idiopathic cases. Finally, another, seemingly idiopathic and sometimes also painful 
brachial plexopathy can be seen in certain patients with a hereditary neuropathy with 
liability to pressure palsies (HNPP), in which a relatively minor stretch or compres-
sive trauma can damage the vulnerable nerves. These patients usually have a (fam-
ily) history of compressive neuropathies at other sites (e.g. carpal tunnel syndrome or 
dropfoot), and signs of a polyneuropathy when they are older. HNPP can nowadays be 
confirmed both at the electrophysiological and DNA level.
Lumbosacral plexopathy
The lumbosacral plexus (figure 3) is most frequently affected by one of the following 
disorders: diabetes mellitus, direct or indirect pelvic trauma, compression, or obstet-
ric complications. Tumours, aneurysms and idiopathic or hereditary neuropathies are 
more infrequent causes of a lumbosacral plexopathy. An overview of possible aetiolo-
gies is given in table 1. This also means that usually the cause of a lumbosacral plex-
opathy is relatively obvious or easily diagnosed once the clinical diagnosis has been 
made. Diabetic amyotrophy or proximal diabetic neuropathy is a syndrome which 
classically occurs in older type II diabetics, who already have some signs of a diabetic 
symmetric distal polyneuropathy, but not yet an overt vasculopathy. It starts with a 
subacute, severe burning neuropathic pain in the leg, thigh, buttock, or lower back, 
with weakness in the proximal leg muscles, usually mainly in the distribution of the 
femoral or obturator nerve, and dysaesthesias. Sometimes patients suffer from bilat-
eral symptoms, but the disorder is always asymmetrical. Some patients suffer from 
considerable weight loss. The neuropathic pain can last for as long as months, and 
gradually decreases, while strength returns in months to years. The cause is probably 
ischemia, induced by a metabolically induced focal microvasculitis.
The clinical picture of idiopathic lumbosacral plexus neuropathy can be almost iden-
tical to that seen in diabetics. It is characterized by extreme neuropathic pain at onset, 
rapidly followed by a patchy paresis and striking atrophy of muscles in the thigh and 
leg. In about 30%-50% of the patients there are also sensory symptoms such as paraes-
thesias and subsequent hypaesthesia in skin regions innervated by the lumbosacral 
plexus. Although the name of the disorder implies that all parts of the lumbosacral 
plexus can be involved (and they sometimes are), the symptoms are usually localized 
to the lumbar plexus region. The severe pain usually lasts for days to weeks, and re-
covery of strength can take months to years.
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Figure 3. The lumbosacral plexus.
 
Table 1. Causes of lumbosacral plexopathy
Vascular:
proximal diabetic neuropathy / diabetic amyotrophy






tumour retroperitoneal or pelvic
abdominal aortic or iliac aneurysm
retroperitoneal haematoma or abscess





hereditary neuralgic amyotrophy (HNA)
hereditary neuropathy with liability to pressure palsies (HNPP)
Infectious:
Herpes simplex (type II) or Herpes zoster
Borrelia
general introduction on plexopathies general introduction on plexopathies
2 2
chapter 2
‘What’s the trouble 
with neuralgic amyotrophy?’
Neuralgic amyotrophy (NA) is a fairly distinct clinical entity. Core features are the 
extreme neuropathic pain at onset and the rapid multifocal paresis and atrophy, 
usually in the upper extremity, as well as the slow recovery in months to years. Sen-
sory signs or symptoms are usually not very marked, although on careful examina-
tion patchy hypesthesia can be found in most patients. In the majority of patients, 
the right shoulder is affected, and the tell-tale sign of NA for most physicians is 
the conspicuous winging of the shoulder blade, the scapula alata, although this is 
present in only two-thirds of the patients. Especially in the hereditary form, but 
sometimes also in extensive attacks of INA, other peripheral nerves outside the bra-
chial plexus can also be involved, such as lower cranial nerves or the lumbosacral 
plexus. Painless attacks are found occasionally, and are only recognized as NA be-
cause of a sudden patchy peripheral paresis in the upper extremities without any 
identifiable cause. 
Neuralgic amyotrophy has both an idiopathic (INA) and hereditary form (HNA). In 
the idiopathic form, patients usually suffer only one attack in their life. The recur-
rence risk in INA is thought to be low, while in HNA attacks recur more frequently. 
NA is more common in men, with an age of onset in INA usually in the second 
or third decade but ranging from the neonatal age to the seventh decade. Patients 
with HNA tend to be younger when their first attack occurs, usually in their 2nd 
decade.
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Although neuralgic amyotrophy is considered a rare disease, the minimum inci-
dence of idiopathic NA is estimated at 2-4/106/year, making the disorder as common 
as the Guillain-Barré syndrome or primary malignant CNS tumours [MacDonald 
2000]. In the Netherlands, this translates to roughly 400-600 new patients each year. 
The hereditary form is much rarer, with about 200 families known worldwide to 
date. HNA (OMIM 162100) is autosomal dominantly transmitted, with a high but 
not complete penetrance estimated at 60-80%. The exact pathophysiological mecha-
nism of INA and HNA is as yet unknown. The current hypothesis is that the at-
tacks are caused by an immunemediated response to one’s own peripheral nerves. 
In HNA there is probably an underlying genetic susceptibility to this type of event, 
but since the occurrence rate is still relatively low for a hereditary disorder, it is very 
likely that environmental factors must also play an important role in triggering 
the attacks. The fact that the recurrence rate in patients with INA is much higher 
than the incidence of INA in the general population suggests that these patients 
too have an underlying susceptibility, albeit not as pronounced as patients with the 
hereditary form of the disorder. 
In the past decades a number of HNA families were found to harbour a genetic 
locus for the disorder on chromosome 17q25. In other families this could not be 
confirmed, implying that HNA is a heterogeneous disorder. Recently, by effort of 
an extensive international collaboration three mutations in the SEPT9 gene were 
found in several 17q25-linked families [Kuhlenbäumer 2005], but the role of these 
mutations in HNA is as yet unknown.
Both the idiopathic and hereditary form of neuralgic amyotrophy were first de-
scribed in the late 19th century, by Joffroy and Dreschfeld respectively, [Joffroy 1879; 
Dreschfeld 1886] In 1948 Parsonage and Turner published 136 cases, and the disorder 
is often called Parsonage - Turner syndrome in their honour since [Ref]. There are 
many synonyms for the disorder as can be seen on the list on page 12-13 of this 
thesis which is certainly not exhaustive. On closer examination one easily discerns 
certain patterns in this multitude of synonyms. They seem to focus on one of three 
themes in neuralgic amyotrophy: its most prominent clinical features of acute pain 
and paresis, the anatomical localisation of the disorder, or its presumed inflamma-
tory origin; and of course combinations of the above. It is not just linguistic fancy 
that makes the existence of all these synonyms of interest to this thesis. The fact 
that no single appropriate name can be given to the disorder illustrates simulta-
neously that its essence is still unknown, and that it has many different facets of 
which our knowledge is not yet complete.
For example, because NA is still relatively unknown to many physicians, the in-
itial diagnosis is very often thought to be shoulder joint pathology or a cervical 
radiculopathy caused by disk herniation. Patients with NA are usually referred to 
neurologists and/or orthopedic surgeons, but maybe even more frequently to and 
subsequently by physiotherapists, especially in the initial phase when the diagno-
sis has not yet been established. One of the major problems in diagnosing neuralgic 
amyotrophy is that the course and localisation of both pain and paresis can vary 
considerably among patients, and even among recurrent attacks in one patient. 
Sometimes the only signs of an attack are a nasty pain in the upper arm lasting a 
few hours with a subsequent loss of pinch grip for a few months, caused by a lesion 
of the anterior interosseus nerve. Or conversely, the patient may have suffered from 
severe pains in both shoulders and arms for weeks on end, has a serious orthopnea 
requiring nocturnal positive pressure ventilation, and cannot use either of his or 
her arms or hands in daily life for several years because of severe bilateral plexus 
damage with involvement of both phrenic nerves. 
A typical referral pattern we often came across would go something along the fol-
lowing lines: one early morning the patient wakes up with a severe pain in one 
shoulder and upper arm. At first, he or she may attribute it to lifting a particularly 
heavy object in the days before, but after a few hours the pain has become so severe 
that the family practitioner or emergency department is visited in a slight panic. 
The attending doctor will look at the extremity and see nothing wrong with it apart 
from the fact that the patient is trying to hold it very close to the body and keep it as 
immobile as possible. The patient is then reassured that nothing seems to be seri-
ously wrong, is given a NSAID, and sent home with the advice to go see a physical 
therapist. Possibly the glenohumeral joint will be injected with a local anaesthetic 
and corticosteroid too. After a few sleepless weeks for the patient because of the 
relentless pain, and several unsuccesful therapeutic sessions, the physical thera-
pists notices something peculiar about the shoulder and arm: the scapula seems to 
be protruding or the whole shoulder looks as if it has sagged. And several muscles 
seem to be atrophic too. The patient is sent back to his or her general practicioner 
with the suggestion for a referral to a neurologist or orthopedic surgeon because 
of suspected radicular or joint pathology. After spending a delay of several weeks 
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to months on a waiting list, the consulting specialist will hopefully recognize the 
clinical picture. More often however, the patient first will have to wait again for 
an radiological study of the cervical spine or shoulder region. Usually this shows 
back up negative, and without a proper explanation of his or her symptoms the 
patient may then be referred for a second opinion, or sent back to the general prac-
titioner, delaying the diagnosis even further. Alternatively, when the radiological 
study does turn out to show some pathology things can get really complicated, and 
it has not been unusual to find patients that had undergone surgery for suspected 
cervical stenosis, thoracic outlet syndrome or rotator cuff pathology.
Eventually, when all of these steps and measures have done nothing to explain or 
improve the symptoms, sometimes - and we do not know how often or not - some-
one thinks of this peculiar neurological disorder called neuralgic amyotrophy. It 
might be one of the treating physicians, but could also very be the physical thera-
pist, or the patient him- or herself upon hearing a similar story from an acquaint-
ance, family member, or via an internet search. And then finds him or herself dis-
charged from further specialist care with the message that nothing can be done but 
spontaneous recovery will follow in a few years. If this enumeration of events might 
sound somewhat exaggerated to the reader, rest assured of its seriousness; it most 
certainly isn’t.
So even though NA has been in the textbooks for over a century, it rapidly became 
evident during the first few years of working with neuralgic amyotrophy patients 
that for them too many questions were still unanswered. Table 2 gives an overview 
of the questions we encountered over the past decade, arranged according to their 
place in the hierarchy of medical knowledge. The research presented in this the-
sis tries to answer some of these questions and open the road to a more thorough 
knowledge of NA that should ultimately lead to better patient care. 
Table 2. Questions and issues in neuralgic amyotrophy on different levels of knowledge of the disorder
Genetic
   • what is the underlying genetic defect in HNA?
   • is there a genetic predilection in INA as well?
   • how much of the phenotype is explained by the genotype?
Pathophysiological
   • how can we prove the attacks have an immunological basis?
   • if they are auto-immune, what is the mechanism?
   • is NA a mononeuritis multiplex, i.e. a form of peripheral nervous system 
    vasculitis?
   • which part of the peripheral nerve is affected?
   • is NA primarily a motor disorder?
Epidemiological
   • is the estimated incidence correct or is NA more frequent?
   • is HNA underdiagnosed?
   • how often do attacks recur in INA and HNA?
   • do clusters of INA cases occur in the Netherlands?
Phenotypic
   • what is NA and what is not: where are the boundaries of the NA   
    phenotype?
   • what is the easiest way to diagnose NA and set it apart from other   
    disorders?
   • are there NA subtypes, and should we lump or split?
   • are there differences between INA and HNA? Men and women? Young and 
    old patients?
Prognostic
   • what is the natural course of an NA attack?
   • what complications can occur and can they be predicted?
   • is the outcome as optimistic as reported in the literature?
   • can outcome be predicted on individual patient level?
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Table 2 - continued
Therapeutic
   • can the attacks be prevented?
   • can the attacks be treated or mitigated by immune-modulating therapy?
   • what is the best pain treatment in the acute phase?
   • what is the best supportive therapy once a clinical deficit has occurred?
   • are physical therapy and rehabilitation useful in NA?
   • how should complications be treated?
   • are sports, hobbies and work allowed after an attack?
Public relations
   • why is NA often not recognized by physicians and how can this be
    improved?
   • why are patients often discharged from further care once the diagnosis has 
    been made?
   • what should patients tell their company doctor and Disability Insurance 
    Act health officials?
what’s the trouble with neuralgic amyotrophy
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The natural history of hereditary 
neuralgic amyotrophy in 
the Dutch population 
Summary
On investigation of 101 attacks in 24 patients with hereditary neuralgic amyotro-
phy (HNA) from nine different families, we found that HNA can run two distinct 
courses: a ‘classic’ relapsing-remitting and a chronic undulating type with exacer-
bations. Only one type occurred per family, suggesting genetic heterogeneity. This 
is supported by the finding that only in a family with ‘classic type’ HNA are data of 
linkage analysis compatible with linkage to the 17q24-q25 interval which harbours 
a locus for the disease.
The average number of attacks per patient during a follow-up of 26 years was four 
in the classic form of HNA and five in the chronic undulating type. All patients 
suffered from residual symptoms on follow-up, with a median Rankin score of 2 in 




Hereditary neuralgic amyotrophy (HNA) is an autosomal dominant disease character-
ized by recurring attacks of acute severe pain followed by paresis and sometimes sensory 
deficits, with a gradual recovery over the next months to years. Recently, a locus for HNA 
was detected on chromosome 17q24–q25. [Pellegrino 1996, Stögbauer 1997, Wehnert 1997] 
Mildly dysmorphic features such as hypotelorism have been reported in affected fam-
ily members. [Windebank 1993]. HNA predominantly involves the brachial plexus, but 
the lumbosacral plexus, lower cranial nerves, phrenic nerve, autonomic nervous system 
or a combination of these may also be involved. [Taylor 1960, Jacob 1961, Dunn 1978, 
Arts 1983, Windebank 1993] The condition is also known as hereditary brachial plexus 
neuropathy, but this term is inaccurate since the lesion is not restricted to the brachial 
plexus. [Geiger 1974] The age of onset usually lies in the first or second decade of life. 
HNA is a rare disease; so far only  ˜ 200 patients from 35 families have been reported in the 
literature. [Ross 1893, Gardner 1968, Chance 1994, Serrano-Castro 1995] Our clinical expe-
rience suggested the presence of different  phenotypes of HNA and we also doubted the 
favourable prognosis reported in the literature. To clarify further the natural history of 
this disease, we studied 24 patients from nine Dutch families with HNA. 
Subjects and methods
Clinical studies 
In our study, we included 24 (17 male and seven female) patients from nine Dutch 
families. One of these families has been described in part by Arts and colleagues. [Arts 
1983] Patients were evaluated by the same person (NvA) by standardized, structured 
(familial) history, including a review of their medical history concerning HNA and a 
standardized neurological examination. All patients gave their informed consent to 
the investigations, which were part of their normal care. 
An attack of HNA was defined as any distinct clinical episode not related to any other 
cause, consisting of pain and paresis, and sometimes sensory and autonomic distur-
bances, distributed in the brachial or lumbosacral plexus, lower cranial nerves or other 
peripheral nerves. Separate attacks were defined as an onset of symptoms in different 
areas more than 4 weeks apart. The duration of follow-up was defined as the time be-
tween the time of onset and the time of investigation. We investigated epidemiologic 
features, symptoms of motor, sensory and autonomic nervous system involvement, 
the nature, severity and treatment of pain, dysmorphic features, precipitating events 
and recovery. Patients’ present functional impairments were assessed using Rankin 
scores. [van Swieten 1988]
Genetic analysis
DNA was isolated from peripheral blood according to the method of Miller and 
colleagues. [Miller 1988] DNA markers were typed as described by Kremer and col-
leagues. [Kremer 1994] Two-point lod scores were calculated using the subroutine 
Mlink of the linkage program (version 5.1). [Lathrop 1986] A frequency of the mutat-
ed allele of 0.0001 and a penetrance of 80% were assumed. DNA analysis also served 
to exclude deletions in the 17p11.2 region and the hereditary neuropathy with li-
ability to pressure palsies genotype in all our families.
Results
Epidemiology
The average age of onset of HNA was 24 years (range 3–59, median 20 years). The av-
erage duration of our retrospective follow-up was 26 years (range 1–50). The distri-
bution of right-versus left-handedness was the same as for the general population 
(22 : 2). Characteristics of patients with HNA in the present study compared with 
those reported in the literature are given in Table 1.
Table 1. Clinical features in patients with HNA from the present study as compared with those reported 
in the literature 
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The predominant features of HNA are pain and motor symptoms. Lower limb plex-
opathy has similar clinical features to brachial plexus involvement, and occurred in 
12% of the attacks, either in isolation or combined with brachial plexopathy (Table 
1). Comparing this with the 7% of attacks reported in the literature suggests that a 
more extensive examination could reveal a higher incidence of such involvement. 
Features of autonomic nervous system involvement in HNA are that it is mainly 
sympathetic, and that it occurs in 9% of the attacks. [Jacob 1961, Windebank 1993, 
Pellegrino 1996] Thus far, there are no indications that the parasympathetic nerv-
ous system is affected in HNA. 
 
Fig. 1. ‘Pathograms’ which visually represent (A) the classic relapsing–remitting course of HNA, 
with pain preceding the onset of paresis and maximum recovery between attacks and (B) the chronic 
undulating type of HNA, with gradual appearance of symptoms until the onset of the real attacks, 
and continuing pain between attacks. 
Patterns in clinical course
We found two distinct patterns in the clinical course of the disease, which we desig-
nate as a ‘classic’ and a ‘chronic’ type of HNA. The classic type represents HNA as it 
is usually described, with severe attacks of pain followed by paresis and a relatively 
symptom-free interval in between. The chronic type is characterized by the interic-
tal persistence of pain and paresis. There was only one type of course per family.
In 12 patients (50%) from five families, the disease ran a classic, relapsing–remit-
ting course (Fig. 1A). There were attacks with an acute onset of severe pain lasting 
from 4 days to 3 weeks, and in many cases paresis ensued when the pain diminished. 
However, there was also one patient who first developed acute pareses, followed by 
intense pain a few hours later. Sometimes the attacks were accompanied by sensory 
disturbances and (or) autonomic disturbances. Recovery of strength began after a 
few weeks, progressing slowly over a period of months to years. Attacks recurred 
after an interval of  ˜ 8 years (average number of attacks was four per 26 years; median 
4). During this interval, the patients were free of pain and had only slight residual 
paresis; however, after each subsequent attack, recovery was less complete.
In the other 12 patients (50%) from four families, the disease followed a chronic un-
dulating course with gradual appearance of symptoms such as painful muscles over 
a period of 6 weeks to 2 years, until the onset of the first real attack (Fig. 1B). From 
then on, paresis remained nearly unchanged. The pain would remit to a lower level 
and exacerbations occurred at this clinical ‘baseline’, sometimes consisting only of 
worsening of pain for a few days (‘abortive attacks’) [Geiger 1974], but at other times 
manifesting as new attacks which would lead to a more permanent loss of function 
in the affected area. The average number of attacks in this group was five during 26 
years (median 4).
Motor symptoms
We were able to record data on motor symptoms in 101 attacks of HNA. Fifty-six 
per cent of the attacks involving the brachial plexus were right-sided, 24% left-
sided and 20% bilateral. Lumbosacral plexus involvement was evenly distributed 
(33% each). Isolated attacks involving the lumbosacral plexus only occurred in the 
chronic undulating type of HNA, whereas attacks affecting both the brachial and 
lumbosacral plexus occurred in both classic and chronic types. Apart from this fea-
ture, there was no significant difference in distribution of the attacks between the 
classic and chronic type.
Pain and pain treatment
In our study, pain in the acute stage of an attack scored an average of 8 out of 10 
(range 5–10) on a Visual Analogue Scale. [Chapman 1985] It could be aggravated by 
movement of the affected limb, exposure to cold and physical or emotional stress. 
The best therapeutic results in terms of pain relief were obtained by a trial of anal-
gesics, starting with opiates combined with an NSAID (non-steroidal anti-inflam-
matory drug) in acute situations, and with an NSAID combined with amitriptyline 
or benzodiazepines in chronic pain, and supportive physical therapy including the 
use of a transcutaneous electrical neurostimulation (TENS) apparatus.
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Sensory involvement
Sensory involvement was not prominent in HNA patients, so a reliable history on 
its extent could not be obtained after a long follow-up period. On follow-up, 58% of 
the patients had vital hypaesthesia of some part of their skin, 33% also had gnostic 
hypaesthesia, 29% dysaesthesia and 42% paraesthesias.
Autonomic nervous system involvement
In eight attacks, vasomotor changes of the skin and appendages were reported. One 
patient suffered a persisting left-sided Horner’s syndrome combined with brachial 
plexus dysfunction. On follow-up, we found 11 patients with changes in perfusion 
and perspiration of skin, and (or) growth of hair and nails, which was not always 
confined to areas affected in the attacks.
Dysmorphic features
We measured a median interpupillary distance of 57 mm for both male and fe-
male Caucasian patients (ranges 48–63 and 53–63, respectively). The average inter-
pupillary distance is very stable among races and normally measures 63 +/- 3 mm. 
[Bogren 1986, Murphy 1990] If hypotelorism is defined as an interpupillary distance 
of < 60 mm, then 16 patients (67%) with HNA met this criterion. Other dysmorphic 
features found included bilateral pes cavus in five patients.
Preceding events
In 73% of the attacks, no preceding event was found. Twenty-seven per cent of the 
attacks followed non-specific events such as strenuous exercise of the affected limb 
(11 times), upper respiratory tract infection (five times), childbirth (four times), cold 
weather (four times), trauma to the affected upper limb (twice) and surgery with 
general anaesthaesia (once). We found that strenuous exercise, direct trauma and 
weather influences were followed by an attack in a matter of hours, and that infec-
tions or childbirth preceded an attack by days to weeks. There was no difference in 
preceding events between the classic and chronic type of HNA. 
Recovery 
Only 28 out of 101 episodes (28%) were followed by complete functional recovery; 57% 
of these episodes was either a first or second attack. At present, all 24 patients have 
residual symptoms (Table 2). Two patients have suffered a subluxation of the shoul-
der joint as a complication of an attack of HNA, another two have persistent hoarse-
ness due to recurrent nerve dysfunction. In terms of the International Classification 
of Impairments, Disabilities and Handicaps (World Health Organization), 14 out of 
24 patients have functional impairments. Eight of these are handicapped by HNA, 
and because of this permanently are unable to work; six of these suffer from chronic 
undulating HNA. On a modified Rankin scale ranging from 0 (no symptoms) to 5 
(severe symptoms causing total dependence day and night), the median score for 
both types was 2 (range 1–3).
Table 2. Residual signs and symptoms in 24 patients with HNA after an average follow-up of 26 
years 
Genetic studies 
In only two families, each with a different phenotype of HNA, were enough mem-
bers available for linkage analysis to be performed. In the first pedigree, with classic 
type HNA, there were four known affected members, with a total of eight individu-
als available for linkage analysis. In the second pedigree, with chronic undulating 
type HNA, 13 members were available for linkage analysis, including eight known 
affected individuals. Linkage analysis was carried out using microsatellite mark-
ers derived from the 17q24–q25 interval, harbouring a gene involved in HNA. In 
the first family (classic type), the markers D17S949, D17S801, D17S802, D17S836, 
D17S1806, D17S784 and D17S928 show co-segregation with the disease (Fig. 2). This 
is compatible with linkage to the  ˜ 6 cM (centiMorgan) candidate region between 
the markers D17S1301, located between D17S949 and D17S801, and D17S802. [Pel-
legrino 1996, Stögbauer 1997] Non-penetrance is assumed in one non-affected in-
dividual. As the number of individuals tested is small, no significant positive lod 
scores were found, the maximum lod score being 0.50 at q = 0.00 with the markers 
D17S949 and D17S1806. In the second family (chronic type), there is recombination 
between the disease gene and the DNA markers derived from the candidate region 
in two of the patients (III-2 and III-7) (Fig. 3). The maximum lod score calculated for 
this family is 0.98 at q = 0.1 with the marker D17S1806, which is located distal to the 
candidate region. 
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Fig. 2. Pedigree of a family with classic type HNA, showing co-segregation of the disease with known 
markers for the candidate region. Non-penetrance was assumed in individual II-2. 
Discussion 
Based on the large number of patients and families and the long period of follow-
up, we conclude that HNA can run two distinct clinical courses. The classical re-
lapsing–remitting form is a very protracted disease with a low frequency of exac-
erbations (one per 6.5 years). Patients with the chronic undulating type also have 
persisting pain between attacks. In retrospect, this chronic undulating type of HNA 
is also found in case descriptions by other authors. [Jacob 1961, Geiger 1974, Arts 1983, 
Zuazo-Zamolloa 1992, Pellegrino 1996] However, it is not mentioned as a separate 
entity in standard texts on the subject of HNA. [Windebank 1993] We found only 
one type of course per family, suggesting genetic heterogeneity. The widespread 
distribution of symptoms, including lumbosacral and cranial nerve dysfunction 
and Horner’s syndrome, and the finding of pes cavus suggest that the underlying 
process is a more disseminated neuropathy rather than a brachial plexopathy only, 
and that HNA can indeed involve multiple peripheral nerves but has a predilection 
for the right-sided brachial plexus independent of the clinical type.
Twenty-seven per cent of the attacks were preceded by a non-specific event. Data 
from both the present study and the literature suggest that strenuous exercise, se-
vere emotional stress and exposure to cold are followed by an attack in a matter of 
hours in susceptible individuals, while (respiratory) infections usually precede HNA 
by  ˜ 1 week, and immunizations by a few weeks to a month. [Dreschfeld 1886, Taylor 
1960, Jacob 1961, Poffenbarger 1968, Smith 1971, Arts 1983, Thomas 1993, Windebank 
1993] The time differences could signify different pathophysiological pathways, the 
exact natures of which remain unsolved. 
In the literature, the extent of recovery was commented on in 17 publications, 13 of 
which reported that prognosis of functional recovery was usually good and overall 
prognosis of HNA favourable. [Ungley 1933, Taylor 1960, Jacob 1961, Poffenbarger 
1968, Smith 1971, Guillozet 1973, Erikson 1974, Geiger 1974, Wiederholt 1974, Wind-
ebank 1982, Airaksinen 1985, Zuazo-Zamolloa 1992, Windebank 1993, Gouider 1994, 
Pellegrino 1996, Stögbauer 1997, Wehnert 1997] Only four papers concluded that 
clinical evolution is not always favourable and that ‘attacks resulted in persisting 
atrophy and weakness’. [Ungley 1933, Taylor 1960, Guillozet 1973, Zuazo-Zamolloa 
1992] We found the long-term prognosis to be even less favourable; 100% of patients 
suffered from persisting symptoms and had a median Rankin score of 2 on follow-
up, and 33% of patients were permanently unable to work due to HNA. 
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Linkage analysis in the two largest families showed that data in the tested family 
with the classic type of HNA are compatible with the involvement of a gene from 
the 17q24–q25 region. In the family with the chronic undulating type of HNA, link-
age analysis excludes the candidate region. Our data indicate the existence of two 
genotypically and phenotypically different subtypes of HNA.
 
Fig. 3. Pedigree of a family with the chronic undulating type of HNA, showing recombination between 
the disease gene and DNA markers derived from the candidate region, between the markers D17S1301 
(located between D17S949 and D17S801) and D17S802, in patients III-2 and III-7. 
Acknowledgements 
The authors wish to thank the patients and their families participating in this 
study, professors HFM Busch and PA van Doorn for their kind cooperation, and 
PJLA Bernsen for initiating the research. 
chapter 
The clinical spectrum 
of neuralgic amyotrophy 
- revisited 
Summary
We investigated the symptoms, course and prognosis of neuralgic amyotrophy (NA) 
in a large group of patients with idiopathic (INA, n = 199) and hereditary neuralgic 
amyotrophy (HNA, n = 47) to gain more insight into the broad clinical spectrum of 
the disorder. Several findings from earlier, smaller-scale studies were tested, and 
for the first time the potential differences between the hereditary and idiopathic 
phenotypes and between men and women were explored.
Generally, the course of the pain manifests itself in three consecutive phases with 
an initial severe, continuous pain lasting for approximately 4 weeks on average. 
Sensory involvement was quite common and found in 78.4% of patients but was 
clinically less impairing than the initial pain and subsequent paresis. As a typically 
patchy disorder NA can affect almost any nerve in the brachial plexus, although 
damage in an upper and middle trunk distribution with involvement of the long 
thoracic and/or suprascapular nerve occurred most frequently (71.1%). We found no 
correlation between the distribution of motor and sensory symptoms. In INA recur-
rent attacks were found in 26.1% of the patients during an average 6-year follow-up.
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HNA patients had an earlier onset (28.4 years vs. 41.3 years), more attacks (mean 3.5 
vs. 1.5), more frequent involvement of nerves outside the brachial plexus (55.8% vs. 
17.3%) than INA patients, and a more severe maximum paresis, with a subsequent 
poorer functional outcome. In men the initial pain tended to last longer than it 
did in women (45 vs. 23 days). In women the middle or lower parts of the brachial 
plexus were involved more frequently (23.1% vs. 10.5% in men), and their functional 
outcome was worse.
Overall recovery was less favourable than usually assumed, with persisting pain 
and paresis in approximately two-thirds of the patients who were followed for 
three years or more.
 
Introduction
Neuralgic amyotrophy (NA), which was first described as a distinct clinical syn-
drome in the late 19th century, is characterized by attacks of neuropathic pain and 
subsequent patchy paresis in the upper extremities. Apart from other names, the 
Parsonage - Turner syndrome is probably the second most common denomination 
for the disorder. [Wilbourn 1993] NA can occur as a sporadic disorder but also exists 
as an autosomal dominant hereditary trait, known as hereditary neuralgic amyo-
trophy (HNA), which predisposes to recurrent attacks of peripheral nerve damage. 
Very recently a mutation in the SEPT9 gene was found in several HNA families. 
[Kuhlenbaumer 2005] The attacks are currently assumed to be autoimmune in ori-
gin, but the precise mechanism is unknown. [Suarez 2005] Idiopathic NA has a re-
ported incidence of 2-3 / 100.000 / year. [Beghi 1985, MacDonald 2000]
It is likely that, rather than a single disease entity, NA is a syndrome comprising 
different underlying mechanisms, phenotypes and prognoses. [Byrne 1987, Cruz-
Martinez 2002, England 1987] The present study aimed to gain a deeper insight into 
the various clinical manifestations of NA and to further delineate its course and 
prognosis, thus facilitating a better distinction from other disorders. Since 2000, our 
institute has been the national referral centre for NA patients in the Netherlands. 
The ultimate goal of our explorations is to help clinicians identify patients more 
rapidly – making early therapeutic intervention possible –, to find clues to help 
target pathophysiological research better, and finally, to provide patients and car-
egivers with a more detailed overview of the condition, its prognosis and the most 
effective therapeutic approaches. 
Methods
Patients
To be included in our consecutive case-series analysis patients needed to have suf-
fered an attack of acute, painful, patchy brachial and/or lumbosacral plexopathy 
that followed a monophasic course, for which no specific (other) aetiology could be 
identified at onset and after follow-up. Our selection criteria followed the diagnos-
tic guidelines as put forward in a 1999 European Neuromuscular Centre workshop 
for HNA, but, obviously, regardless of family history. [Kuhlenbaumer 2000] Because 
NA is known to involve a wide phenotypic variation [e.g., Byrne 1987, England 1999], 
we also included patients in whom paresis preceded pain, or who suffered painless 
but otherwise typical attacks, or attacks that also involved nerves outside the bra-
chial plexus. Although we mainly tried to include patients seen at our centre in a 
prospective manner, data was also collected retrospectively, and well-documented 
cases seen by colleagues elsewhere were also included. Episodes with symptoms in 
these patients were only counted as attacks if they had been confirmed by clinical 
assessment.
Statistics 
The demographic, epidemiologic, and clinical data available from chart reviews 
were recorded as variables in a SPSS database. Statistical analyses were performed us-
ing SPSS version 12 (SPSS Inc., Chicago, Illinois, USA). For each variable the number 
of available cases was noted, and percentages represent parts of the available cases 
per variable unless noted otherwise. In each patient, one attack was further ana-
lysed for time course, pain characteristics, localization and severity of paresis, sen-
sory symptoms, and functional impairments experienced. We also collected infor-
mation on the initial diagnosis and the time elapsed before the diagnosis of NA 
was established. Some of the continuous variables were redefined in several discrete 
categories to allow further calculations (see below).
Clinical data
Pain was assessed using the Numerical Rating Scale (NRS; range 0-10). The maxi-
mum severity of the paresis during an attack was defined as the average MRC grade 
of the affected muscles and denoted as mild (MRC 4-5-), moderate (MRC 3-4-) or 
severe (MRC < 3). During processing of the data, the loci of the pain as described by 
the patients were clustered into four different patterns according to the most prox-
imal locus involved. The distribution of sensory symptoms was clustered in five 
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anatomical regions, and also separately according to their truncal distribution in 
the plexus for comparison with motor deficits. Besides an upper, middle and lower 
trunk, a fourth region, involving the more proximal parts of the plexus or cervi-
cal roots was encoded. Likewise, we also classified the distribution of the paresis 
into six anatomical regions, and again according to truncal distribution within the 
plexus. In the anatomical regions, attacks in the upper and/or middle part of the 
plexus in which the long thoracic nerve was affected were classified separately, be-
cause the presence of a winged scapula seems to facilitate clinicians in recognizing 
NA. We did not systematically assess the presence of minor dysmorphisms in HNA 
patients, or the prevailing clinical course (intermittent or chronic-undulating) in 
the HNA families.
The results of ancillary investigations, e.g. blood analyses, CSF studies, electrodiag-
nostic examinations and imaging studies, were noted when available. In a number 
of patients who had had a painless attack or a concomitant pressure palsy (e.g., car-
pal tunnel syndrome), or a family history of pressure palsies, DNA was tested for 
the presence of a PMP22 deletion found in hereditary neuropathy with liability to 
pressure palsies (HNPP).
We evaluated various treatments and their efficacy. Pain relief resulting from medi-
cation was subjectively categorized by the patient as ‘good’, ‘some’ or ‘none’.
Because there is no standard definition of recovery for NA, several parameters were 
recorded representing residual symptoms (neuropathic and musculoskeletal pain; 
paresis), a subjective estimate of overall recovery (patient judges ‘full recovery’ 
based on a yes/no question; estimated overall recovery percentages in six catego-
ries: none, < 50%, 50-70%, 70-80%, 80-90%, 90-100%), and functional outcome (i.e. the 
ability to work; modified Rankin score). We excluded 43 patients from this analysis 
because they had received treatment with prednisone for one or more of their at-
tacks; they will be reported on separately. Because of the variable follow-up times 
within our case series, we grouped the patients in five categories delineated by the 
duration of the follow-up since the last NA attack: 0-6 months, 6-12 months, 1-2 
years, 2-3 years and 3 years or more. For comparison with other studies, the long-
term results for patients in the latter category will be presented in more detail. 
Due to the considerable between-patients variation in follow-up durations and 
intervals, we were unable to perform a survival analysis for recovery over time for 
the group as a whole. 
Subgroup analysis
On clinical grounds we expected there would be no significant difference in clini-
cal characteristics between INA and HNA patients, except for the age of onset and 
the total number of attacks, and possibly for the involvement of nerves outside the 
distribution of the brachial plexus, such as the phrenic, lumbosacral plexus, inter-
costals or cranial nerves, which has mainly been reported in HNA. [van Alfen 2000] 
We also compared men and women to see if there are sex-related differences in NA. 
Preceding further analysis, differences for both subgroups were tested for categori-
cal variables using the Pearson’s Chi-Square method (two-sided testing for a sig-
nificance level of ≤ 0.05); an independent Student’s t test was used for continuous 
variables. When different, results for these variables will be reported separately for 
INA and HNA patients or men and women; all other variables will be reported for 
the patient group as a whole.  
Descriptive data on patients that had received open-label prednisone treatment is 
provided, and where possible compared to untreated patients with respect to epi-
demiological and outcome variables. Differences for both subgroup divisions were 
also tested with Pearson’s Chi-Square and independent Student’s t tests. Two pa-
tients were excluded from analysis because they participated in a placebo-control-
led trial with prednisone.
We used linear regression to evaluate attack and recovery over time in a subgroup 
of patients who had suffered only one attack and had not received prednisone. De-
pendent variables were NRS scores at onset and follow-up, severity of the paresis 
during the attack, maximum strength level at recovery, estimated recovery per-
centage and Rankin score. Independent variables were sex, age, HNA, presence of 
an antecedent event, contractions at wrists or fingers, presence of distal vasomotor 
dysfunction, weight loss and time (five categories, see above).
 
Results
I. Study population characteristics
A total of 246 patients with either INA or HNA were identified from our centres’ 
neuromuscular database, of whom 104 (42.3%) were evaluated by the first author 
(NvA). All but 14 patients were seen at our centre (94.3%); 192 (78,1%) could also be 
followed prospectively, and retrospective data only was available in 54 (21.9%). We 
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included 174 (70.7%) patients that met the ENMC criteria, and 72 (29.3%) with a phe-
notypic variation, including nine (3.7%) patients with painless attacks, eight (3.3%) 
with paresis preceding pain, and 55 (22.4%) who also had involvement of nerves out-
side the brachial plexus, either in the evaluated (27, 11%) or in a previous attack (28, 
11.4%). The study population contained 67.5% men (68.3% in INA and 63.8% in HNA, 
difference not statistically significant); 87% of the patients were right-handed, 11.1% 
left-handed and 1.9% ambidextrous, and 19% had a family history of the disorder 
(HNA, n = 47, from 36 families), which had been confirmed in 35 patients by exami-
nation of an affected family member. The data of seven of the HNA patients was 
also used in a previous study [van Alfen 2000]; the total number of HNA patients 
seen in our centre at the time of writing was 52.
Six of the 34 clinical variables differed significantly between HNA and INA patients: 
age of onset (p < 0.0001), total number of attacks (p < 0.0001), the involvement of 
nerves outside the brachial plexus (p < 0.0001), increasing pain in the first few weeks 
after the onset of an attack (p = 0.03), maximum severity of paresis during an at-
tack (in- or excluding patients receiving prednisone treatment; p = 0.04 and 0.01, 
respectively), Rankin score (p = 0.008), and the legally established disability to work 
(‘sick leave’; p = 0.005). Men and women also differed significantly in 6 variables: the 
duration of the primary pain (p = 0.006), the presence of neuropathic pain on last 
follow-up (p = 0.04), presence of atrophy (p = 0.02), pattern of motor paresis (p = 0.01), 
increased mechanical sensitivity of the plexus (p = 0.02) and Rankin score on follow-
up (p = 0.004). The corresponding numbers and percentages for these differences are 
described in the specific Results sections below.
The mean age of onset in INA was 41.3 years (median 40.5, range 10-79.8 years), and had 
a normal distribution. From the total of 194 INA patients in this category, 3.1% had 
experienced their first attack in childhood, i.e. before the age of 16. As expected, onset 
for HNA patients (n = 44) was earlier at a mean of 28.4 years (median 28.0, range 3-56.3 
years), with 22.7% of patients suffering their first attack during childhood. After an 
average follow-up from onset of 6.2 years, the mean number of attacks in INA patients 
was 1.5 (median 1) and 3.5 (median 3) in HNA. The mean time before NA was diagnosed 
was 43.8 weeks (median 10.5) with 75% of the patients being diagnosed within 28 weeks 
from onset. In 61.9% of the cases patients had received a different initial diagnosis, usu-
ally either glenohumeral joint pathology or cervical radiculopathy.
II. Characteristics of NA attacks
II.1. General features. In 90% of the patients the onset of an NA attack was announced 
by the disorder’s typical pain (for more details see section II.2), which usually 
emerged within a few hours. When absent initially, 62.5% of the patients would still 
develop the pain during the course of the attack. In 60.9% of the cases the attacks 
began at night (between 00.00 and 07.00 hours). In 71.5% they involved only one arm, 
in 28.5% both arms, typically in an asymmetric fashion (97.1%). There was only one 
documented attack (0.4%) in an HNA patient that was not associated with paresis 
(pain only, or ‘abortive attack’).
In 55.8% of the HNA patients, nerves outside the brachial plexus were also involved 
during an attack, e.g. the lumbosacral plexus (32.6%), phrenic nerve (14%), recurrent 
laryngeal nerve (18.6%) or other (7%; percentages do not add up due to combina-
tions). In INA patients this type of involvement was seen less frequently (17.3%; 8.2% 
lumbosacral plexus, 6.6% phrenic nerve, 2% recurrent laryngeal nerve, 2.6% other).
As expected, attacks recurred in a large number (74.5%) of HNA patients. Nineteen 
percent had suffered only one attack during our follow-up, 29.8% two attacks, 17% 
three, 10.6% four and 23.4% five or more attacks, with a maximum of 13. More sur-
prisingly perhaps, recurrences were also seen in 26.1% of the INA patients (19.1% two, 
4.5% three, 4% four and 1% five or more attacks). The median time to a recurrence 
slightly exceeded two years (109 weeks; mean 250 weeks) in INA patients and almost 
six years (300 weeks; mean 349 weeks) in HNA, but this difference was not statisti-
cally significant (p = 0.08). Two-thirds (n = 42) of the INA patients with recurrences 
were referred to our centre after their last attack. One-third (n = 21), out of a total of 
163 INA patients (i.e. 12%) we prospectively followed after their first attack, suffered 
a recurrence during follow-up at our centre, within a median time of six months 
(mean 1.1 years) after their first visit. INA patients with recurrences were signifi-
cantly younger at onset (35.0 years), compared to INA patients that had suffered 
only one attack (43.9 years; p < 0.001), but did not differ in other aspects. Recurrences 
could affect the same peripheral nerve territory in each attack (23.5%), completely 
different territories (32.1%), or sometimes the same and sometimes different ter-
ritories (44.4%). See table 1 for further characteristics of the NA attacks.
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Table 1. Characteristics of NA attacks
II.2. Pain characteristics
Overall, 96.3% of the patients experienced the typical, very severe, relentless, neuro-
pathic ‘NA pain’ during their attacks. This initial pain was continuous in 93.8% and 
had a median NRS rating of 8 at onset, and 9 at maximum intensity. Put differently, 
initially 60% and subsequently 90% of patients had a NRS score of 7 or more. In the 
subgroup of 133 patients who had only suffered one untreated attack, the NRS score 
at onset was on average two points higher in HNA patients (7.3 vs. 9.4, p = 0.04).
Pain had a stuttering onset in 18.7%, which implies that pain could have been 
present on-and-off for a few weeks before the ‘real’ attack, characterized by the con-
tinuous severe pain, began. After onset, pain severity increased even further during 
the first few weeks in 38.5% of the INA patients versus 18% of the HNA patients. In 
88.6% of all patients the pain was worse at night and caused sleep disturbances in 
93.5%. There was evidence of increased mechanical sensitivity (e.g. pain elicited by 
movement or pressure on the affected limb; a ‘Lasègue sign of the arm’) in 80% of 
the men and in 97.4% of the women.
In men the initial pain lasted on average twice as long (45.3 days, median 21 days) as 
it did in women (23.3 days, median 17 days). For the group as a whole average pain 
duration was 27.5 days (median 19.5 days). In 4.9% of the cases the pain disappeared 
within 24 hours, in 22.7% it persisted between one to seven days, and in 10% it lasted 
60 days or more. Six patients who reported their initial pain to have lasted for over 
a year were excluded as outliers. It is likely that, as time progressed, they suffered 
from one of the subsequent pain types reported in NA (see below) but had been un-
able to distinguish between the pain types.
Many patients (76.5%) described two additional pain phases in the course of their 
attack. The continuous initial pain was followed by severe neuropathic stabbing 
or shooting pains usually elicited by movement, lying on or prolonged postur-
ing of the affected limb that lasted from a few weeks to several months (data not 
quantified) and dissipated gradually. Many patients (65.1%) reported a subsequent 
persisting musculoskeletal-type pain, usually localized to the origin or insertion of 
the paretic - or compensating - muscles, especially in the periscapular, cervical and 
occipital regions. Twenty-three percent of the men and 37.5% of the women still 
suffered from neuropathic pains at the final follow-up. In addition, sometimes pa-
tients also developed pain related to glenohumeral joint pathology after an NA at-
tack with paresis of the rotator cuff muscles or decreased glenohumeral excursions 
due to paresis, and 17% developed a true frozen shoulder (glenohumeral adhesive 
capsulitis) during the course of their attack. Glenohumeral subluxation or luxation 
occurred in 8.4% of cases, and 9.6% developed contractures of the wrist or fingers 
due to long-standing distal paresis. On follow-up, 29% developed chronic, usually 
therapy-resistant, continuous pains in the previously affected region.
The locus of the initial pain was quite variable: the patients described 32 different 
patterns. After re-clustering the loci into four regions, which were either uni- or 
bilateral, in 39.7% the pain was found to occur in and/or radiated from the shoulder 
to the arm, in 35.4% from the cervical spine or neck down into the arm, in 18.8% 
from the scapular or dorsal region to the chest wall and/or arm, and in 6.1% the pain 
was confined to a lower plexus distribution (e.g. medial arm and/or hand, axilla). 
A small proportion of the patients reported pain in a very restricted area: scapula, 
neck or upper arm only (1.3%, each), or the posterior cervical and chest-wall region 
(3.5%).
In about two-thirds of the patients the initial pain could be partly relieved by avoid-
ing movement or certain postures. The local application of warmth provided relief 
in 26 out of 38 patients. Many (83.5%) used analgesics during their attack. The medi-
cation used and the subjective relief it provided are listed in Table 2. The most effec-
tive pain relief was achieved with the combination of an NSAID and an opiate (e.g. 
diclofenac slow-release 100 mg bid with slow-release morphine 10-30 mg bid).
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Table 2. Analgesics used
II.3. Paresis and atrophy
In the attacks characterized by initial pain, the first signs of weakness appeared 
within 24 hours in 33.5% of the patients, after one to seven days in 39.3% and one to 
two weeks in 14.1%. In 27.2% of all cases paresis did not manifest itself until more 
than two weeks later. The mean time to the onset of weakness was 13.6 days in the 
male and eight days in the female patients, but the difference was not statistically 
significant (p = 0.18). An increment of the paresis occurred in 30.2% of the cases with 
severity progressing over a period of days (8.6%), weeks (16%) or months (5.6%).
The distribution of the motor deficits as found for the male and female NA patients, 
clustered in anatomical regions is shown in Table 3. 
Table 3. Distribution of motor paresis
Women more often had involvement of the middle or lower parts of the brachial 
plexus (23.1% vs. 10.5% in men; p = 0.01). Overall, paresis of the distribution of the 
upper part of the brachial plexus was by far the most common (71.1%), either with 
(50.2%) or without (20.9%) involvement of the long thoracic nerve. Any part of the 
plexus, and clinically any muscle, could be involved (see Table 4), but paresis of the 
infraspinate (72%) and serratus anterior muscle (70%) were the most common, and 
involvement of the sternocleidomastoid (7.2%) or neck extensors (1.5%) infrequent. 
Although the maximum severity of the paresis during an attack differed statistical-
ly between INA and HNA patients (p = 0.04), it was generally severe in both groups 
(64.9% and 69.8%, respectively). In these severely affected patients, paralysis (MRC 
grade 0/5) was more frequent in HNA than in INA (11.6% vs. 3.7%). Conversely, there 
were more INA patients (13.1%) than HNA patients (2.3%) with a mild maximum 
motor deficit. The remainder of the patients (22% INA and 27.9% HNA) suffered a 
moderate paresis.
Table 4. Muscles affected
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In most patients (59.8%) recovery of motor function began between the first and 
sixth month. A small group (7.9%) already reported to have noticed some recovery 
within one to four weeks. In 18.9% recovery set in after 6 to 12 months, in 8.5% after 
1 to 2 years, and in 4.9% not until 2 to 3 years after onset. 
In 88.5% of the men and in 75.4% of the women clinical assessment revealed muscle 
atrophy during an attack; this difference was significant (p = 0.02). The median time 
for atrophy to first appear was five weeks; in 20% of the patients it was perceived as 
early as two weeks after onset. Isolated long thoracic nerve palsy (in which serratus 
anterior atrophy is difficult to detect clinically) was about 20 times as common in 
the 15.5% of patients without visible atrophy as it was in the group with atrophy 
(11.4% vs. 0.5%, respectively). Six patients spontaneously mentioned fasciculations 
at onset in the later paretic muscles.
II.4. Sensory symptoms
Sensory symptoms during an attack were reported by 69.2% of the patients, and af-
ter clinical examination sensory involvement was found in 78.4%. Similar to atro-
phy, we found that in patients without sensory involvement, motor involvement of 
the upper plexus including the long thoracic nerve was more common (52%) than in 
those who did exhibit sensory symptoms (21.8%). Hypaesthesia was the most com-
mon complaint (45.9%), followed by a combination of paraesthesia and hypaesthesia 
in 39.2%, and paraesthesia only in 14.2%; only one patient (0.5%) reported allodynia. 
Paraesthesia usually occurred at the onset of an attack, or afterwards with traction 
on the affected parts of the plexus (data not quantified).
The in total 39 different distribution patterns reported for sensory symptoms were 
regrouped into five anatomical regions as listed in Table 5. Ranging from der-
matomes C3 and C4, or the lumbar region, to a combination of the axilla and fin-
gertips, it is safe to say that ‘almost anything goes’ when it comes to the possible 
distribution patterns of sensory symptoms in NA. However, hypaesthesia and/or 
paraesthesia over the deltoid and lateral upper arm region were most common 
(48.9%). When sensory and motor deficits were recoded according to their truncal 
distribution within the plexus and compared, no correlation was found in the lo-
calization of the two affected modalities.
Table 5. Distribution of sensory symptoms
In more than half the patients (51.7%) there was no recovery of the sensory symp-
toms on follow-up. Moderate recovery was found in 19.6% and full recovery in 28.7%. 
In those who had fully recovered, recovery had set in between 0 to 3 months after 
onset in 19.5% (7.3% within the first week), after 3 to 6 months and 6 to 12 months in 
29.3% each, and in 24% after 1 to 3 years.
II.5. Autonomic and other symptoms
In 32 patients (15.4%) signs of peripheral autonomic nervous system involvement, 
mainly the so-called distal vasomotor dysfunction [Low 1997], were found in the 
areas with sensory or motor affection: vegetative and trophic skin changes, oedema 
at onset of the attack, temperature dysregulation, increased sweating, and, rarely, 
changes in nail or hair growth (details not quantified). Autonomic dysfunction 
proved significantly more common in patients with motor involvement of the 
posterior cord, lower part or all parts of the brachial plexus than in patients with 
upper and/or middle brachial plexus involvement (p = 0.006). Conversely, of all the 
patients who (also) had lower plexus involvement, 32.5% showed signs of vasomotor 
dysfunction. Almost all attacks with autonomic dysfunction were accompanied by 
sensory symptoms (93.8% vs. 76.2% in attacks without autonomic dysfunction, p = 
0.05). There was no correlation between the presence or absence of autonomic dys-
function and the distribution of pain or sensory symptoms. None of the patients 
exhibited a Horner’s sign.
Twenty of 99 patients (20.2%) reported significant weight loss (> 5 kg within a few 
weeks) during an attack. In this small group more people reported a antecedent 
event (68.4% vs. 41.6%), which also more often was an infection (76.9%) than in people 
without weight loss (50%).
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III. Predisposing factors and medical histories
In 53.2% of the attacks the patient reported an antecedent event. The nature of these 
events and their occurrence are presented in Table 6. Of note was that in women 
attacks during pregnancy or in the puerperium occurred in both INA and HNA pa-
tients. In 52.3% of the cases, the event occurred in the week preceding the attack; in 
17.4% it occurred only hours before. The timing of the most common events versus 
the onset of the attacks is shown in Table 7. In the subgroup of 133 patients with 
only one untreated attack, the occurrence of an antecedent event yielded an average 
NRS pain score at onset that was 1.25 points higher than in patients without such 
an event (6.7 vs. 7.9, p = 0.02).
Table 6. Antecedent events 
Table 7. Time to onset of attack per type antecedent
The medical history of our patients appears to be a reasonable cross-section of the 
general population, judging from the prevalence of lumbar spine pathology (9.4%), 
malignancies (2.6%), and reported allergies (32.3%), which match that of the Dutch 
population. [National Dutch compass for public health and health care 2005] The 
prevalence of diabetes mellitus in our study population was 3% (6 INA, 1 HNA), ver-
sus 4% in the general population. In this small group, there were no patients with 
lumbosacral plexus pathology or weight loss during an attack. The mean age of 
onset in the 6 INA patients with diabetes mellitus was 57.4 years, 4 of them had 
multiple attacks, and 2 had had facial nerve involvement during an attack, which 
was not seen in other INA patients. We did not find other differences in course or 
outcome.
IV. Ancillary investigations
IV.1. Laboratory findings. Blood analyses were performed in 135 patients (54.9% of to-
tal) and 27.8% of these cases one or more abnormalities were found. Most conspicu-
ous were 10 patients with elevated liver enzymes in the early phase of their attacks, 
for which no explanation could be found (even after liver biopsy in two patients). 
Clinically, it concerned mostly middle-aged men (8), with idiopathic NA (n = 9), suf-
fering from bilateral (n = 8), severe (n = 8) attacks which involved the phrenic nerve(s) 
and/or lumbosacral plexus in more than half of the cases (n = 5). DNA was tested for 
HNPP in 36 patients (14.6% of total); none were positive. We also found signs of a 
recent infection in 4.5%, a previous infection in 1.5%, mildly elevated creatinekinase 
in 1.5%, positive rheumafactors in 0.8%, and other findings in 8%.
In 9 out of 34 patients (26%; 5 men; 2 HNA) anti-ganglioside antibodies were found. 
Anti-Gm1 IgM was present in 6, anti-Gm2 IgM in 1; anti Gm1 and Gm2 IgG were 
(also) found in 3 patients each, and 1 patient had only anti-Gm3 antibodies (no type 
specification available). As our laboratory performs a qualitative analysis for anti-
ganglioside antibodies (using immunostaining high performance thin-layer chro-
matography), titers were not available.
IV.2. Lumbar puncture
Cerebrospinal fluid (CSF) analysis was performed in 32 patients (13% of total). One pa-
tient was tested because of a clinical diagnosis of viral meningitis, subsequently prov-
en, occurring concurrently with the NA attack. In four other patients (12.5%) the CSF 
proved abnormal, with elevated protein in two, elevated protein with slight pleocyto-
sis in one, and oligoclonal bands (with an identical profile in serum) in one.
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IV.3. Electrodiagnostic tests
The most commonly used diagnostic test was an EMG examination, which was used 
in 214 (87%) of all patients. In 96.3% it was abnormal and compatible with NA. [Suarez 
2005] Somatosensory evoked potential studies were performed in 11 patients, and ab-
normal in one: a male INA patient in whom the dermatomal SSEP of both arms showed 
a slowed and less well-defined response from the C5 root on the affected left side, while 
the C4, C6, C7 and C8 responses were within normal limits.
IV.4. Imaging studies
In 85 patients (34.1% of total) a chest X-ray was performed, which was abnormal in 21 
cases. We found no superior sulcus (Pancoast) lung tumour, but in 11 cases one (n = 8) 
or both (n = 3) diaphragm halves were elevated due to phrenic nerve involvement. In 
four patients we found signs of thus far undiagnosed obstructive pulmonary disease. 
Other findings included post-thoracotomy changes resulting from previous surgery 
(unrelated to the onset of symptoms), old sarcoidosis and old tuberculosis lesions.
Many patients (n = 107, i.e. 43.5% of total) also underwent an MRI scan of the cervical 
spine, which showed degenerative changes (including six cases with myelopathy) in 
more than half of the cases (52.8%). None of the abnormalities found was able to explain 
the clinical picture and course in these patients. Fifty patients (20.3% of total) also un-
derwent an MRI scan of the brachial plexus, which was abnormal in three (6.3%), show-
ing focal T2 hyperintensities in two and focal thickening of the plexus in one patient; 
the latter is shown in figure 1.
Figure 1. T2-weighted non-contrast MRI scan of the brachial plexus, showing a thickened and slightly 
hyperintense middle trunk on the right.
V. Functional recovery and employment
V.1. Untreated patients In 200 HNA and INA patients that had not received corticos-
teroid treatment, recovery parameters were grouped into five categories accord-
ing to follow-up duration (0-6 months, 59 patients; 6-12 months, 56 patients, 1-2 
years, 55 patients; 2-3 years, 19 patients; 3 years or more, 49 patients). Results are 
depicted in Table 8 and figures 2, 3 and 4 (percentages in category 2-3 years slightly 
skewed due to smaller number of patients in this particular group). Overall, there 
were more women with a Rankin score of 3 (requiring some assistance in daily life) 
(16.9%) than men (3.4%) at the last follow-up visit. We found no correlation between 
age and outcome parameters such as muscle strength, sensory recovery, Rankin 
score or estimated recovery rate.
Table 8. Subjective recovery rates + Fig 2, Fig 3 and Fig 4 % of patients with residual symptoms
In the subgroup of 133 patients (125 INA, 8 HNA) who had suffered only one attack, 
pain at the most recent follow-up tended to be worse (average NRS score 2.4 points 
higher, 3.7 vs. 6.1) in those who had distal vasomotor dysfunction (p = 0.06). The 
Rankin score was significantly higher in patients with distal vasomotor dysfunc-
tion (1.5 vs. 2.0, p = 0.01), and in patients with joint contractures (1.6 vs. 2.3; p = 0.01). 
It also tended to be slightly higher in women (1.5 vs. 1.8; p = 0.07). Linear regression 
of recovery over time (defined in five successive time intervals) showed an increase 
of the subjective recovery percentages (also in categories) of 0.3 ‘category’ per time 
unit (p = 0.05), and also an increase in maximum MRC defined strength at follow-
up of 0.2 ‘category’ per time unit (p = 0.001). Univariate and multivariate analysis 
yielded similar results.
The outcome results for INA (n = 39) and HNA (n = 10) patients with a long-term 
follow-up of three years or more were separated because, overall, both Rankin score 
and employment ability differed statistically between the two patient types. Many 
of these patients (INA 61.5%, HNA 80%) still had pain since their attack(s), with a 
tendency to a slightly higher mean NRS pain score in HNA patients (5.3 vs. 3.7 in 
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INA). In both groups a considerable proportion (INA 46.2%, HNA 62.5%) suffered 
from chronic pain. In the INA patients mild paresis was still present in 69.4% of 
cases, moderate paresis in 13.9% and severe paresis in 2.8%. The outcome for the HNA 
patients was worse: 40% had a mild paresis, 30% a moderate and 20% severe paresis. 
Most importantly, only two patients, i.e. 4.1% of the total and both with INA, had 
made a full recovery. As assessed by the patients themselves, 34.8% of those suffer-
ing from INA and 33.3% afflicted by HNA had made a 90-99% recovery. Conversely, 
21.7% of INA patients reported less than 50% recovery, which was 66.7% for the HNA 
patients. The median Rankin score for patients with a follow-up of 3 years or more 
did not differ between HNA and INA; both groups had a score of 2, meaning that 
patients experienced some impairments in daily life but did not need help from 
others (van Swieten et al., 1988) In the INA group, 22.3% was unable to work, and 
36.8% had had to find a different type of job because of NA. Four HNA patients (40%) 
were unable to work, and two (20%) had changed jobs. 
V.2. Corticosteroid treated patients
There were 41 patients that had received open-label corticosteroid treatment for one 
of their attacks; in 29 it had been the attack we further evaluated. The median time 
to the start of the treatment was 10 days, but the mean 29.8 days (range 0-390 days). 
Dose regimens varied between patients; in only 18 the same schedule was followed, 
using a two-week course of oral prednisone, 60 mg daily in the first week, and taper-
ing the dosage by 10 mg per day (and 5 mg as a last step) in the second week. The me-
dian duration of treatment was 13 days (median 12.4, range 2-56 days). Side effects 
were present in eight of 26 patients (30.8%), and in four they were severe enough to 
stop using the corticosteroids. When asked if they had noticed a favourable effect on 
their symptoms, four out of 20 patients responded ‘yes, definitely’, nine said they’d 
experienced ‘some’ effect, four had only noticed a temporary relief, in one it had 
been ‘unclear’ and two reported no favourable effect whatsoever. The median time 
to a noticable decrease in their initial pain in 19 patients was five days (mean 6.7, 
range 0-20 days), and the median time till any noticable recovery of strength was 15 
days (mean 29.8, range 0-130 days). In three out of 37 patients a full, documented re-
covery of their symptoms had taken place within one month after onset; they had all 
started their treatment within two weeks after onset (5, 6 and 12 days, respectively).
When statistically comparing the corticosteroid-treated patients with the untreated 
group, we found that subsequently treated patients had on average suffered more 
attacks (median 2 vs. 1 in the untreated group; p < 0.001), and had a higher maxi-
mum NRS score during their treated attack (median 10 vs. 9 in untreated group; p 
0.02). No differences were found in other baseline variables such as age, sex, type of 
NA, handedness, onset symptom, duration of the initial pain, time till and severity 
of the initial paresis, or the occurrence of atrophy, sensory or vasomotor symptoms 
during the attack. When comparing outcome variables, the only statistically signif-
icant finding was the time untill the start of paresis recovery, which was shorter in 
treated patients (28.2% within the first month, versus 6.3% in the untreated group; 
p = 0.001). We could not detect a difference in other variables such as the duration of 
the initial pain, maximum present NRS score and use of analgesics, the occurrence 
of a chronic pain syndrome, maximum MRC level of strength recovery, complica-
tions such as frozen shoulder or shoulder dislocation, or Rankin score.
Discussion
Although the most common, typical phenotype of an attack in both HNA and INA 
is relatively well known (i.e. an acute, very painful upper brachial plexopathy with 
a winged scapula), our data show that neuralgic amyotrophy is a syndrome with a 
broad range of clinical manifestations. Patients can present with isolated unilat-
eral interosseus anterior nerve palsy and an inability to flex their index finger and 
thumb, or a bilateral severe paresis of both upper extremities with severe orthop-
nea due to phrenic nerve palsy - and anything in between. Painless attacks occur 
in a small minority (3.7%) and do not automatically mean the patient is suffering 
from HNPP. The variability in the location and severity of symptoms most likely 
depends on exactly which parts of and the extent to which the plexus is affected by 
the presumed autoimmune process. From a clinical perspective, a ‘radicular’-type 
pain in the neck region or a pain provoked by passive movement or involvement of 
the paraspinal muscles on EMG examination does not exclude the disorder either. 
In addition, the disorder proved not to be limited to the brachial plexus; the lum-
bosacral plexus, phrenic nerve, intercostal nerves or recurrent laryngeal nerve could 
also be involved. This again [England 1999] suggests that it is probably not accurate 
to describe NA as a pure brachial plexopathy, and that from an anatomical perspec-
tive it would be more apt to call it a form of mononeuropathia multiplex - albeit 
with preferential involvement of the cervical roots, plexuses or nerves. 
Besides the typical severe neuropathic pain at onset (with a NRS score ≥ 7 in 90%), 
the ‘patchiness’ of NA attacks remains a distinctive feature that will prompt the 
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diagnosis in almost every case. There are also several limitations to the clinical phe-
notype: a perfectly symmetric involvement of both brachial (and/or lumbosacral) 
plexuses is very rare, as noted earlier [Tsairis 1972], and even then it will not involve 
all peripheral nerves. A Horner’s sign does not seem to belong to the NA phenotype 
either, although 15% of patients do exhibit symptoms of autonomic nervous system 
dysfunction and the actual symptom has been reported in one HNA patient. [van 
Alfen 2000] In practice its finding should warrant a prompt search for underlying 
structural plexus pathology. 
Although motor symptoms are said to predominate in NA, almost 70% of the pa-
tients reported sensory symptoms in addition to the pain, and on examination hy-
paesthesic skin areas were found in almost 80%. This at least shows that the disorder 
itself does not seem to have a preference for affecting motor nerves. We came to a 
similar conclusion in an earlier histologic study of HNA. [van Alfen 2005] The com-
bination of our data and a previous report in the literature [Seror 2004] suggests 
that attacks can also be either pure motor or pure sensory. The fact that paresis still 
predominates the clinical picture (over sensory symptoms) after the initial pain 
has disappeared, could be explained by the predominance of proximal symptoms 
in most cases: the tactile spatial resolution is much lower on the back and shoul-
der than more distally in forearm or hands, and as the shoulder is not involved in 
any tactile process relatively large proximal hypaesthetic areas may go unnoticed in 
daily life. Our finding that the localization of motor symptoms does not correlate 
with that of the sensory loss seems to stress the multifocal character of NA lesions.
Of course the broad range of symptoms encountered in this study could be in-
fluenced by the fact that about a third of the patients were especially referred to 
our centre because of a somehow atypical clinical picture according to their refer-
ring physician. This may also have influenced the severity of symptoms found, as 
it seems likely that uncomplicated cases with good recovery within a few months 
would have a smaller chance of being referred for a second opinion. Considering the 
large number of patients that had first been diagnosed with another disorder, it 
may even be that very mild cases never get referred to a neurologist, but are simply 
treated as ‘aspecific shoulder pain’ in a primary care setting. 
This study also confirms the predominance of male patients in both INA and HNA, 
which is perhaps remarkable considering that the attacks are presumed to be auto-
immune in origin (in which case one would usually - but not always, as in Good-
pasture’s syndrome - expect a female predominance). The reason for this difference 
has not yet become evident. It might be that an unknown sex-specific factor in this 
disorder makes male patients more prone to the attacks. But alternatively it could 
also be that a persistent bias exists that makes male patients get referred more fre-
quently for analysis of their symptoms, for example because they are more depend-
ent on physical strength to to generate an income for the household.
A novel finding was that we found that the NA attacks quite often follow a course 
comprising three different, consecutive types of pain. The acute and continuous 
neuropathic pain that heralds the onset of an attack is followed by a period of in-
creased mechanical sensitivity of the damaged nerves, and subsequently a substan-
tial number of patients suffer from musculoskeletal-type pains in both the affected 
and compensating muscles, especially at the site of their origin and insertion. The 
identification of these subsequent pain types and the finding that the continu-
ous neuropathic pain at onset on average lasts for almost four weeks rather than 
two weeks as has often been assumed [Suarez 2005], are important because in our 
experience the diagnosis is often questioned or discarded when the pain persists 
longer than expected. It is also important because many patients will seek and need 
medical advice for this complication. The acute pain responds best to a combina-
tion of a long-acting NSAID with a slow-release opiate, and the increased mechani-
cal sensitivity sometimes needs treatment with co-analgesics. The musculoskeletal 
pain is usually hardly responsive to medication, and here physiotherapists tend to 
achieve the best results by having the patient maintain a fluent motion and normal 
daily use of the affected shoulder or limb, paying special attention to the so-called 
scapulothoracic and glenohumeral rhythms.
In contrast to previous reports [Suarez 2005] we found abnormalities in over a 
quarter of the patients in whom additional laboratory tests had been performed. 
Although the results did not directly contribute to the diagnosis of NA, they gener-
ated two interesting findings. Firstly, there were the grossly elevated liver enzymes 
for which no cause could be identified in ten, usually male, patients, most of whom 
seemed to have a clinical subtype of NA with extensive bilateral brachial plexus 
and phrenic nerve involvement. This subtype may be triggered by a specific but 
unknown antecedent infection that also causes a transient hepatitis. The future 
isolation of this potential infectious agent could shed more light on the autoim-
mune mechanism involved in NA. The second abnormality was the finding of 
anti-ganglioside antibodies in 26% of the patients tested. As previously reported 
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by others [Suarez 2005] we also found CSF abnormalities such as elevated protein, a 
slight pleiocytosis, and oligoclonal bands in a few patients. The main implication 
of this finding is that NA can affect the peripheral nerves as proximally as the nerve 
root segments. This was also indicated by involvement of the paraspinal muscles 
in some patients.
The role of electromyography (EMG) in NA has been commented on by many re-
searchers. [For a summary, see Suarez 2005] Apart from facilitating the differentia-
tion of NA and HNPP, we found EMG served two additional purposes. Firstly, the 
technique supplemented the clinical examination by confirming or excluding the 
involvement of certain peripheral nerves or parts of the plexus, and secondly, it con-
tributed to an estimation of the degree of recovery, even when this was not yet clini-
cally apparent to the patient or physician.
Imaging studies serve several purposes in NA. Chest X-rays in one third of the pa-
tients, mainly requested to exclude a Pancoast tumour, did not find space-occu-
pying lesions but revealed a diaphragmatic palsy in several patients. Plexus MRI 
scanning may be warranted in case of an initially progressive clinical picture or 
when recovery fails to occur. Results were occasionally abnormal in our series (3 of 
50 patients), and the abnormalities found were possibly related to the focal inflam-
matory process, but otherwise non-specific. MRI scanning of the cervical spine in 
NA is controversial, because, although they were abnormal in more than half of 
the cases, the scans were always unable to explain the patient’s clinical picture and 
course. Of course we did not look at all the patients who underwent an MRI scan 
for cervicobrachial pain during the period covered by our review, so we cannot say 
how many patients were finally diagnosed with a cervical radiculopathy. But our 
results show that any MRI findings should be interpreted with care and only in 
the light of a thorough history and physical examination to prevent patients from 
being misclassified as suffering from a cervical radiculopathy, which is liable if too 
much emphasis is placed on the radiological rather than the clinical picture.
We have shown that the course of an NA attack can be quite variable, with an acute, 
subacute or more insidious onset of symptoms, and with recovery setting in as 
early as within a month to no observable recovery after several years. We found no 
relationship between recovery and age. Group comparisons revealed that relative 
to INA patients HNA patients were prone to a more severe motor deficit. They also 
exhibited more functional disabilities on follow-up as reflected by their higher 
Rankin scores. In women, the initial neuropathic pain lasted shorter than in men. 
They more often had involvement of the lower and total brachial plexus, and more 
functional impairments on follow-up.
Unexpectedly, in patients with idiopathic NA the recurrence rate after a first attack 
was much higher than previously reported: 26.1% versus an estimated 5% in the lit-
erature [Tsairis 1972], even after a follow-up of only six years. This implies that the 
lifetime risk of recurrence could be even higher. Of course a referral bias could also 
have influenced the number of recurrences found in this INA population, as we saw 
two-thirds of these patients only after their recurrence. It might also be that some 
of these patients actually suffered from HNA, but were unaware of affected family 
members. Nevertheless, 12% of the patients we prospectively followed developed a 
recurrence within the first year, suggesting that once the diagnosis has been made 
a higher index of suspicion probably reveals a higher recurrence tendency in INA 
than hitherto assumed. Because the recurrence rate is much higher than the re-
ported incidence of INA in the general population, the peripheral nervous system of 
INA patients also seems to have an underlying vulnerability for the immune-medi-
ated attacks, analogous to what was hypothesized earlier for HNA. [Klein 2005] HNA 
patients, however, were still found to suffer the most recurrences (74.5% of patients 
in this series), indicating that the genetic defect makes them even more prone to 
the attacks. 
Fortunately, most of the patients we reviewed tended to recover from a severe to a 
mild residual paresis in the course of months to a few years. This is still in contrast 
with many descriptions in the literature that usually report that 80-90% of the pa-
tients will have recovered after two to three years. [Tsairis 1972, Cruz Martinez 2002, 
Tonali 1983] This discrepancy can probably at least partly be explained by the differ-
ences in the definition of recovery used in the various reports. Recent studies have 
already reported less optimistic prognoses. [van Alfen 2000, England 1999, Geertzen 
2000] Still, our case series shows that almost a third of patients suffer from chronic 
pain, and the majority of both INA and HNA patients exhibit persisting functional 
deficits after an average follow-up of more than six years. The recovery rate was 
slow in most patients, especially when bearing in mind that in the Netherlands 
sick employees are evaluated six and 12 months after the onset of their illness when 
it is officially determined whether they are legally fit to return to work. Such a de-
finitive decision at that point in time is unrealistic for NA patients who may show 
further recovery for several more years. It is therefore recommended for attending 
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health professionals to communicate this and the patient’s status to the evaluating 
authorities.
As to incidence, although with this study we did not set out to obtain data on a pre-
defined population, during the course of the study we did see one fellow physician 
from our hospital (with a medical staff of 909) each year suffering from new-onset 
NA. And, even if this is by no means a solid way of calculating the NA incidence rate, 
it does suggest that NA is (much) more common than generally assumed. Finally, 
in many patients it took quite some time to arrive at the proper diagnosis, with 
a median period to diagnosis of 10.5 weeks and with the mean time at a lengthy 
43.8 weeks. The difficulty is probably due to an inability to recognize the clinical 
picture as that of NA, especially when patients present without the indicative 
winged scapula. In most patients, however, the typical pain at onset combined with 
a patchy paresis is pathognomonic for the diagnosis. An early identification may be 
essential, since it has been suggested that the attacks could be alleviated by immu-
nomodulating therapy in the earliest stage. [Suarez 1996] Our very preliminary data 
on patients treated with open-label corticosteroids suggests that in some patients 
it is possible to favourably influence the course of the symptoms. We did not find 
a favourable effect on long-term outcome, but this may well be due to the large 
interindividual variability in symptoms and courses inherent to the NA phenotype, 
making it difficult to find effects on a group level, and being further complicated 
by the variability in treatment and follow-up assessment in this patient group. A 
randomized placebo-controlled trial evaluating the effect of oral prednisone in the 
acute phase is now underway in the Netherlands.
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Figures
Figure 2. Percentage of patients with persisting pain for each of the five follow-up periods.
Figure 3. Percentage of patients with residual paresis for each of the five follow-up periods.
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Two cases of neuralgic amytrophy (idiopathic brachial plexus neuropathy) in chil-
dren are presented and combined with a review of the literature. Difficulties in es-
tablishing the diagnosis are illustrated, and we give an overview of the phenotype 
of childhood neuralgic amyotrophy and its distinctions from the adult type.
Pain, in adult cases present in over 95% of the cases, is less frequent in children, and 
its absence by no means excludes the diagnosis. In children under 8 weeks of age, 
the literature shows that a subsequent osteomyelitis of the shoulder or arm always 
seems to be involved, which warrants a close follow-up. Overall, recovery is less fa-
vourable in children, but when they fully recover they seem to do so in a shorter 
period of time than adults.
We conclude that neuralgic amyotrophy in children is distinct from the adult va-
riety, and that it has a definite place in the differential diagnosis of a sudden limp 
arm, even if it is painless.
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Introduction
Idiopathic neuralgic amyotrophy (NA) is a distinct syndrome characterized by se-
vere pain, usually in the shoulder or arm region, followed by paresis in a brachial 
plexus distribution. The disorder is also known as brachial plexus neuropathy or 
Parsonage Turner syndrome. In classic adult cases pain is a prominent feature of 
the diagnosis and occurs in over 95% of the patients. Sensory involvement, if any, is 
not prominent. Although recovery may take several months, the prognosis is re-
ported to be favourable, with more than 90% recovery after 4 years. The age of onset 
is usually between 20 - 40 years, the male to female ratio is 2.4 to 1.
Most attacks occur on the right side (53-95%), and 12-34% of the attacks is bilateral. 
[Wilbourn 1993] Attacks can also involve the lumbosacral plexus, in which case the 
disorder is called idiopathic lumbosacral plexus neuropathy. [van Alfen 1997] The 
etiology of the attacks in NA is thought to be immune-mediated, since they are 
frequently preceded by a nonspecific immunologic event. In 25% of the cases this is a 
preceding (viral) upper airway infection, and attacks have been described after vac-
cination, serum therapy, pregnancy and childbirth, or surgery. [Wilbourn 1993] NA 
occurs as an idiopathic disorder, but also has a familial form called hereditary neu-
ralgic amyotrophy (HNA). HNA is an autosomal dominant disorder with recurrent 
attacks of plexopathy, and some patients have hypotelorism or other dysmorphic 
features. In a number of families it is linked to chromosome 17q25. [van Alfen 2000]
Reports of children (< 16 years of age) with NA are rare. Before 1970 NA was not well 
recognized as a clinical entity in children, due to the outbreaks of poliomyelitis and 
its clinical similarities to NA. [Devathasan 1980] Even as a distinct clinical entity, 
NA remains a diagnosis by exclusion. This means that some additional investiga-
tions will always be necessary to rule out other diagnoses. Therefore, a work-up 
examination existing of general laboratory blood and CSF studies, infectious pa-
rameters and (neuro-) imaging is warranted. From about two weeks after the onset 
of paresis an EMG study can support the diagnosis of NA, by demonstrating den-
ervation in the affected muscles, not confined to the distribution of a single root or 
peripheral nerve, and excluding a polyneuropathy. Usually findings are limited to 
signs of axonal damage, although there are indications in adults that in the acute 
stage of an attack conduction blocks might be present. A completely normal EMG 
examination in the affected muscles (after the time for Wallerian degeneration to 
occur has elapsed) makes the diagnosis unlikely.
We present two cases to illustrate the typical phenotype of neuralgic amyotrophy in 
children and discuss the difficulties and possible pitfalls in establishing this diag-
nosis. The literature is reviewed and we combined our data to present an overview 
of the clinical features of childhood NA and it’s distinctions from the adult type.
Materials & Methods
Case I 
A male toddler presented at the age of 5 1/2 months with an acute loss of spon-
taneous movement in the right arm. Sixteen days previously he had received his 
third vaccination against diphteria, pertussis, tetanus, poliomyelitis, mumps, mea-
sles and rubella. A week after the vaccination his parents found severe pain when 
manipulating his right shoulder. The further medical and family history were un-
remarkable. Examination 18 days after the onset of paresis showed an otherwise 
healthy infant with a flaccid paralysis and areflexia of the entire right arm, with 
only a persisting grasp reflex on the right. There were no dysmorphic features.
EMG and median nerve SSEP examination showed an upper brachial plexus lesion 
on the right (C5-C7), with slowing of conduction velocities but no conduction block 
or signs of denervation. An enterovirus (Coxsackie A9) could be isolated from the 
faeces. Other additional investigations including general blood analysis, viral serol-
ogy, CT scan of the cerebrum and spine, and chest X-ray showed no abnormalities. 
Lumbar puncture was not allowed.
Follow-up examination 4 months later showed atrophy of the suprascapular and 
upper arm muscles on the right. The shoulder abductors and exorotators, elbow 
flexors and supinators and the wrist and finger flexors and extensors were paretic, 
without signs of improvement of strength or function of the right arm. The lat-
eral part of the right arm was hypesthetic. Follow-up EMG showed normal con-
duction velocities in the right arm, a total denervation of the right deltoid muscle 
and signs of partial denervation and reinnervation of the biceps and extensor carpi 
radialis longus muscles. Six months later only the signs of reinnervation persisted 
on the EMG. MRI scanning of the cervical spinal cord and brachial plexus region 
performed two years after the onset of the disease was normal. There was little or 
no spontaneous recovery of muscle strength in the following years, and the patient 
was maintained on a rehabilitation program to prevent contractures and optimize 
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functional ability. Because of the severity of his impairments, a transposition of 
the flexor digitorum superficialis III tendon to the extensor side of the wrist was 
recently performed in an attempt to stabilize the wrist.
Case II
A young boy presented at the age of 4 years and 8 months with an acute limp left 
arm and drooping of the right corner of his mouth on waking up. He had been ill for 
a week, with fever and coughing, and since one day also had a red face and pain in 
the right ear and neck region. The arm was never painful. Medical history included 
birth by cesarean section because of fetal distress at 37+4 weeks, hypospadias, atopic 
dermatitis and recurrent otitis media. He had been fully vaccinated. Family history 
for neuromuscular disorders was negative. Examination showed a sick boy with a 
right facial nerve paresis, including the branches to the eye and forehead, and a flac-
cid paresis of the left arm, proximally graded MRC 2/5 and distally 3/5. There was a 
hyporeflexia of the left arm without sensory disturbances. There were no signs of 
pyramidal tract or posterior column dysfunction and micturition was normal.
Routine blood studies showed no abnormalities, nor did a chest X-ray, and CT and 
MRI scanning of the cerebrum. Lumbar puncture was performed the same day and 
showed 20 leucocytes (15 monocytes) per ml, normal protein and also otherwise nor-
mal values. CSF virology studies for Herpes Zoster virus, Varicella Zoster virus and 
Epstein Barr virus, as well as paired serology samples for Mycoplasma Pneumoniae, 
Chlamydia Psittacosis, Q-fever, adenovirus, respiratory syncytial virus, Influenza A 
and B, and para-Influenza I-III were all negative.
Because of the fever, facial palsy and the presence of 20 leucocytes in the cerebros-
pinal fluid the patient was suspected of having a meningo-encephalitis. Treatment 
was started with aciclovir and amoxicillin. The fever and coughing, as well as the 
facial palsy subsided within a week. The flaccid paresis of the arm remained un-
changed however. An EMG study 11 days later showed a lack of voluntary contrac-
tion in the left deltoid muscle, with an occasional positive spike, and low CMAP 
voltages of the abductor pollicis brevis and abductor digiti minimi muscles on the 
left. The conduction velocities were normal, as were median nerve SSEP’s. The EEG 
was within normal limits for age.
Based on the above, the diagnosis of meningo-encephalitis was rejected and, al-
though there was no pain during the course of the disease, the paresis was diag-
nosed as a neuralgic amyotrophy of the left arm. The boy was given supportive 
physical therapy. Two months later there was still an extensive paresis of the left 
arm: deltoid, biceps and triceps muscles MRC grade 0/5, brachioradial muscle 2/5, 
extension and flexion in the wrist 3/5, finger extensors 3-/5 and finger flexors 4-/5. 
Nine months after the onset, the shoulder rotators and deltoid remain paralytic, 
but function in the elbow, wrist and hand has substantially improved (figures 1a 
and 1b).
Figures 1a and 1b.
Photographs showing a five year old boy (case II) from the front (1a) and back (1b), with marked 
atrophy of the left deltoid, supraspinatus and infraspinatus muscles, 9 months after the onset of 
neuralgic amyotrophy. Note the compensatory lifting and adduction of the shoulder by the trapezius 
and pectoralis major muscles to obtain maximum stability for arm movements.
   
Results
A review of the literature yielded 34 previously published cases of idiopathic NA in 
children. [Bale 1979, Charles 1980, Clay 1982, Devathasan 1980, Dussaix 1986, Gabriel 
1996, Kennedy 1989, Magee 1960, Martin 1973, Masson 1994, McCarthy 1999, Sadleir 
1998, Schott 1983, Serratrice 1992, Shaywitz 1975, To 1999, Tonali 1983, Tsairis 1972, 
Wang 1994, Young 1982, Zeharia 1990] Features of these cases including the two pa-
tients presented here are given in Table 1. The male to female ratio is 1.8 to 1 (18 
males, 10 females, 8 unknown). The median age of onset in these children was 3 
years (average 5), and both the left and right side seem equally involved (14 vs 13; 9 
unknown). There were no reports of bilateral plexus involvement.
neuralgic amyotrophy in children neuralgic amyotrophy in children
 
Table 1. Clinical features of 36 cases of childhood NA
age at onset sex side pain preceding event recovery author, year of  
      publication 
     
3d m L yes osteomyelitis full Sadleir  1998
3d f L yes osteomyelitis full Sadleir  1998
6d - R - osteomyelitis - Wang  1994
10d - R - osteomyelitis - Wang  1994
14d m L yes osteomyelitis full Sadleir  1998
24d f R no osteomyelitis full Clay  1982
4w - - - septic arthritis - Young  1982
5w - - - osteomyelitis partial Gabriel  1996
7w f R no osteomyelitis full Clay  1982
      
3mth - - - - - Devathasan  1980
3mth m - yes DTP vaccination - Tsairis  1972
5mth m R yes DKTP/HIB vaccination none present study
5mth m R yes DTP vaccination full Martin  1973
10mth m L yes upper airway infection full Charles  1980
11mth f L no fever none Bale  1979
16mth m R no otitis media partial Zeharia  1990
18mth m L yes EBV infection partial Dussaix  1986
2y6mth m L no upper airway infection full Charles  1980
3y6mth f L no upper airway infection full Bale  1979
4y8mth m L no otitis media none present study
5y m L yes vocal cord palsy full To  1999
6y m L no burn with tracheal HSV full McCarthy  1999
7y6mth m L yes trauma and fever partial Charles  1980
8y m - - - - Magee  1960
8y f R yes cervical adenitis full Masson  1994
9y - - - - - Magee  1960
9y m R yes upper airway infection partial Shaywitz  1975
9y f - - - - Tonali  1983
<10y - - - - - Devathasan  1980
11y - - - - - Serratrice  1992
11y f R no none full Zeharia  1990
12y m L no fever full Zeharia  1990
14y m R yes chickenpox partial Kennedy  1989
14y f R no none full Schott  1983
14y m R no none full Zeharia  1990
15y f L no none full Schott  1983
In over a third of the cases there was no pain during the course of the disease (13/36 or 
36%; 10 unknown). The main preceding events were (viral) upper airway infections 
(12/36 or 33%) and, in a subgroup of 9 newborns (< 8 weeks old) there was always a 
concomitant osteomyelitis of the shoulder or humerus, but no direct spread to the 
plexus region. The osteomyelitis usually became apparent days after the paresis of 
the arm, as opposed to the viral infection, which preceded the paresis by 3-15 days. 
In only 3 children the paresis was preceded by a vaccination: DTP after 2 and 3 days 
and DPTP/HIB after 15 days respectively. Typically, the episode of NA follows the 
second or third injection rather than the first. [Wilbourn 1993] The Coxsackie virus 
infection found in our first patient could also have been a direct luxating factor. An 
epidemic form of NA concurring with an outbreak of Coxsackie A2 virus has been 
described by Bardos and Somodska. [Bardos 1961]
Seventeen children (47%) made a full (functional) recovery, in 6 (17%) it was only 
partial and 3 children (8%) had made no recovery at all on a median follow-up of 6 
months (average 10 months). In 10 cases the outcome is unknown.
Discussion
The diagnosis of NA in children is not always obvious, especially when one or more 
of the distinct clinical features such as pain are lacking or difficult to assess. This 
may have unpleasant implications for the patients and their parents, as it can lead 
to unnecessary investigations, misdiagnosis, and inappropriate therapeutic inter-
ventions.
Children with idiopathic NA form a distinct subgroup within it’s clinical spectrum. 
There are a number of distinguishing features. Pain, in adults one of the hallmarks 
of the disease, occurs in only two-thirds of the patients under 16 years of age. This 
means that the absence of pain in a child with an acute brachial plexus palsy by 
no means excludes the diagnosis of NA. The differential diagnosis of a seemingly 
idiopathic and painless brachial plexopathy in children includes few disorders. The 
first is a bout of hereditary neuropathy with liability to pressure palsies, but in these 
cases there is often a positive family history as it is an autosomal dominant condi-
tion. [Gabrëels-Festen 1992] When in doubt, DNA analysis should be performed to 
exclude a deletion on chromosome 17p22. The other is acute or vaccination polio-
myelitis, but cases of purely asymmetric upper limb poliomyelitis are rare, and the 
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CSF usually shows signs of an aseptic meningitis. Finally, pseudoparalysis due to 
mechanical factors, e.g. in trauma, should be considered; but this will probably in-
volve some pain too.
When a child less than 8 weeks of age presents with an acute brachial plexopathy, 
follow up should be focused on the detection of an osteomyelitis of the affected arm 
or shoulder, since in the literature it appears to be a constant factor in NA occurring 
at this age. Children do not seem to have bilateral plexus involvement during the 
attacks, and the distribution is equal between the left and right side, possibly re-
flecting the influence of handedness as a predisposing factor in adults. As could be 
expected, in children a preceding upper respiratory infection seems even more fre-
quent than in adults (34% vs 25%). When such an immune-mediated event is present 
it supports the diagnosis. The frequent occurrence of these preceding events sug-
gests that they are an important contributing factor in the etiology of idiopathic 
NA. In this respect, NA could be considered the PNS variety of similar immune-re-
lated disorders in children such as acute chorea and acute ataxia.
Recovery in children is less favourable than in adults: less than half of the patients 
gained full recovery. Perhaps part of this difference could be explained by the lack 
of therapeutic trials in children. In adults, hopeful results have been reported from 
early treatment with immune-modulating agents such as prednisone. [Martin 
1974] In future cases an early trial of intravenous methylprednisolone or gamma-
globuline should be considered. With respect to recovery it also has to be pointed 
out that the average follow-up time in children was relatively short (10 months). 
Tsiaris et al have estimated recovery rates for adults with NA of 36% after the first 
year, 75% after the second and 89% after 3 years. [Tsairis 1972] The 17 children in the 
present study who did fully recover, did so in an average of 6 months, suggesting 
that the rate of recovery in children also differs from adults with NA. For an accu-
rate prognosis the family history is important, because patients with HNA suffer 
on average one attack per 6.5 years. [van Alfen 2000]
We conclude that neuralgic amyotrophy in children has distinct clinical properties, 
which sets it apart from the adult variety, and that NA has a definite place in the 
differential diagnosis of a sudden limp arm, even if it is painless.
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Lumbosacral plexus neuropathy (LSPN) is an idiopathic clinical syndrome charac-
terized by the sudden onset of neuropathic pain, followed by weakness and some-
times sensory disturbances in the distribution of the lumbosacral plexus. Prognosis 
is usually favourable, although complete recovery may take several months to years. 
LSPN is the lumbosacral counterpart of the neuralgic amyotrophy syndrome (idi-
opathic brachial plexus neuropathy). We present a patient who initially was misdi-
agnosed with a radicular syndrome, but illustrates the typical signs and symptoms 
of LSPN. We also give clinical and electromyographical criteria for the diagnosis of 
LSPN and review the literature.
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Introduction
Lumbosacral plexus neuropathy (LSPN) is a clinical syndrome characterized by (sub-) 
acute pain in parts of the area innervated by the lumbosacral plexus, followed by 
paresis, muscular atrophy and sometimes sensory disturbances. The pain is severe 
and neuropathic, and difficult to relieve. Sensory disturbances manifest themselves 
as paresthesias, and (or) hypesthetic, dysesthetic, or hyperpathic areas of the skin. 
The most striking feature however is the loss of muscle strength, which can vary 
from slight paresis (MRC grade 4/5) to a total paralysis of the affected muscles (0/5).
LSPN is the lumbosacral variant of neuralgic amyotrophy (brachial plexus neuropa-
thy). [Donaghy 1993, Russel 1994, Evans 1981, Sander 1981, Marra 1987, Verma 1994] 
The underlying cause of both disorders is unknown. In general, prognosis of LSPN 
is favourable. The clinical picture usually stabilizes after a few weeks, followed by a 
protracted period of recovery which may take from several months up to years. [Don-
aghy 1993, Russel 1994] As may be concluded from the abovementioned, lumbosacral 
plexus neuropathy is a disorder that should be included in the differential diagnosis 
of the radicular syndrome. However, neurosurgical intervention is never indicated 
in LSPN. [Russel 1994, Evans 1981, Sander 1981, Awerbuch 1991, Byrne 1987
In this paper we present a patient with LSPN, who illustrates the signs and symp-
toms, the course, and differential diagnosis of this disorder, and who was initially 
diagnosed as suffering from a radicular syndrome. Findings are discussed with a 
review of the literature. 
Case report
The patient was a previously healthy, young man aged 16 who one evening com-
plained of pain in the back, followed within a few hours by numbness and loss of 
strength in the left leg, again followed within hours by a very severe pain in that 
area which did not respond to 1200 mg of ibuprofen. The symptoms occurred dur-
ing a summer job which required stooping and lifting of heavy objects. Additional 
neurological and general history taking showed no other abnormalities. On physical 
examination a paralysis of the left iliopsoas, quadriceps, adductors, and gluteus me-
dius and maximus muscles was found (MRC grade 0/5). There was analgesia in the 
femoral nerve area. The patellar reflex was absent on the left; ankle jerks and plantar 
responses were normal. Electromyography showed signs of denervation in the left 
rectus femoris, adductor magnus and iliopsoas muscle; the paravertebral muscles 
were unaffected. Except for a raised protein concentration in the cerebrospinal fluid 
of 890 mg/l (normal values: 200-580 mg/l), laboratory tests showed no abnormalities.
At first, based on lower motor neuron symptoms and on a protruding disc found at 
the L2-L3 level on a CT-scan, the diagnosis of a ‘radicular syndrome’ was considered. 
It was rejected because signs and symptoms could not be explained by a lesion of 
one nerve root, and paralysis and sensory disturbances persisted in spite of thera-
peutic measurements consisting of bed rest, dexamethasone, analgesics and nerve 
blocks of several spinal levels. The patient was referred to our center.
Additional history taking showed that a few years before the patient had developed 
numbness in his fingers after walking with crutches for an evening. The family his-
tory revealed that his father had experienced episodes of similar symptoms brought 
on by pressure of his palms on the handlebars of a bicycle. Further family histo-
ry was blank. In the patient and his father, DNA analysis excluded a deletion on 
chromosome 17 indicating hereditary neuropathy with liability to pressure palsies 
(HNPP). [Gouider 1994] A therapeutic regimen consisting of physical therapy and 
rehabilitation was prescribed.
Follow-up 5 months later still showed paralysis of the left quadriceps muscle and a 
hypesthetic patch of skin extending from the groin to just below the left ankle. In 
addition there was a dysesthetic area from 10 cm below the left hip to the knee, and 
the occurrence of paresthesias in the left upper leg after exercise. Strength in the 
iliopsoas, adductor magnus and gluteii muscles had improved to MRC-grades 3/5, 
5/5 and 4/5 respectively, and a slow improvement in sensory function was noted. 
Electromyography showed signs of reinnervation in the iliopsoas muscle. Support-
ive physical therapy was continued.
Discussion
The clinical diagnosis of a lumbosacral plexus neuropathy is based on the dem-
onstration of a pattern of loss of muscle strength, asymmetrical hyporeflexia and 
sensory disturbances, that cannot be explained by a lesion of a single nerve root or 
peripheral nerve. Figure 1 shows the anatomical relationships of the various parts 
of the lumbosacral plexus and its peripheral nerves.
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Fig. 1. The lumbosacral plexus and its main peripheral nerves. There are many possible causes for painful disorders of the lumbosacral plexus; 
the most important of which are mentioned in Table 1. [Donaghy 1993, Russel 
1994, Evans 1981, Sander 1981, Marra 1987, Verma 1994, Awerbuch 1991, Byrne 1987, 
Thomson 1993, Zeharia 1990, Shukla 1987]
Table 1. Causes of painful disorders of the lumbosacral plexus
Based on the localization of his signs and symptoms, and because of the lack of a 
clear causal factor on additional examination, the patient presented by us is suffer-
ing from an idiopathic lumbosacral plexus neuropathy. Unusual clinical features 
in this patient are the onset of paresis before the onset of pain in the leg and the 
evolving of the complete clinical picture in a matter of hours. Generally, the disease 
starts with pain, and paresis is noted after 5-10 days progressing over the next few 
days or weeks, suggesting an especially severe form of the disorder in our patient. 
[Donaghy 1993]
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Criteria for making the diagnosis are, apart from the typical course mentioned 
above: (a) a clinical paresis, associated with electromyographical signs of denerva-
tion in muscles supplied by at least two lumbosacral segmental levels and innervat-
ed by at least two different peripheral nerves; (b) no EMG evidence of involvement 
of the paravertebral spinal muscles, proving that the lesion is located distally of the 
nerve roots; and (c) exclusion of all other causes of lumbosacral plexus neuropathy. 
[Evans 1981] The characteristic increase in pain brought on by raising the intra-ab-
dominal pressure in radicular syndromes is nearly always absent in LSPN. [Russel 
1994, Evans 1981] Except for an increase in cerebrospinal fluid protein concentration 
in some cases, extensive laboratory examination usually shows no abnormalities.
LSPN is still a fairly unknown syndrome. It is not included as a separate diagnosis 
in the ‘Classification of Neuromuscular Disorders’, but grouped under the same 
heading as HNPP. [World Federation on Neurology 1994] A search of the literature 
using the Electronic Reference Library (MEDLINE, 1966- 1995) and subsequent ref-
erences yielded nine publications with a total of 33 patients with LSPN. [Evans 1981, 
Sander 1981, Marra 1987, Verma 1994, Awerbuch 1991, Thomson 1993, Zeharia 1990, 
Shukla 1987, Awerbuch 1989] Characteristics, including the present case history, are 
summarized in Table 2. The age of onset varied from 2.5 to 81 years, with peak oc-
curences before 20 and between 40 and 60 years of age. In most cases there was (mo-
tor) involvement of both the lumbal and the sacral part of the plexus (15/31); in 10 
cases just the lumbal and in six just the sacral part of the plexus. Fourteen out of 25 
attacks were localized on the left, seven on the right, and four had bilateral plexus 
involvement. The male-to-female ratio was 12:15 (n = 27). In 11 (32%) of a total of 34 
patients recovery was complete. In the majority of these cases, recovery took place 
within 6 months (ranging from 5 days to 1 year for pain, and 1 months to 2 years 
for strength). When patients are divided in two age groups, recovery was complete 
in 63% (5/8) of people aged 14 or under, and in only 23% (6/26) of people of 15 or over. 
Three out of 27 people of whom these data were available were affected more than 
once.
A number of clinical subgroups can be distinguished in LSPN. The first consists of 
patients younger than 14 years of age, in which a striking feature is that in half (4/8) 
the cases the attack was preceded by an upper airway infection. In the adult group 
this occurred in only three out of 26 patients. Furthermore only 1 out of 7 children 
showed sensory disturbances on testing. It should be noted however that in chil-
dren, sensory dysfunctions can be difficult to assess. About half of the attacks in 
adults were accompanied by paresthesias,and in 1/3 objective sensory disturbances 
are observed. [Russel 1994, Evans 1981] Besides this, children more often show com-
plete recovery of motor and sensory function after an attack.
Another subgroup consists of patients with an atypical, chronic progressive form of 
LSPN; in this group good therapeutic results have been reported using intravenous 
human immunoglobulin preparations with adjuvant corticosteroids. [Verma 1994] 
From this we conclude that (a) prognosis of LSPN is more favourable if attacks occur 
at an earlier age, and (b) recovery is more protracted and less complete if there is 
(also) sensory dysfunction, a more widespread plexus involvement, and (or) recur-
ring attacks.
Table 2. Patient characteristics in literature and present case history
Pharmacological treatment of pain or plasmapheresis usually give only minimal 
relief of pain and discomfort. [Verma 1994, Awerbuch 1991] As yet, the best therapy 
consists of making the right diagnosis and preventing unnecessary surgical inter-
vention; and further of a combinationof pain treatment, physical therapy, coun-
selling and a supportive attitude towards the patient. The occurrence of attacks of 
LSPN after infections or other immunologically mediated events (such as serum 
therapy, intravenous injection of heroin after a period of withdrawal, or an atopic 
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constitution), and the improvement reported in a number of patients after intra-
venous administration of a human immunoglobulin preparation combined with 
corticosteroids, are indicativeof an immunologically mediated pathogenetic mech-
anism. [Donaghy 1993, Russel 1994, Marra 1987, Shukla 1987, Awerbuch 1989] A simi-
lar hypothesis has also been proposed for neuralgic amyotrophy (brachial plexus 
neuropathy), the upper extremity equivalent of LSPN. [Russel 1994, Sierra 1991]
In a retrospective study the incidence of neuralgic amyotrophy was estimated be-
tween 1 and 3 per 100,000 person years. [Beghi 1985] There are two possible explana-
tions for the fact that LSPN is much less commonly diagnosed. First, the less pro-
tected localization of the brachial plexus may make it especially vulnerable to all 
kinds of injury. [Byrne 1987] The difference in incidence could also be the result of 
an underestimation due to diagnostic confusion of LSPN with radicular syndromes. 
[Evans 1981] Lumbosacral plexus neuropathy is a severe clinical syndrome which is 
much less frequent than neuralgic amyotrophy, but is most likely underdiagnosed 
due to confusion with lumbosacral disc disease. For this reason we have asked your 
attention for this unknown disorder.
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We report the findings in 5 muscle and 3 sural nerve biopsies, and in 1 postmortem 
plexus specimen, of 6 patients with hereditary neuralgic amyotrophy (HNA). We 
found that the sensory nerves are definitely involved in HNA despite the mainly 
motor symptoms, and that lesions in nerves and muscles are more widespread 
throughout the peripheral nervous system than clinically presumed, but, simulta-




All patients fulfilled the existing criteria for HNA. [Kuhlenbaumer 2000] Their clini-
cal details have already been described in more detail elsewhere [van Alfen 2000, Arts 
1983], and are summarized in table 1.
Table 1. Features of HNA patients with nerve and / or muscle biopsy
The biopsy material, originally obtained to distinguish between HNA and HNPP 
in a time when DNA diagnosis for HNPP was not yet available, was re-examined. 
In 5 patients a muscle biopsy was obtained for routine staining with haematoxylin-
eosin (HE), NADH-tetrazolium reductase (NADH-TR) and myofibrillar ATP-ase, at 
various time points after the onset of the most recent attack. Three sural nerve bi-
opsies were taken at mid-calf level, and prepared for light and electron microscopic 
examination, including teased fibres studies, using standard techniques. In patient 
1, additional immunohistochemical staining was performed to detect T-helper and 
T-suppressor lymphocytes, macrophages and immunoglobulins. New and existing 
paraffin sections of the cervical and brachial plexus of patient II-7 described earlier 
by Arts and colleagues were systematically (re-)examined. [Arts 1983]
In 3 patients (1-3) an electrophysiological examination, including nerve conduction 
studies and electromyography was performed using standard techniques.
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Introduction
Hereditary neuralgic amyotrophy (HNA), or hereditary brachial plexus neuropathy, 
is a rare autosomal dominant disorder (OMIM 162100) linked to chromosome 17q25 
in a number of families. [Kuhlenbaumer 2001] Clinically, the picture is well-defined, 
and characterized by recurring attacks of acute and severe neuropathic pain, fol-
lowed by paresis and marked muscular atrophy. Attacks involve one or both of the 
brachial plexuses, but can also affect a lower cranial nerve, the phrenic nerve, in-
tercostal nerves or the lumbosacral plexus. [van Alfen 2000] Sensory involvement is 
usually absent or not prominent clinically, but on electrophysiological examina-
tion patients do have sensory nerve abnormalities. In addition, we and others have 
the clinical experience that peripheral nervous system involvement is not restricted 
to the clinically affected nerves. [Windebank 1993] This suggests a more dissemi-
nated disorder of the peripheral nervous system, although there is no evidence for a 
generalized neuropathy in HNA.
The pathophysiology of HNA is still unclear, and the underlying genetic defect is 
not yet known. Possibly it predisposes the patient’s peripheral nerves to subsequent 
auto-immune attacks. The pain and multifocal, scattered affection of nerves sug-
gest the phenotype of a mononeuritis multiplex. This raises the question whether 
the attacks in HNA could be a manifestation of an isolated peripheral nervous sys-
tem vasculitis.
Reports of histological findings in HNA are scanty; only 7 nerve biopsies and 4 mus-
cle biopsies have been described so far. [Windebank 1993, Klein 2002, Airaksinen 
1985, Arts 1983, Poffenbarger 1968, Smith 1971, Taylor 1960] This is understandable 
in such a rare and non-lifethreatening disease, especially since a nerve biopsy is no 
longer required to make the distinction between HNA and its main differential di-
agnosis, hereditary neuropathy with liability to pressure palsies (HNPP). This can 
nowadays be done by electrophysiological or DNA studies. [Andersson 2000, Gouid-
er 1994] We re-examined 5 muscle and 3 sural nerve biopsies of 6 HNA patients, per-
formed before DNA analysis of HNPP was available, and we revised the brachial 
plexus material obtained on postmortem examination previously described by Arts 
and co-workers. [Arts 1983]
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Fig 1. Findings in HNA biopsies
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Results
Muscle
Four out of five muscle biopsies were abnormal. In two biopsies (from patient 1 and 
3) typegrouping of type I and II muscle fibres was present, pointing to previous rein-
nervation (fig. 1a). The biopsy from patient 5 showed many (20%) so-called target 
fibres, pointing to recent de- and reinnervation (fig. 1b). In the biopsy of patient 
4, mean muscle fibre size diameter was different for various fascicles, which also 
points to a neurogenic condition. In none of the biopsies cellular infiltrations and 
signs of vasculitis were observed.
Nerve
Biopsies of two of the clinically unaffected sural nerves showed no abnormalities. 
The density of myelinated fibres in the clinically affected sural nerve was also with-
in normal limits. Occasionally a degenerating axon was seen. Two small fascicles 
showed a remarkable loss of large myelinated fibres (fig. 1c) and an occasional clus-
ter. Immunocytochemistry of this nerve did not show any inflammatory cells or 
immunoglobulin deposition.
Light microscopic examination of paraffin sections of the postmortem cervical and 
brachial plexus, which have not been reported on previously, showed a number of 
fascicles embedded in loose connective tissue. Fascicles of the cervical plexus showed 
no abnormalities. In the brachial plexus all but one fascicle also showed a normal 
density and a normal diameter distribution of myelinated fibres. However, one 
large fascicle was different. Density of myelinated fibres was markedly decreased 
and fibres were mainly of a small diameter, often grouped in clusters. In some seg-
ments of this fascicle large fibre loss was more pronounced. Endoneural collagen of 
this fascicle was substantially increased (fig. 1d). The bloodvessels in all nerve speci-
mens were unremarkable, and there were no signs of a tomaculous neuropathy (e.g. 
HNPP) in any of the biopsies.
Other studies
In 3 adult patients (1-3), extensive EMG and ENG examination revealed abnormali-
ties compatible with scattered axonal lesions in the distribution of the brachial, 
and in patient 1 also in the lumbosacral plexus. None had diffuse slowing of sen-
sory abnormalities, prolonged distal latencies, or signs of nerve entrapment as are 
found in HNPP. 
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of fibrinoid necrosis. [Klein 2002] Since the diagnosis of non-systemic peripheral 
nervous system vasculitis (NSPV) requires histological demonstration of both ves-
sel wall inflammation and necrosis, there is no definite evidence as yet that HNA is 
a limited form of NSPV.
Conclusions
Summarizing, the available histological data in HNA confirm that the disorder af-
fects the PNS more widespread than is clinically presumed, and yet affects individ-
ual nerves very focally, with lesions restricted to isolated fascicles. Sensory nerves 
are definitively involved in HNA, even though patients often do not mention other 
sensory symptoms than pain. The retrospective nature of this study of historical 
biopsy material did not allow for further conclusions on the underlying etiology 
of HNA.
Discussion
Here we report on the re-examination of unique histological material consisting 
of 5 muscle and 3 sural nerve biopsies, and a postmortem brachial plexus, of 6 HNA 
patients. This study allows us to characterize the histology of HNA more precisely.
Focal involvement
The signs of neurogenic lesions in the two clinically unaffected muscles show that 
the lesions in an attack of HNA are more widespread throughout the peripheral 
nervous system than is apparent on clinical evaluation. This is supported by the de-
scription of Arts and colleagues, who found that the biopsy of a clinically unaffected 
sural nerve showed a slight and focal decrease in the number of myelinated nerve 
fibres suggesting an axonal lesion in a few fibres. [Arts 1983] We also found evidence 
that HNA causes very focal lesions within individual nerves.
Even though the sural nerve is not the most likely nerve to find pathology in HNA 
patients, in whom the lumbosacral plexus is only affected in 12% of the attacks [van 
Alfen 2000], the one clinically affected sural nerve of one of our patients was ab-
normal, but only in two small fascicles. Convincing evidence of focal involvement 
of nerves was also found in paraffin sections of the postmortem brachial plexus 
specimen. The Epon-embedded 1 mm sections showed hardly any abnormalities, 
whereas one fascicle of the paraffin-embedded part of the brachial plexus was defi-
nitely abnormal. 
Sensory involvement
Of the now known total of 10 nerve biopsies in HNA, 8 were taken of a sensory nerve, 
one of a proximal motor fascicle of the median nerve, and one was the post-mortem 
plexus specimen. The finding of abnormalities in 6 out of 8 of the sensory nerves 
confirms that, although clinically the deficit is mainly motor, the sensory nerves 
are definitely also involved in attacks of HNA.
Pathophysiology
In our study and in all (except one) other studies on nerve, muscle or skin biopsies 
in HNA, signs of a necrotizing vasculitis were lacking. Klein and co-workers report-
ed multiple microvessels with epineural perivascular mononuclear inflammatory 
cell infiltrates, and active multifocal axonal degeneration in 2 of the 3 radial sensory 
nerves. Although the inflammation did involve the vessel wall, there were no signs 
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chapter 
Current insights into 
the immunology of 
neuralgic amyotrophy attacks
Introduction
Neuralgic amyotrophy (NA) is supposed to be an immune-mediated disorder and 
thought to be of autoimmune origin. A few authors therefore even choose to call it 
‘immune brachial plexus neuropathy’. [Suarez 2005] Previous reports suggest that 
NA is an organ-specific autoimmune disorder in which attacks are often preceded 
by immunologic events but also occur after mechanical or even psychological stress. 
In a few small studies evidence was found at the histological level that an inflam-
matory respons is mounted in the affected nerves in NA. This chapter summarizes 
the available evidence to support such an autoimmune hypothesis in NA. It will 
also consider whether autoimmunity is the sole pathophysiological mechanism in 
this disorder, and propose some ideas for further research in this area.
NA is an organ-specific autoimmune disorder
Generally speaking autoimmune diseases (AID) result from failure in the mainte-
nance of self-tolerance, and can be classified into two main groups: organ-specific 
and systemic. In organ-specific diseases local injury, inflammation, or dysfunction 
are produced by autoantibody or cell-mediated reactions against a specific target 
antigen located in a specialized cell, tissue, or organ. If one considers NA an autoim-
mune disease caused by focal inflammation in the peripheral nervous system (PNS) 
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ium, ‘stress’ (both mental and strenuous physical exercise), immunisations, and 
immunodulating therapies with interleukin-2 or interferone-alfa2. [van Alfen 2006, 
Suarez 1996, Bernsen 1988] An antecedent infection is the most common trigger (in 
44%), and in this respect NA resembles another immune-mediated postinfectious 
peripheral nervous system disorder, the Guillain-Barré syndrome (GBS).
 
In the majority of NA attacks (65.3%) [van Alfen 2006] the infection precedes the on-
set of NA by 1-7 days, in 16.3% the interval is 1-2 weeks. This time interval suggests 
that the infection itself is not a direct cause of the NA attack. Only in 8.2% of the 
patients symptoms start within 24 hours after the onset of the infection, which 
could imply that NA might be the consequence of a direct infection of the periph-
eral nerve structures in this small subgroup. We have occasionally seen patients 
with a classical NA phenotype that appeared to have been caused by direct infec-
tions with HIV or Borrelia Burgerdorferi, although in these cases the course in our - 
limited - experience was usually progressive instead of monophasic, and responded 
favourably to antibiotics.
Unlike in GBS [Jacobs 1998] there have been no systematic studies of the type of 
infectious agents that can precede NA, but in the literature many species of micro-
organisms have been associated with the disorder in individual cases, as shown in 
table 1. Table 2 shows other autoimmune events or disorders that have been asso-
ciated with neuralgic amyotrophy, also in sporadic or single cases. (References for 
both tables are found in table 3.) It seems that the actual trigger for an attack does 
not have to be very specific, as long as it ‘switches on the immunesystem’.
An interesting study on two other organ-specific autoimmune disorders that can 
similarly have many different antecedent viral infections, autoimmune hemolytic 
anemia and ITP, [Musaji 2005] recently postulated that the development of such an 
AID possibly requires two successive events. The first step is the production of au-
toantibodies with moderate pathogenicity, induced by B-lymphocyte polyclonal ac-
tivation, antigenic mimicry or another mechanism by the first infectious agent, that 
remain clinically silent. After a variable amount of time a cascade of events triggered 
by a second infection with one of many different viruses, and involving the secretion 
of pro-inflammatory cytokines followed by interferone-gamma production enhanc-
ing macrophage phagocytosis of autoantibody-coated target cells, excacerbates the 
autoantibody pathogenicity and leads to disease. It is tempting to speculate that a 
similar ‘double hit’ mechanism might play a role in the triggering of NA attacks.
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and combines it with the fact that no other tissue but the PNS is involved during 
the attacks, this would qualify it as an example of such an organ-specific AID. The 
idea that NA patients have an otherwise normal functioning immune system, i.e. 
without evidence of an immunodeficiency or vice versa a generalized autoimmune 
state such as in connective tissue disorders, is supported by the fact that in our large 
cohort study we found no evidence that other AID occur more often in NA patients 
than in the general population. [van Alfen 2006]
Clinically we presume that the attacks begin as the immune-mediated response to 
the peripheral nerves in the plexus is mounted over the course of a few hours. The 
intense pain in the acute stage is likely to be nerve trunk pain caused by damage 
to the nerves due to this local inflammatory response (with oedema and release of 
pain transmitters), and we usually assume that the time course and subsiding of 
this response can be inferred from following the pain intensity that usually starts 
to decrease after a few weeks. This course of events and the presumed duration of 
the immune-mediated response are not dissimilar to what happens during a ‘nor-
mal’ immune response to an infectious agent. This underscores that NA patients 
do not seem to have a general abnormality of their immune system per se. It also 
suggests they most likely react in an essentially normal way to a PNS auto-antigen 
aberrantly recognized as ‘non-self’.
NA is not a focal PNS vasculitis
One might speculate that phenotypically NA is a focal form of mononeuritis mul-
tiplex, but in none of the histologic reports conclusive evidence was found that NA 
is primarily due to a peripheral nervous system vasculitis, because the hallmarks 
of vessel wall inflammation and necrosis were never demonstrated [van Alfen 2005, 
Klein 2002].
Attacks are triggered by preceding immunologic events
NA as a postinfectious disorder
One of the main indications that NA is an immune-mediated disorder came from 
the fact that about half of the attacks are preceded by an event that could have trig-
gered the immune system, such as infections, surgery, pregnancy and the puerper-
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Table 2. Other immunogenic events associated with neuralgic amyotrophy
Autoimmune disorders
  • SLE
  • giant cell arteriitis
Other disorders
  • Hodgkin’s disease
  • Monoclonal gammopathy with plasmacytoma
  • Addison’s disease
Iatrogenic: during treatment with
  • Interleukin - 2
  • interferone - alfa 2
  • DTP vaccination
  • smallpox vaccination
  • tetanus toxoid
  • streptokinase
  • benzylpenicilline
  • cytosine arabinoside
  • lamotrigine hypersensitivity
  • desensitizing anti-allergy therapy
  • contrast media: iohexol, meglumine
There are also patients who had no obvious immunologic preceding event but de-
scribed strenuous physical activity as a possible trigger. And since there are many 
patients (46.8%) that have not noticed any preceding event whatsoever, neither in-
fection nor mechanical stress seem to be able to explain the whole story of the onset 
of NA attacks. Colloquially phrased it appears that ‘many things have to go wrong 
at the same time’ to actually trigger an attack. This is underscored by the finding of 
asymptomatic carriers and the relatively low number of symptomatic episodes in 
hereditary neuralgic amyotrophy (HNA). HNA patients do have even higher recur-
rence rates (75%) than patients with the idiopathic form (INA), and this is probably 
explained by the addition of a genetic factor further enhancing susceptibility. Still 
it is very unusual for a hereditary disorder to have on average only 6 symptomatic 
episodes in a lifetime, and this in turn suggests that genetic factors alone are like-
wise insufficient to explain the occurrence of attacks.
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Table 1. Micro-organisms associated with the onset of neuralgic amyotrophy

















Other contributing factors triggering an attack
There are two interesting reports of NA epidemics that show that in addition to a 
preceding infection mechanical factors or a specific genetic background may also 
be a prerequisite to trigger an attack. The first epidemic occurred from 1949 to 1953 
in the northeast of Czechoslovakia. [Bardos 1961] During this 4-year period 265 
cases were noted, with an incidence rising from 1.1/103/year in 1949 to 7.3/103/year 
in 1953; which means a 300-fold increase compared to the overall incidence. The 
highest incidence rates were found in one particular factory among workers op-
erating a hosiery knitting machine, which involved holding their bent right arm 
outstretched at 100° elevation for 8 hours a day. The number of new cases showed a 
sharp decline when in November 1953 the main water supply in the lodgings hous-
ing factory personnel were replaced. In many affected workers Coxsackie virus type 
A2 was isolated from stool.
A second smaller-scale outbreak of NA occurred from April to June 1997 in the 
southwest of the United States of America in a native American Indian population, 
where 8 people became affected after an antecedent viral illness that was not further 
specified. [Augé 2000]
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on’ by a similar mechanism as described above for autoimmune hemolytic anemia 
and ITP.
Humoral immune mechanisms
Additional evidence for autoimmunity in NA was found during the acute phase 
of an attack in one patient with a preceding upper respiratory tract infection, by 
showing increased levels of soluble C5b-9 complement with a slightly decreased 
level of C3, but without an increase in the C4 and CH50 levels or signs of immune-
complexes. [Vriesendorp 1993] Immune-complexes had previously been implicated 
as a pathogenic mechanism in NA because of the phenotypical similarities with 
serum sickness brachial plexopathy in which immune-complex formation is the 
main mechanism, but this report did not confirm that hypothesis. The comple-
ment levels had diminished 2 months later. 
In the same study serum anti-peripheral myelin antibodies were also found in 3 
patients. [Vriesendorp 1993] The authors suggested that these findings were relat-
ed to the complement levels, that could have been due to secondary activation of 
the alternative pathway because of peripheral myelin protein exposure due to the 
primary inflammatory damage within the plexus. In our clinical cohort we also 
found several patients with anti-ganglioside antibodies during various stages of 
the attacks [van Alfen 2006], mostly of the anti-GM1 IgM type. Anti-ganglioside an-
tibodies have been found in several autoimmune peripheral nervous system disor-
ders such as the Guillain - Barré syndrome, multifocal motor neuropathy, chronic 
inflammatory demyelinating polyneuropathy and even in motor neuron diseases. 
[Ariga 2005] For some antibodies there is strong evidence that they are involved 
in the primary pathogenic process, such as anti-GM1 in GBS [Yuki 2004] and anti-
GQ1b in Miller Fisher syndrome, but in others disorders there is still controversy 
as to their specific role in the pathogenesis and it is suggested that their finding 
might be a secondary phenomenon. The same currently applies to NA.
An interesting property of anti-GM1 antibodies seems to be that they increase the 
permeability of the blood-nerve barrier, and their generation during an attack 
could make the nerves even more vulnerable to the ongoing immune process. Addi-
tionally, anti-GM1 antibodies are thought to be able to cause nerve dysfunction by 
inducing sodium and/or potassium ion channel dysfunction at the nodes of Ran-
vier, thereby possibly contributing to the extent of axonal failure during an attack. 
In GBS their presence is thought to lead to axonal damage by either macrophage 
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From epidemiology to the cellular level
A major problem remains that the target of the supposed autoimmune attack, the 
peripheral nerves in the brachial plexus, is not easily available for detailed direct 
histological, molecular or immunological analysis when the inflammatory proc-
ess is present during the onset of a NA attack. After the acute phase this type of 
investigation will probably only yield non-specific findings as remnants of previ-
ous damage, but provides no information as to the cause. As an example the one 
postmortem plexus specimen reported in our histological review (JNNP 2005] illus-
trated this with only non-specific very focal loss of large myelinated fibre in a single 
plexus fascicle. Below the few studies that have been able to collect data in the more 
acute stages of an attack are summarized.
Cellular infiltrates
Peripheral sensory nerve biopsies in the (sub-)acute stage showed signs of epineural 
perivascular mononuclear T-cell inflammatory cell infiltrates, in one case with an 
germinal centre containing CD20+ B-lymphocytes, and active multifocal axonal 
degeneration. [Klein 2002, Suarez 1996] The infiltrates were also observed around a 
dorsal sensory spinal ganglion.
This finding of CD20+ B-lymphocytes is interesting, because these lymphocytes have 
been implicated as a possible causative factor in a number of human autoimmune 
disorders, by maintaining autoreactive T-cell activation. In a review of this subject 
[Edwards 1999] it was also noted that autoantibodies can even arise spontaneously, 
by random immunoglobulin gene mutation during the immune response to any 
antigen. Normally such autoantibody producing B-cells would not survive. But 
if the mutated autoantibody would happen to stimulate or mimic T-lymphocyte 
cytokine activity necessary for B-cell survival or shift the balance from unbound 
to bound complexed antigen, than the autoreactive B-cell clone could become self-
perpetuating.
Of course this autoreactive B-cell theory cannot explain the whole story in NA, be-
cause the attacks are self-terminating within a few weeks (after which the patient 
is left with the damage for years), but this in turn could be due to additional regu-
latory mechanisms. However, one thing this theory does suggest is that even in 
the absence of a primary mimicry-inducing infection it is possible that autoreac-
tive antibodies are generated, which could then cause the attacks when ‘switched 
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destruction of axons at the Ranvier nodes, complement-mediated nerve-terminal 
destruction or reversible pre- and postsynaptic blockade of neuromuscular trans-
mission by IgG at the motor nerve terminal. 
T-cells in NA show a mitogenic response to brachial plexus extracts
Probably the strongest evidence for an autoimmune etiology in NA to date comes 
from a study that determined T-lymphocyte subsets in blood of NA patients dur-
ing the first 2 - 8 weeks after the onset of pain, and subsequently examined the 
proliferative response of their lymphocytes cultured with different post-mortem 
nerve extracts from normal subjects. [Sierra 1991] They found decreased CD3 values 
and increased CD4/CD8 ratios due to a decrease of CD8 + T suppressor-cytotoxic 
lymphocytes, indicating the involvement of different lymphocytic subsets in NA. 
This subset profile had been reported earlier in other autoimmune nervous sys-
tem disorders such as GBS, multiple sclerosis, recurrent Bell’s palsy and idiopathic 
polyneuritis. It is unknown what the role of T-cells found in NA is exactly. Just as in 
GBS they could be involved in the pathogenesis of the attacks in a number of ways, 
but could also serve to regulate or even terminate the immune response, depending 
on the subtype present. [Cshures 2005]
The most interesting result of this study was that lymphocytes from NA patients 
showed mitogenic activity in the presence of brachial plexus tissue extracts, es-
pecially the long thoracic nerve, but not to sacral plexus extracts. This response 
strongly suggests that the brachial plexus has a distinct molecular and antigenic 
make-up that sets it apart from other parts of the peripheral nervous system and 
makes it a target in NA.
NA patients have an underlying predisposition to the attacks
The recent finding that in INA patients the recurrence rate after a first episode is 
much higher (10-25%) than the incidence of NA in the general population (2-3/106/
year) [van Alfen 2006] strongly implies that these patients must have some sort of 
innate underlying susceptibility to the attacks. It is tempting to draw another ana-
logue with GBS and postulate that there are host factors that make these patients re-
act with a NA attack to certain types of preceding infections. These host factors could 
be immunological properties such as a specific HLA type or a genetically determined 
structural defect of peripheral nerve tissue that makes the blood-nerve barrier more 
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permeable for example, or maybe even both. Another option could be that the ‘dou-
ble hit’ phenomenon described above ensures a permanent low level of clinically 
silent autoantibodies in NA patients, that become pathogenic each time the patient 
comes into contact with another non-specific triggering immunologic event.
Discussion
How strong is current evidence for an autoimmune hypothesis in NA?
Immunologists classify evidence for an autoimmune pathogenesis in several cat-
egories of probability, that have been formulated by Witebsky in 1957 and later re-
vised by Rose and Bona in 1993.
But at the same time one could also argue that - even though indirect - arguments 
that support an autoimmune mechanism in both triggering the attacks and being 
involved in the local damage done to the plexus nerves are slowly accumulating. It 
does seem fair though to say that autoimmunity alone cannot explain or form the 
whole pathophysiological concept in this disorder. 
Immunology is only part of the story
Immune-mediated mechanisms may explain the occurrence of attacks, but do not 
yet tell us why one person is susceptible to NA while another is not. In patients with 
hereditary NA the genetic factor seems the most logical choice for an explanation 
of at least part of the underlying susceptibility. As INA patients are also more prone 
to the attacks it may well be that they too have a genetically determined change 
affecting the target organ, i.e. the peripheral nerves of the brachial plexus and its 
proximal constituents. And since there does not seem to be a general malfunction 
of the peripheral nerves in NA (such as a polyneuropathy that is for example found 
in hereditary neuropathy with liability to pressure palsies sometimes also present-
ing with recurrent brachial plexopathy) it has already been suggested that the sus-
ceptibility probably does not lie in the axonal or myelin components of the nerve 
but may be due to an alteration of its local connective tissue properties.
The mild dysmorphic features found in some HNA patients and the recent finding 
of a mutation in the SEPT9 gene in some HNA families could also point in that di-
rection. [Kuhlenbaumer 2005] SEPT9 is a gene that has a role in central spindle for-
mation during cytokinesis (the division of the cytoplasm of a cell after the nucleus 
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has divided) [Surka 2002]. Experimental disruption of the transcript protein result-
ed in either total failure of cytokinesis with binucleated cells as a result, arrested 
cytokinesis resulting in bridged cells linked with a DNA-containing midbody, or 
a daughter cell with abnormal morphology and condensed DNA resembling apop-
tosis. The SEPT9 gene also forms filaments and co-localizes with cytoskeletal ele-
ments such as actin and tubulin, suggesting it has a structural function in the cell 
too. Why such a mutation would make the nerve more susceptible to autoimmune 
attacks is still unknown. One might speculate that it could cause connective tissue 
or Schwann cells to fail to complete their cell division, thus leaving cellular remains 
to be removed by the immune system with the risk of generating autoantibodies 
in this fashion. A similar mechanism may play a role in attacks that are preceded by 
strenuous physical exercise that could have focally damaged the nerve structures.
In summary, the available evidence suggests that neuralgic amyotrophy is a disor-
der with a complex pathophysiological mechanism in which autoimmune, genetic 
and external factors all seem to play an interwoven role.
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the neuralgic amyotrophy consultation
Introduction
In the authors 10-year experience neuralgic amyotrophy (NA) is still relatively un-
known to many physicians, even though the clinical picture is usually typical. The 
initial diagnosis is very often thought to be shoulder joint pathology or cervical 
radiculopathy. Patients with NA are usually first seen by a family physician and re-
ferred to neurologists and/or orthopedic surgeons, but maybe even more frequently 
to and subsequently by physical therapists, especially in the initial phase when the 
diagnosis has not yet been established. One of the major problems in diagnosing 
neuralgic amyotrophy is that the course and localisation of both pain and paresis 
can vary considerably among patients, and even among recurrent attacks in one pa-
tient. Sometimes the only signs of an attack are an annoying pain in the upper arm 
lasting a few hours with a subsequent loss of pinch grip for a few months, caused by 
a lesion of the anterior interosseus nerve. Or conversely, the patient may have suf-
fered from severe pains in both shoulders and arms for weeks on end, has a serious 
orthopnea requiring nocturnal positive pressure ventilation, and cannot use either 
of his or her arms or hands in daily life for several years because of severe bilateral 
plexus damage with involvement of both phrenic nerves. 
This chapter aims to provide the neurological practitioner with an update on the 
clinical features of neuralgic amyotrophy and a practice-based overview of the cur-
rent diagnostic and treatment options. Numbers and percentages are derived from 
a recent study of a large cohort of patients. [van Alfen 2006] They will be presented 
in the form that follows our daily practice most closely, the consultation, with sec-
tions of background information interspersed where appropriate.
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Further questions
• Have you ever had this before? 
• Or did you ever have a painless wasting of muscles or a protruding shoulder blade?
• Is there anyone in your family who had something like this?
• Do you or did you have a carpal tunnel syndrome or dropfoot? Anyone in your 
 family?
 
Background information 1. NA pain
Acute phase:
One of two most typical findings in NA is the initial pain that occurs in 96% of all 
patients. In 61% is starts at night or in the early morning and usually increases to 
maximum severity in a few hours. Then it has almost invariably become very severe, 
and unlike anything the patient experienced before (unless he or she had a previous 
attack). Instructing the patient to grade the pain on a scale of 0 to 10 - 0 being no 
pain and 10 the most severe pain imaginable - is an illustrative way of making this 
clear, because initially 60% and subsequently 90% of the patients will have such a 
NRS (Numerical Rating Scale) score of 7 or more, and the median NRS is 8 at onset 
and 9 at maximum intensity.
The pain can also have a stuttering onset, and it can take up to two weeks or more 
for paresis to develop. Pain is usually worse at night and 94% of the patients cannot 
sleep because of it. Typically standard attempts to mitigate it by assuming certain 
postures or using acetaminophen or NSAIDs provide no relief whatsoever, and pa-
tients often told that the pain had them up all night sitting on the couch with their 
arm pressed tightly against their body, sometimes having them crawling desper-
ately on the floor not knowing what to do anymore. It is a story not lightly forgot-
ten once heard, and your next patient will probably recognize it too, making it a 
useful diagnostic tool.
Subsequent pain types:
Once the acute stage of an attack is over, i.e. the initial pain has subsided and a 
patchy paresis and atrophy have become evident, 77% of the patients will go on to 
suffer from one or two additional types of pain. First the damaged nerves in the 
plexus can give rise to an increased mechanical sensitivity, eliciting shooting or ra-
diating neuropathic pain in the affected nerves’ territory by putting strain on them 
through extension, abduction or elevation of the arm (a ‘Lasègue sign’ of the arm). 
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History
Although the time for consultation is usually limited, it is worth while using a lit-
tle bit more of it to take an effective history in cases of acute or severe arm pain and 
sudden paresis and atrophy. Especially when patients are referred for a second opin-
ion or have already formed their own as to the cause of their symptoms it can be 
difficult to elicit a ‘clean’ history not influenced by other peoples (doctors, physical 
therapists, worried family and friends) ideas, and get stranded in a recapitulation 
of all the tests done and therapies prescribed. Below are some questions the author 
has found useful in daily practice. See also background information sections 1 and 2 
on NA pain and motor and sensory symptoms.
The onset of an attack:
• Tell me again: what went wrong with your arm and when?
•  Be honest: how much did it really hurt in the beginning (on a scale of 0 to10)?
• Did the pain disturb your sleep?
• What did you take for your pain? did it help at all?
• How long did that initial pain score last?
• When did you notice that certain movements or postures became difficult?
• Has moving or using your arm overhead become difficult for you?
• Did you see or feel your shoulder blade protrude?
• Did you notice any tingling or numb sensations?
• Did you have other symptoms like hoarseness or shortness of breath lying down 
 or bending over?
• Was the onset preceded by an infection, surgery, pregnancy or giving birth, stress 
 etc? 
Course and recovery
• Do you still have pain?
• If so, is it different from that at onset?
• Can you provoke it? How? (stretch sensitive or postexercise muscular)
• Have you noticed any recovery yet? (e.g. is the shoulder blade back against the 
 chest wall at rest etc.)
• Are there certain activities in daily life that you cannot do anymore? How about 
 work and sports?
• Have you stopped working / have you tried to work again?
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with pain and sensory symptoms only, frequently in the distribution of the lateral 
cutaneous antebrachial nerve.9 In 15% of the attacks there are signs of distal auto-
nomic nervous system dysfunction (e.g. hand oedema, vasomotor instability). Addi-
tionally, nerves outside the distribution of the brachial plexus can also be involved, 
and this occurs in 56% of the attacks in HNA patients and in 17% of the attacks in the 
idiopathic form. They usually involve the lumbosacral plexus (usually in a lumbar 
trunk distribution), phrenic nerve or recurrent laryngeal nerve, but occasionally 
more ‘exotic’ structures such as the facial or abdominal nerves may be affected too.
One of the main pitfalls in the diagnostic phase is that the patients tend to com-
plain about that part of their shoulder or arm that is most impaired by either pain or 
paresis, but hardly notice or give attention to other, lesser impairments in strength 
or sensory loss. About a third of the attacks have bilateral involvement that usually 
is asymmetrical in its severity, so here too one side can easily get overlooked. As a 
clinician one should be aware of this, and supplement the history by a meticulous 
physical examination that specifically pays attention to those muscles or skin areas 
the patient doesn’t mention. Omitting this increases the chance of either diagnos-
tic errors (e.g. making the clinical diagnosis of a mononeuropathy or radiculopathy 
instead of a plexus lesion) or difficulty in correctly explaining certain symptoms, 
such as mistaking an unstable and downwardly displaced scapula for an atrophy 
of the trapezius muscle, or its following inability to move the arm overhead for a 
deltoid paresis. 
Physical examination I: from the back
Because NA attacks frequently involve the proximal or upper parts of the brachial 
plexus it is advisable to have the patient undress their chest, neck, and arms and 
start with an inspection of their shoulder and cervical spine region. Below is an 
example of the physical examination in an order the author has found efficient in 
daily practice. See also background information 3 on shoulder biomechanics.
_   Start with inspection at the back, standing behind the patient: where are the 
shoulder blades? Are they level? (put thumbs on spinae, compare) In case of ser-
ratus anterior weakness the shoulder blade sags 1-2 centimeters downward (be-
cause of the weight of the arm attached) and is usually also laterally displaced 
and the lower border medially rotated at rest. Winging, or a scapula alata, can 
be observed at rest but becomes more prominent with arm movement. If the 
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This hypersensitivity usually dissipates after weeks to months.
Additionally many patients also develop musculoskeletal-type pain localized to 
the origo or insertion of the paretic - or compensating - muscles, especially in the 
periscapular, cervical and occipital regions. This pain may be particularly therapy 
resistant and can sometimes be almost as incapacitating as the paresis itself. The 
main risk for developing it is probably scapular instability caused by a paresis of 
the serratus anterior, rhomboids or trapezius. If this leads to a caudal and lateral 
displacement of the scapula, all the muscles attached cranially and medially (from 
the occiput and cervicothoracic spine) will both become stretched and have be more 
active to compensate for the loss of scapular stabilization, giving rise to contrac-
tions that cause muscle pain and discomfort [Clarkson 2002]. For more details also 
see section on treating pain and complications.
Background information 2. Motor and sensory symptoms in NA
The second typical feature of NA, that can at the same time make it difficult to rec-
ognize by clinicians, is the patchiness of the motor and sensory symptoms. Histo-
logical studies had already shown that the pathologic, presumably inflammatory, 
process can cause very focal damage to one or a few of the fascicles that make up a 
brachial plexus trunk or cord or a peripheral nerve while simultaneously scattered-
ly affecting several parts of the plexus as a whole [van Alfen 2005, Klein 2002]. This 
is reflected clinically by a wide variety in the possible distribution - and severity 
- of paresis and sensory deficits. Any part of the brachial plexus, and clinically any 
muscle or skin area can be involved, in all sorts of combinations. Sensory symptoms 
or pain tend not to correlate with the localisation of the paresis. It is precisely the 
recognition of this patchiness that is a very important clue to the diagnosis of the 
plexopathy in NA.
Fortunately for the clinician there are several overall patterns of paresis that occur 
more frequently than others. An upper brachial plexus distribution - the periscapu-
lar and perihumeral muscles - is most common, and occurs in 71% of the patients, 
either with (50%) or without (21%) involvement of the long thoracic nerve that leads 
to an unstable or winged scapula. Women have symptoms in a middle or lower bra-
chial plexus distribution twice as often (23%) as men (11%), including symptoms that 
mainly affect the interosseus anterior nerve, with reduced pinch grip strength due 
to weakness of the long thumb and index finger flexors. Patients can also present 
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ing pain towards the lateral forearm or thumb. Likewise, involvement of the 
middle trunk will radiate towards the extensor side of the arm and to the hand, 
etc.
Physical examination II: the front
_   When the examination of the shoulder region is finished, stand in front of the 
patient and look at the diaphragm during deep inspiration and expiration - is 
there paradoxical movement (does the abdominal wall move inward and up in-
stead of downward and out during inspiration)? When present this is strongly 
suggestive of (hemi-) diaphragmatic paralysis, and a next test would be to have 
the patient bend over or lie down supine to check for orthopnea (which occurs 
due to even further restriction of the lung volume by upward movement of the 
abdominal contents in these positions).
_   Test elbow, wrist and finger flexion and extension, and specifically the deep flex-
ors of the thumb and index fingers (weakness points to involvement of the an-
terior interosseus nerve), wrist pronation and supination, and finger abduction. 
For more selective testing of elbow flexion and pro- and supination have patient 
adduct the flexed arm against the chest. Always support the proximal part of the 
joint which muscle you’re testing with your other hand when applying force for 
MRC 4 or 5.
_   Comparing left to right, test pinprick sensation over the shoulder blades, neck, 
lateral upper arm, ventral and dorsal sides of arm and forearm and hand for vital 
hypaesthesia. Look at the forearm and hands for signs of vasomotor instability 
indicating focal autonomic system dysfunction.
_   When suspected from history, test for patchy leg weakness or sensory defects 
 
Background information 3. Shoulder biomechanics
For most clinicians the biomechanics of shoulder and arm movements are not part 
of daily practice. However, a little knowledge about the anatomical relations be-
tween the scapula, chest wall and humerus will greatly facilitate the understand-
ing of why damage to certain parts of the plexus or peripheral nerves gives rise to 
impaired movements or joint complications that cannot be explained by paresis 
only. A good way to start is to realize that the scapula, through its glenoid cavity 
and acromial extension, forms half of the glenohumeral joint, i.e. the socket.
For fluent movements of the arm it is necessary that the other half, the humeral 
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affected shoulder appears to be higher than the unaffected side it is usually be-
cause the patient is compensating the downward scapular sagging by tensing 
the trapezius muscle; have them relax and you will see the drop at rest.
_   Look and feel for atrophy of periscapular, scapular, periglenohumeral and arm 
muscles groups, compare sides. Palpate the upper parts of the trapezius and the 
levator scapulae (a thick cord-like structure just anterior to the trapezius at the 
point where the neck changes into the shoulder) for hypertrophy and myalgia 
that point to strain of these muscles.
_   With your hands on both acromions and humeral heads, feel for an anterior 
subluxation of the humerus (will occur when scapula is caudally displaced or 
supraspinatus is weak).
_   If possible test all individual periscapular and periglenohumeral muscle groups 
for MRC grade, first 3 (patient only, makes full movement against gravity) then 
to 5 (physician provides maximum resistance).
_   At least test maximum forward movement of the arm (scapula should push the 
arm forward and move several centimeters to a more anterior position on the 
chest for MRC 3, then push the arm back for maximum strength testing: the 
scapula may not move for MRC 5), have patient shrug shoulders (quick test if 
trapezius is < MRC 3), adduct shoulder blades + put thumbs between them and 
move hand off body (quick test rhomboids < MRC 3), and test exorotation of the 
arm (infraspinatus muscle) and abduction (test below 80 degrees lateral eleva-
tion if there is periscapular weakness).
_   Make a ‘large circle’ in two directions by having the patients slowly abduct and 
elevate the arm in a coronal plane to the maximum of 170 degrees and then mov-
ing it downward in the sagital plane, and vice versa. Inspect the scapular motion 
(‘scapulothoracic rhythm’) outwards and inwards during this movement: is it 
normally fluent outwards and back or is scapular movement impaired or jerky 
indicating weakness of the serratus, rhomboids or trapezius?
_   Test glenohumeral joint for impingement by gently lifting the patients flexed 
arm to maximum abduction in the coronal plane while keeping your other hand 
on the acromion and humeral head; there should be no crepitation, restriction 
of movement or local pain in part of the arc, the humeral head should not lux-
ate (keep it fixed with your fingers to prevent this). Test for restricted capsular 
movement by passive arm exorotation, compare to contralateral side.
_   During the previous test it is also possible to note any mechanical stretch sensi-
tivity of the affected nerves (a ‘Lasègue of the arm’). If the upper brachial plexus 
is most affected, moving the arm up and towards the back usually elicits radiat-
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displacement of the scapula on the chest wall in case of serratus weakness also leads 
to a changed position of the glenoid and acromion at rest which makes the humeral 
head protrude - or subluxate - anteriorly.
When in doubt whether insufficient scapular movement or paresis of the deltoid 
is responsible for decreased arm abduction, try fixating the scapula by compress-
ing it against the chest while exerting counterpressure with the other hand placed 
underneath the patients arm anteriorly on the chest. In case of pure serratus weak-
ness the patient should now be able to lift the arm more easily to maximally 110° (to 
complete this motion to 170° elevation scapular movement is required). 
The periscapular – serratus anterior, trapezius, rhomboid - muscles are not just 
important for abduction and elevation of the arm. They also serve an important 
postural function in stabilizing the scapula to provide a fixed support for any arm 
and hand movements in front of or behind the trunk. In this capacity they have to 
be active in any body posture except when lying supine. This means that even when 
sitting or walking these muscles need to be active, and that these activities will 
cause symptoms when some of them are paretic. When scapular instability and im-
paired motion is present patients often subconsciously attempt to compensate and 
increase stability by adducting the shoulder through contraction of the trapezius, 
in addition with lateroflexion of the trunk to the contralateral side to elevate the 
affected shoulder further and facilitate abduction by helping tilt the humeral head 
anteriorly. Although in itself at least partially effective, this strategy frequently 
leads to myalgia in the trapezius and paraspinal muscles due to strain.
Differential diagnosis
Once heard or seen before, neuralgic amyotrophy is a very distinct clinical syn-
drome 95% of the time, that can usually be recognized from the patients history 
only. There are very few if any disorders in the shoulder or arm region that are só 
extremely and non-abatingly painful at onset, and once the patchy paresis or atro-
phy sets in the diagnosis should be readily apparent.
However, there are some disorders that can mimic this clinical picture (see table 
1). In the shoulder and arm cervical radiculopathies typically present with posture-
dependent radiating pain and sensory disturbances, and sometimes paresis, in the 
corresponding dermatome. As they are usually caused by nerve root compression 
due to degenerative spinal column disease, they occur most frequently at the lev-
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head, remains approximately centered in its socket during the whole range of mo-
tion. This is normally achieved through two simultaneous mechanisms: rotation of 
the scapula to optimize the position of the glenoid cavity, and the action of several 
muscles that lift, depress or rotate the humeral head during abduction to ensure its 
optimal position (fig. 1* and 2*). These two mechanisms must be able to work in a 
well-coordinated fashion because otherwise there is a real chance that the humeral 
head will get impinged against the acromion, initially compressing elements of the 
interposed rotator cuff and subsequently making further movement mechanically 
impossible due to collision of both joint surfaces. The rotator cuff is made up of the 
supraspinatus, subscapularis, teres minor and biceps tendons. At rest, the humeral 
head is also kept in place by the action of the deltoid muscle. Weakness < MRC 3 
of this muscle can lead to sagging of the humeral head itself, creating a dynamic 
subluxation that depends on the residual strength and fatigue of this muscle. Vice 
versa if the deltoid is unaffected but the other cuff muscles are weak it can also lead 
to a dynamic impingement because of unopposed cranial elevation of the humeral 
head during deltoid contraction (fig. 2*).
 Figure 1.            Figure 2.
   
For fluent abduction of the arm at level of more than 80° elevation scapular sup-
port of the humeral head is indispensable. The arm has to be tilted up and outward 
by contraction of the supraspinatus and deltoid, which can only be fully achieved 
when the rotated humeral head is supported from below by the scapular socket to 
be moved further up and out. This means that an impairment of scapular move-
ment, e.g. when the serratus anterior is < MRC 3, automatically means that abduc-
tion and elevation will be impaired above this level, even when the deltoid supply-
ing the force for this movement is completely intact. The downward and lateral 
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* Figures with kind permission from K. van Nugteren, adapted from ‘Orthopedische Casuïstiek’)
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2 Is there a limitation of passive arm exorotation or abduction? If no: NA likely. If 
 yes: shoulder joint pathology (bursitis, tendinitis calcarea) likely.
3. Are all symptoms, i.e. pain, paresis and sensory disturbances in the same root 
 distribution? If no: NA likely. If yes: cervical radiculopathy likely.
Table 1. Clinical mimics of NA 
Differential diagnosis: How is it different from NA:
cervical radiculopathy, degenerative insidious onset, slowly progressive
cervical radiculopathy, disk rupture acute onset, pain varies with posture, pain, 
 paresis, sensory symptoms in same dermatome
mononeuritis multiplex / PNS vasculitis symptoms start in legs or distally in arm, subacute 
 onset, progressive, less extreme pain that remains
multifocal motor neuropathy painless, no sensory symptoms, distal paresis i.e. in 
 forearm predominate, slowly progressive
brachial amyotrophic diplegia (focal  insidious onset, painless, slowly progressive 
motor neuron disease; very rare) 
shoulder joint pathology pain luxated by joint movements or posturing, 
 usually relief at rest, passive restriction of 
 movement
Etiological diagnosis
Although neuralgic amyotrophy can manifest itself by symptoms in the distribu-
tion of a single nerve (e.g. long thoracic) or root only, it usually presents as a brachial 
plexopathy meaning that the symptoms cannot be explained by a lesion of a single 
nerve root or peripheral nerve.
When the clinical diagnosis of a brachial plexopathy has been made, the etiological 
possibilities are usually limited (see table 2). Many plexopathies are either caused by 
direct trauma (e.g. a motor vehicle accident) or iatrogenic damage such as following 
radiation or surgery. The lower brachial plexus lesion seen in patients with a Pan-
coast tumour has a distinct, ominous course, with progressive pain and sensory dis-
turbances and eventually paresis, spreading from the T2 and T1 segments to more 
proximal sites as the tumour grows. A Horner’s sign should alert the clinician to 
this etiology, as it usually not seen in NA. A similar typical lower plexus distribu-
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els that suffer the largest amount of mechanical strain during life. The estimated 
incidence of these radiculopathies is highest at the C7 level (150/106/year), and de-
creases exponentially towards more cranial levels (C6: 40/106/year, C5: 4/106/year). 
When they present in an acute fashion it is likely that the cause is a disk rupture 
with herniation, which usually occurs at a single level at a time. If there is a pro-
gressive degenerative spondylosis with foraminal stenosis patients can suffer from 
radiculopathies at multiple levels simultaneously, but will present with gradually 
progressive symptoms.
A true mononeuritis multiplex, i.e. a peripheral nervous system vasculitis, can give 
rise to multiple, progressive focal nerve lesions in the arms. As the chance of being 
affected by such a vasculitic process is highest in the longest axons, patients usually 
also suffer from focal neuropathies in the legs and will often progress to a polyneu-
ropathy-like distribution of their symptoms. Multiple focal paresis in the arm can 
also be found in multifocal motor neuropathy, a patchy, painless, and pure motor 
inflammatory peripheral nervous system disorder with a predilection for the fore-
arm. Sometimes a carpal tunnel syndrome can present atypically, with pain and 
paraesthesias radiating up the arm to the shoulder region. Rarely, a brachial plex-
opathy-like distribution is seen in a focal subtype of motor neuron disease called 
brachial amyotrophic diplegia.
Of course non-neurological disorders, such as inflammatory or degenerative shoul-
der, elbow, or wrist joint disease also present with pain and limitations of upper 
extremity movements. ‘Shoulder complaints’ for example, are very common in the 
general population, with an estimated incidence of around 1500 / 100.000 / year. Care-
ful examination will usually reveal the arthrogenic cause, and sensory symptoms 
or a real paresis are typically not seen with these disorders. It can be difficult to rule 
out a paresis clinically though, for example in cases with a biceps or supraspinatus 
tendon rupture resulting in an inability to convey muscular contraction strength 
to the joint, or movements resulting in increased pain that prevents any further at-
tempts at motion. Correctly identifying these symptoms as non-neurological will 
require an adequate index of suspicion and appropriate testing from the examiner.
A simple three-step way to diagnose NA and differentiate it from its most common 
differential diagnostic entities would be the following:
1. Is the pain acute, very severe (NRS score >7) and unlike anything the patient had 
 before? If yes: NA likely. If no: NA possible, consider other diagnoses.
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is really progressive, as would be expected in case of a neoplasm, or slowly improv-
ing as it will in idiopathic cases. Rarely another seemingly idiopathic and some-
times also painful brachial plexopathy can be seen in a patients with a hereditary 
neuropathy with liability to pressure palsies (HNPP), in which a relatively minor 
stretch or compressive trauma can damage the vulnerable nerves. These patients 
usually - but not always - have a (family) history of compressive neuropathies at 
other sites (e.g. carpal tunnel syndrome or dropfoot), and signs of a polyneuropathy 
when they are older. HNPP can nowadays be confirmed both at the electrophysi-
ological and DNA level.
Ancillary investigations
Laboratory investigations can show some abnormalities in about 25% of the pa-
tients (signs of previous infection, mildly elevated CK, elevated liver enzymes prob-
ably related to preceding infection, antiganglioside antibodies, slightly increased 
CSF protein content), but usually these findings do directly not contribute to the 
diagnosis. In typical cases laboratory investigations are therefore unnecessary, but 
if patients are in any way at risk it can be wise to rule out a direct infectious cause for 
the plexopathy due to neuroborreliosis or HIV because the initial clinical picture 
can be identical.
Many clinicians will perform additional cervical spine imaging by MRI or CT scan, 
in search for or to rule out a cervical disk herniation. When the clinical lesion is that 
of a pure monoradiculopathy with pain, sensory symptoms and paresis all in the 
same dermatome it is certainly recommended as this combination of symptoms 
would also be unusual in NA, but one should bear in mind that a certain number 
of  people have asymptomatic disk herniation, especially at the C6-C7 level, and also 
that the incidence of a cervical radiculopathy at the C5 level is equal to that of NA 
itself. In more than half of otherwise typical NA cases degenerative changes of the 
cervical spine are found, and one should therefore be cautious to place too much 
emphasis on the radiological rather than the clinical picture.
Often, a chest X-ray is performed to exclude an apical lung (or Pancoast) tumour, 
although the chance of such a lesion is small when the patient has an upper trunk 
brachial plexopathy of acute onset. One advantage of this relatively simple investi-
gation is that it simultaneously evaluates the position of the diaphragm halves, de-
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Table 2. . Other brachial plexopathy causes
Etiological diagnosis plexopathy How is it different from NA:
traumatic direct relation in time with trauma, direction of 
 mechanical force predicts localisation of damage
postradiation slowly progressive, usually 2-10 years after 
 radiotherapy, paraesthesia prominent
post-thoracotomy typically a lower plexus lesion with direct relation 
 in time to surgery, resolves in weeks-months
true neurogenic thoracic outlet syndrome slowly progressive painless wasting of thenar > 
 hypothenar with hypaesthesia in medial forearm
Pancoast tumour insidious onset, progressive pain, sensory 
 disturbances and paresis from lower plexus to 
 middle and upper parts, Horner syndrome
hereditary neuropathy with liability to  Usually painless attacks with complete and quick
pressure palsies  resolution after weeks - months
tion pattern, of a more benign but still disabling nature, can be seen in true neuro-
genic thoracic outlet syndrome (incidence: 1 per million), in which the lower trunk 
of the plexus containing the C8 and T1 root extensions gets compressed by a fibrous 
band extending from an elongated C7 transverse process to the first rib. Typical-
ly the sensory disturbances are in the medial forearm and ulnar side of the hand, 
while motor symptoms and atrophy prevail in the thenar and to lesser extent in the 
hypothenar muscles. 
When no cause is apparent and the plexopathy had a rapid painful onset, the cause 
is most likely neuralgic amyotrophy. Rarely, a similar picture but with usually pro-
gressive symptoms can be found with direct PNS infections such as neuroborrelio-
sis or HIV. A severe viral illness followed by rapid flaccid paralysis of the upper ex-
tremities, neck and respiratory muscles is found in a small percentages of patients 
with tick-borne encephalitides, especially the Asian variants.
In painless idiopathic brachial plexopathies with only limited paresis and sensory 
symptoms it can sometimes take weeks to months before the patient notes anything 
is wrong. In such a case it can be difficult to exclude other insidious causes such as 
a nerve or nerve sheath tumour of the plexus. Even without additional investiga-
tions clinical follow-up will then usually tell them apart, by showing the disorder 
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• Current pain types: onset nerve trunk pain, nerve stretch pain, musculoskeletal 
 pains
• Main functional impairment at this moment: e.g. scapular instability with 
 reduced elevation of the arm
• Complications: e.g. shoulder joint pathology, orthopnea
For example, a case summary might be as follows: ‘36-year old male, INA, first attack, 
bilateral upper trunk, right worse than left, still has pain at the origo and insertion 
of the serratus anterior, cannot raise arm overhead, also slight glenohumeral im-
pingement on the right’
What to tell the patient
A consultation cannot be complete without giving the gathered information back 
to the patient, so he or she can put symptoms and impairments in the right per-
spective and re-establish a form of control over the situation in daily life. It also 
helps the patient communicate effectively with other caregivers such as physical 
therapists or medical examiners judging the ability to work or right to a benefit.
Below are the items the author tries to cover in the information for NA patients.
Diagnosis: anatomy, functional impairments and aetiology
One way to make the patient understand why the doctor has come to the conclusion 
that his or her symptoms are caused by this disorder called ‘neuralgic amyotrophy’ is 
to go stepwise through the process of neurological diagnosis making. First the ana-
tomical diagnosis is explained by telling the patient that neurologists divide the nerv-
ous system in two large parts, the central and the peripheral, and that this disease has 
nothing to do with the brain or spinal cord but is caused by damage to the nerves that 
go from the spinal cord to the skin and muscles. The next question for a neurologist 
will then be to figure out where exactly the nerves have been damaged along this way. 
It can be helpful to show patients a drawing of the brachial plexus region and point 
out that their symptoms cannot be explained by a lesion of a single whole nerve root as 
in a cervical hernia or a single peripheral nerve, so that we assume the damage will be 
somewhere in between in this braided structure called the plexus.
For an explanation of the nature of their symptoms to patients it usually works well 
to describe peripheral nerves as the human body’s variety of electricity wiring, that 
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tecting a paresis in some 10% of the patients. If such a paresis is already suspected on 
clinical grounds it is advisable to include a ultrasound examination of diaphragm 
movement or fluoroscopy, and a pulmonary function study comparing supine and 
sitting positions in the diagnostic workup. A vital capacity difference of > 400-500 
ml in lying supine versus sitting is considered pathological and suspect for dia-
phragm dysfunction.
An electrophysiological examination including electromyography (EMG) and nerve 
conduction studies (NCS) is generally the only ancillary investigation that can 
positively support the diagnosis of NA. NCS can show reductions in the sensory 
nerve action potential amplitudes in different brachial plexus branches, excluding 
a solely radicular problem. Motor nerve conduction studies are usually not very 
informative unless the paresis is severe, in which case the compound motor action 
potentials will be reduced in affected nerves. It can also be helpful in evaluating the 
phrenic nerves. NCS can also help making other diagnoses unlikely, such as HNPP 
or multifocal motor neuropathy in painless cases. Needle examination will identify 
neurogenic abnormalities in affected muscles, inform the examiner on the severity 
of the lesions, and can confirm that the involvement is in a multifocal plexus dis-
tribution when clinical doubt exists. Of course the same pitfall exists for the EMG 
as for the clinical examination: one has to know which affected muscles to study or 
otherwise the diagnosis will be missed. In the first years after an attack EMG can 
show the extent of - sometimes clinically unnoticeable - reinnervation and recovery, 
making it an important tool in helping predict functional outcome.
Describing the diagnosis
When summarizing the findings in your patient it can be useful to document a 
little bit more than just the words ‘neuralgic amyotrophy’ in the chart. To make 
it easy for you to oversee the current problems at a glance a concise way to do this 
could be to include the following items:
• NA type: idiopathic (INA) or hereditary (HNA)
• How many attacks the patient has had
• Part(-s) of plexus affected: e.g. upper, middle or lower trunk, or diffuse, bilateral, 
 left worse than right or vice versa
• Other nerves: e.g. diaphragmatic palsy, lumbosacral plexus
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go undetected. The fact that in our centre we see about one fellow physician suffer-
ing from NA each year supports this notice.
Hereditary or not?
Once patients hear that NA can also have a genetic predisposition and that in HNA 
the recurrence risk is much higher, they usually wish to know if they could be suf-
fering from the hereditary form of the disorder. As a general rule we tell them that if 
there is no-one else in their family with similar complaints the chance of suffering 
from HNA is very small and it is best to regard their disorder as idiopathic. Currently 
it is not yet possible to genetically test individuals for HNA, but hopefully this will 
change in the near future as the first mutations in a number of families have been 
found [Kuhlenbaumer 2005]. A little caution is warranted though, because not all 
families are linked to the locus on chromosome 17q25, meaning that HNA must be 
heterogeneous, and even in some that were linked no SEPT9 mutation was found. 
Prognosis and treatment
When discussing the prognosis with patients a few questions often arise:
• Are my nerves going to recover at all?
• Can I take any medication that will help my nerves heal?
• Why do I not notice any recovery in daily life yet?
• How come I’m so tired since the attack?
• Is it okay for me to do strength exercises or resume my sports activities? Which 
 exercises should I do or avoid?
• When can I go back to work?
For most patients it will already be a relief to hear that their nerves are going to 
regrow and heal by themselves, in contrast to what usually happens to damaged 
nerves in the brain or spinal cord. For more information on the assessment of sever-
ity of nerve involvement and its implications for recovery see background informa-
tion 4.
Patients often ask if there is any medication that will help their nerves heal. Al-
though current animal research indicates that some neurotrophic factors might 
possibly be used to promote reinnervation, there is no substance available yet that 
can be used effectively and safely in humans. A special caution should be made 
about taking large doses of vitamins, because some such as B6 will even be neuro-
toxic at higher concentrations.
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has bundles of fibres made up of a copper wires inside called ‘axons’ surrounded by 
an insulating layer called ‘myelin’. Then one can explain that NA is a disorder of the 
copper wires themselves and that within the bundles some of these wires get dam-
aged by an inflammatory process. When this happens part of the electrical signals 
cannot get through to the muscles wired by that particular cable, and that causes 
a reduction in strength, or analogously a reduction in skin sensation because some 
impulses are not relayed to the brain. The inflammation is probably what causes 
the extreme nerve pain at onset, and it lasts only a few days or weeks after which 
the patient will have to recover from damage done, a process that can take months 
to years. It also helps to explain that damaged nerves themselves become irritated 
and extra sensitive to stretch or compression, giving off signals that our brain inter-
prets as pain, tingling, tightness or cold or hot phenomena coming from the part of 
the arm the nerve supplies even though the site of the actual damage is somewhere 
else.
The etiological concepts in NA can be a bit harder to explain, because not many 
patients are aware of the difference between inflammation and infection. It some-
times takes a little effort to give them a grip on the concept of auto-immunity and 
next avoid the misperception that their immunesystem is working inadequately, 
while in fact one could say that it is working too hard in fighting off a microbe or 
virus from outside the body, taking one’s own nerves with it in the process. It is 
also important to point out that the fact that one of their attacks was preceded by 
an immunologic event does not mean that the next time such an event occurs they 
will automatically suffer another attack. Currently there is no way to predict if and 
when a recurrence will occur, and there is nothing patients can or cannot do to lux-
ate or prevent one. The only certainty is that if they have suffered one attack they 
are more prone to another than the average person is, and this is even more so when 
the disorder runs in the family.
Epidemiology: ‘how many other people have this?’
The estimated incidence of neuralgic amyotrophy is 2-3 people per 100.000 per 
year.[Beghi 1985, McDonald 2000] In the Netherlands this translates to around 500 
new cases each year for a population of about 16 million people. However, NA seems 
to be a disorder with a ‘public relations’ problem, especially if one recalls the typical 
referral pattern described in the introduction of this text. It could very well be that 
this also influences the reported incidence, and that a more familiarity with the 
clinical syndrome and a higher index of suspicion will reveal more cases that now 
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a theoretical point of view, there are almost no exercises of this type that can be per-
formed without concomitant serratus activation. This makes patients very prone to 
developing (additional) myalgia and fatigue in this muscle which will in turn keep 
them from further exercises. A similar pitfall is seen when muscles with strength 
below MRC 3 are trained using weights. Here one can safely assume that if a muscle 
is not able to lift the attached bodyweight against gravity it will certainly not be 
able to do so if extra kilos are added. And finally one can say that in general trying to 
train muscles that are already strained due to altered biomechanics will inherently 
carry a risk of additional strain and increasing symptoms of pain and fatigue.
Since initially the severe pain will prevent many patients from attending their jobs, 
the inevitable question will arise when it is wise to return to work. The simplest 
answer to this question from the NA perspective would be ‘at the earliest time pos-
sible’, because there is no evidence that physical activities will prevent nerve recov-
ery or provoke another attack. However, it’s obvious that depending on the type of 
posture and the activities required certain jobs will increase the chance of compli-
cations described in the section on the third pain phase in NA below. A gradual in-
crease of activities, with spreading of the amount of time spent in certain postures 
(e.g. sitting behind a desk, working with a keyboard, lifting objects) and alternating 
these physically demanding activities with other less demanding tasks will usually 
be preferable as long as weakness and impairment is significant. For more specific 
help and advice we offer patients the consultation of a rehabilitation specialist as a 
part of standard care.
 
Background information 4. Assessing severity and prognostic factors
‘Severity’ is a very global term that can be used on different levels of dysfunctioning: 
purely physical or ‘hardware’ -wise (e.g. in NA impaired action potential conduction 
by affected nerves), functional (extent of paresis), and with regard to impairments or 
the inability to fully perform certain activities in daily life.
There are several factors that can be used to form an impression of the severity and 
the prognosis of an NA attack on each of these levels.
On the physical level of nerve dysfunction the severity of the lesion and prognosis 
will largely depend on how damaged the different parts of the nerve are. NA typically 
causes an axonotmesis to a lesser or larger extent, which is probably located proxi-
mally in the brachial plexus. Peripheral nerve recovery in case of axonotmesis largely 
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After explaining the process of nerve recovery to patients some of them remark that 
this is all good and well, but even after several months they haven’t noticed any 
recovery in daily life yet. It can be useful to try and explain this difference between 
‘hardware healing’ and ‘useful recovery in daily life’ by pointing out that physicians 
measure strength on a non-linear but continuous MRC scale – or ultimately as a 
linear continuous change in the amount of weight that can be moved against grav-
ity (i.e. in Newtons). But for any amount of force to be useful it will have to make 
the patient able to perform discrete steps, such as yes or no lift the weight of an 
arm against gravity. In terms of everyday function there is a much larger difference 
between MRC grade 2 and 3 then there is between 1 and 2. And as the MRC muscle 
strength grading system is non-linear, increasing in an almost exponentially curved 
manner, it takes a much longer time in terms of linear (Newton) strength recovery 
to go from MRC 4 to 5 than it takes from 3 to 4. For everyday use most muscles need 
about 70% of their maximum strength, so usually patients that have recovered to an 
MRC grade 4 1/2 will be able to function reasonable well in daily life. But if they re-
quire additional efforts (e.g. bear more weight or longer exercises) they will probably 
notice that their strength is not yet back to the previous 100% level. For NA patients 
an unfortunate exception to this 70% rule seems to be the serratus anterior, which 
in practice seems to need > 90% of its strength to perform daily life duties without 
noticeable problems. This means that its functional recovery will take even longer 
as on this linear scale one has to wait till the 90% mark is passed instead of 70%.
Fatigue was found to be an unexpected side effect of NA attacks in over a quarter of 
the patients (unpublished observation), and although we currently cannot really 
explain its occurrence it seems to be part of the NA phenotype in some. Spreading 
one’s activities over the day and choosing what to spend one’s energy on and what 
not so far seems the most reasonable advice for these patients.
Physical therapy can be a useful addition in the management of NA patients (see 
also section on pain treatment below). Besides pain recognition and prevention, 
and instructing the patient how to maintain a fluent scapulothoracic and gleno-
humeral motion most therapists will attempt to optimize residual strength by cer-
tain exercises. And although overall we have the impression that patients who keep 
their affected limb active are better off functionally, there are a few pitfalls when it 
comes to these strengthening exercises in NA. The most common therapy failure 
occurs when attempts are made to strengthen the intact compensating periscapular 
muscles while the serratus anterior is weak. Although the concept seems valid from 
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Very mild cases exist in which only a slight paresis is found on clinical examination 
that often was unnoticed by the patient because it caused no impairment in daily 
life. Vice versa, some patients have a severe bilateral paresis of many upper extrem-
ity muscles and a phrenic nerve palsy, and cannot function indepently for years and 
may need nocturnal respiratory support. In the population from our tertiary refer-
ral center, a majority of about two-thirds of both INA and HNA patients was se-
verely effected with a mean MRC score of < 3 in paretic muscles. About one-quarter 
suffered a moderate paresis (MRC 3-4), and only 13% of the INA and 2% of the HNA 
patients had a mild deficit with a mean MRC score of 4 or more. However, these 
numbers need to be interpreted with some care, as they do not provide information 
about how many muscles were affected in each patient. And even more importantly 
the loss of strength in some muscles is much more bothersome than that in others. 
From clinical practice it appears that especially patients with scapular instability 
due to severe serratus anterior paresis, patients with a severe deltoid paresis pre-
venting arm abduction, those with severe distal lower plexus paresis and vasomo-
tor disturbances, and those with phrenic nerve palsy are worst off. And generally 
women and HNA patients also have a less favourable outcome.
The extent of the impairments in daily life is usually most easily gathered by ask-
ing the patient which activities he or she is now less or unable to perform because 
of the symptoms, and if this interferes with either work, domestic duties or sports 
and other hobbies.
Treating pain and complications
Finally, some elaboration on the treatment of pain in NA is warranted. If and how 
pain should be treated depends mainly on which stage of the attack the patient is 
in. Remember that the pain in NA has three distinct phases: the acute neuropathic 
pain at onset, residual neuropathic and mechanical hypersensitivity pain next, and 
finally musculoskeletal pains in paretic and compensating muscles and sometimes 
the shoulder joint that can remain as long as recovery is incomplete. And although 
the initial pain is one of the most characteristic features of the disorder the impact 
of the subsequent paintypes should not be underestimated, as about 1/3 of the pa-
tients still suffer from these pains after an average follow-up of 6 years.[van Alfen 
2006]
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depends on two repair mechanisms. Denervated muscle and skin areas can first be 
collaterally reinnervated by the remaining intact axons in the fascicle, but if this fails 
will have to wait for regrowth of the proximal nerve fibers from the site of the lesion. 
It has been suggested that minimally about 30% of the original motor neuron pool 
is needed to achieve normal muscle force [Witoonchart 2003]. The fact that differ-
ent nerves contain different amounts of axons is important, because in nerves with 
relatively fewer axons, such as the long thoracic or phrenic, it seems more likely that 
an inflammatory process damages a relatively large number of them. This in turn 
leaves less intact axons capable of collateral reinnervation, meaning that reinnerva-
tion will then largely depend on regrowth of damaged axons in a length-dependent 
fashion. While collateral reinnervation is usually completed in a few months, the 
rate of proximal to distal regrowth is estimated at a few millimeters per week. This 
means that for most nerves damaged at the brachial plexus level it will take months 
or to years to reconnect to the muscle or skin in this fashion, and this especially ap-
plies to patients with damage to long nerves such as again the long thoracic, phrenic 
or those derived from the lower brachial plexus (median and ulnar).
Another important aspect of nerve repair is that regrowing axons need the help of 
neurotrophic factors released by the partially or wholly denervated muscle. There 
are indications that this neurotrophic influence is present when at least a part of 
the muscle active. This means that in completely paralytic muscles the chance of 
recovery is probably smaller because no residual muscle activity can be generated. 
One should be careful with the intensity of exercises however, because there is also 
evidence that more intensive exercise actually prevents axonal sprouting in severe-
ly denervated muscle [Tam 2001]. Muscle tissue also needs electrical impulses to 
maintain its electrical and contractile properties. In case of total denervation and 
paralysis which cannot heal within one to two years there is a real chance that the 
denervated muscle will lose its electrical properties altogether and is replaced by 
fibrous tissue. Paralysis of affected muscles occurs in 4% of the attacks in INA, and 
in 12% of the HNA patients, and although complete failure of reinnervation in these 
patients is probably not common it does occur in individual muscles occasionally.
From a functional perspective it can again be useful to realize that NA causes very 
patchy axonal damage to anywhere from a single to almost every fascicle in one 
or both brachial plexuses [van Alfen 2005, Klein 2002]. After the initial stage domi-
nated by pain has subsided the residual clinical picture will usually be dominated 
by paresis. Obviously, the more nerve fibers are affected the more severe it will be. 
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tus anterior and / or rhomboid become paretic; the trapezius being involved much 
less often. This means that often the trapezius and the levator scapulae (which is 
not a very strong muscle) will have to try and compensate for both the downward 
and lateral scapular displacement in an attempt to provide a fixed scapular position 
that supports arm and hand movements, and for a decrease in scapular rotation 
on abduction and elevation by trying to maximize scapular rotation from a me-
chanically unfavourable position. This is hard work for these muscles that will now 
only get rest when the patient is supine. And to make it worse, because the scapula 
is displaced they will have to attempt these compensations from an elongated or 
stretched-out starting position which leads to a more unfavourable force produc-
tion-muscle length relationship and probably also pain.
Second pattern: myalgia in paretic muscles 
The same mechanism above probably also explains the second pattern of pain in 
the paretic muscles and their sites of attachment. In our experience it is most often 
found in the serratus anterior region, extending from the medial scapular edge via 
the subscapular region and axilla to the midaxillary chest wall where the muscle 
inserts onto the ribs. This pain can be so bothersome that it even prevents normal 
breathing, because chest wall movement will further increase it. Obviously this 
complication can be even more impairing when the patient also has concomitant 
phrenic nerve dysfunction. It can also disturb sleep because lying on the painful 
side is very uncomfortable. Besides in the serratus anterior region it may occur in 
the area of any paretic muscle in NA.
In practice both patterns above were found to be very resistant to pharmacologi-
cal and even sophisticated (e.g. nerve block) pain treatment. The only thing that 
seems to help is to re-establish an optimized biomechanical situation by a com-
bination of physical therapy to maintain fluent periscapular motion and prevent 
dysfunctional compensating strategies, and well-timed alternation between rest 
and activities in daily life. The use of a foam rubber sling to support the weight 
of the arm when sitting, standing or walking – relieving the scapula-stabilizing 
muscles of the arm weight – can be a useful part of this strategy, but one should 
assure that at the same time the patient maintains full joint motion by passive or 
active movement a few times a day to prevent contractures. Quite often patients 
themselves are already applying this support ‘trick’ by tucking their arm and hand 
in a coat pocket when standing or walking. Commercially available scapular braces 
(that resemble a shoulder gun holster) can also provide support, but have the disad-
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Acute phase
Pain in the acute phase was found to respond best to a combination of a long-act-
ing NSAID and opiate, such as diclofenac slow-release 100 mg bid with slow-release 
morphine 10-30 mg bid.[van Alfen 2006] The use of an over-the-counter prescrip-
tion such as acetaminophen or a NSAID only as a rule does not provide adequate re-
lief and should not be advised. Co-analgesics such as gabapentin, carbamazepine or 
amitriptyline have the disadvantage that their onset of action usually takes several 
weeks while the median duration of acute phase pain is about three weeks, so it will 
probably have started to abate by itself by that time. In our cohort study they rarely 
provided good relief even when combined with other analgesics.
Second phase
Co-analgesics may be helpful for the second phase pain, that is characterized by 
spontaneous or movement-induced shooting pains and tingling sensations due to 
aberrant impulse firing in the damaged, hypersensitive parts of the plexus. In prac-
tice though many patients will refrain from this type of medication once they learn 
that the pain is typically luxated by posture or movement and will probably disap-
pear in a few months, especially when weighed against the possible side effects of 
co-analgesics and the fact that they have to be used continuously and cannot be 
taken on-demand for this intermittent pain.
Third phase
Treatment of the third, musculoskeletal type of pain following an NA attack is much 
more of a challenge. A first step is determining which factor or factors play a role in 
an individual patient. In practice we’ve found three common patterns, which are all 
related to altered biomechanical stability of the scapulothoracic and glenohumeral 
joints (recall physical examination part I and background information on shoulder 
biomechanics).
First pattern: myalgia in compensating muscles
The first pattern is local myalgia and muscle strain in the trapezius and levator 
scapulae if they have to compensate for a downward and laterally displaced scap-
ula. It is most often maximally felt at the points where these muscles attach to the 
occiput, cervical spine or shoulder blade, and can radiate further to the forehead 
– resembling tension-type headache – or interscapular region. Remember that the 
periscapular (serratus anterior, trapezius, rhomboid) muscles have both a postural 
or stabilizing as well as a kinetic or movement function. In NA usually the serra-
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time to the start of recovery is a statistically significant shorter in those treated.[van 
Alfen 2006] The results also indicate that the treatment has to be initiated as soon 
as possible after the onset of symptoms, probably within the first 2 weeks, other-
wise ‘the damage is already done’. The hypothesis is that corticosteroids can stop 
the attacks, but not turn back any damage already present. A randomized placebo-
controlled trial formally evaluating the effect of this treatment in now under way 
in the Netherlands.
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vantage that they can only optimize one of the two periscapular muscles function 
at a time. When applied as designed they have to be worn very tightly around the 
chest to fixate the scapula on the thorax. This is both uncomfortable and may even 
restrict normal breathing excursions, and it prevents arm abduction above 110∞ 
elevation because of lack of scapular movement. The NA patients that have found 
them supportive usually wear them less tightly, but just tight enough to provide 
a little bit of support for the arm weight during sitting and standing, similar to 
what a sling would do.
Third pattern: glenohumeral joint pain 
The third pattern of musculoskeletal type pain is that related to shoulder joint pa-
thology, which occurs in about 20% of the patients as a consequence of NA [van Al-
fen 2006]. Its mechanism is explained in the background information on shoulder 
biomechanics in this text. Glenohumeral rotator cuff lesions or chronic bursitis can 
be evaluated with ultrasound or MRI imaging. Capsular irritation or inflammation 
are diagnosed by their clinical picture of impaired exorotation more than abduc-
tion more than endorotation.
Treatment involves physical therapy and local injection with a combined anaes-
thetic and corticosteroid when capsular or tendon / cuff irritation or bursitis are 
present. In case of a partial cuff tendon rupture rest is advised; a complete rupture 
has to be surgically treated. It is also important to look for work or daily life associ-
ated movement patterns that can maintain this type of complication (especially re-
petitive arm movements or excessive weight-bearing) and make the patient aware 
of this association. In severe cases where conservative management fails, it may be 
necessary to resort to orthopaedic surgical intervention, but it goes without saying 
that if possible one should aim to prevent this.
Current research: aborting the attacks with corticosteroid treatment.
As anecdotal evidence from the literature suggested that corticosteroids might be 
beneficial in NA, we have started treating patients in the acute phase of the attack 
in an attempt to stop the inflammation thereby preventing further nerve damage. 
The preliminary results from 43 patients treated with an open-label 2-week course 
of oral prednisone (60 mg per day first week, tapering to zero in second) show that a 
few patients recovered completely within one month, and that on a group level the 
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part iv






General discussion and directions 
for further research
Introduction
Having arrived at the final chapters it becomes clear that the work presented here 
has closely followed the authors interests as a physician, scientist and person, as 
represented by the old French proverb cited on one of the first pages of this thesis. 
Going from ‘consoler toujours’ back to ‘soulager souvent’ and only then towards 
‘guérir parfois’, the main focus lies on two intimately linked aspects of neuralgic 
amyotrophy in its clinical context: an exploration of the phenotype in all its dimen-
sions, and the implications of these findings for that one particular patient that 
sits expectantly in front of you in the consulting room - looking for tailor-made 
answers to his or her questions and problems.
Of course the direction of the authors inquisitiveness does not mean that funda-
mental research is of less importance in medical science. Often research advances 
as a to and fro motion between the fundamental and the phenomenon. Here phe-
nomenology comes first and last, and has been used as a prerequisite for both pre-
dicting a further clinical course and prognosis for the individual patient and a clue 
and starting point for exploring the underlying pathophysiological mechanisms in 
NA as a syndrome. Just as medical science throughout history, this work begins at 
the patient level by careful exploration, definition and interpretation of symptoms 
and signs to decide on what this particular disorder is and what it is not. Next come 
the findings of additional investigations that help to make the step towards knowl-
edge at the following histological, i.e. tissue, level. Both levels are described in part 
I-III below. From here on research using biochemical and physical techniques can 
attempt to elucidate disease mechanisms at the molecular level. A preview of what 
this research may look like is provided in part IV and V.
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Table 1. The neuralgic amyotrophy attack phenotype
Core features
  • monophasic attacks
  • rapid onset of symptoms within hours
  • severe neuropathic pain (NRS ≥ 7) at onset
  • onset of both motor and sensory deficits after hours to weeks
  • typically patchy distribution of deficits with dissociation of symptom 
   localisation
  • deficits in brachial plexus distribution
  • vital sensory dysfunction much more pronounced than propriocepsis
  • resolution of the attack itself after a few weeks
  • partial to nearly full resolution of residual neurological deficits in months 
   to years
Phenotypical variations
  • no pain, or initial pain with NRS < 7, or stuttering onset
  • more / recurrent attacks
  • distal vasomotor dysfunction without parasympathetic involvement
  • lumbosacral plexus distribution or involvement of other lower cranial, 
   cervical plexus or trunk nerves
Not part of the phenotype
  • Bilateral symmetric involvement of all brachial plexus nerves
  • Horner syndrome
  • Progression of initial pain or symptoms over a course of more than 
   2 months
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As often nowadays in disorders in which hereditary traits play a role such as HNA, 
there are simultaneous research efforts by others that work their way backward 
from the genetic or DNA level up to the molecular and then towards the histology 
and the patient as a whole. Their results will be gratefully incorporated where 
applicable.
I. Refining the phenotype
On the phenomenological level this thesis takes several steps forward towards a 
better definition of the neuralgic amyotrophy phenotype. The traditional concept 
of the disorder is both broadened and better restricted. Neuralgic amyotrophy is 
characterized by monophasic attacks of patchy immune- mediated damage to the 
brachial plexus, and less commonly other PNS structures such as the phrenic nerve, 
lumbosacral plexus, lower cranial or trunk nerves. Idiopathic lumbosacral plexopa-
thy and idiopathic phrenic nerve palsy are very likely parts of the neuralgic amyo-
trophy spectrum or syndrome, instead of separate disorders. The duration of and 
time course between symptoms of pain, paresis and sensory disturbances can vary 
considerably, but usually pain precedes the clinical deficits. Although pain and mo-
tor symptoms predominate sensory axons are very commonly involved in the at-
tacks. In a small proportion of patient the postganglionic sympathetic nerve fibres 
that run in the peripheral nerves are affected too.
Core features of the attacks remain the extreme neuropathic pain at onset and the 
rapid multifocal paresis and atrophy, usually in the upper extremities, as well as the 
slow recovery in months to years. This recovery was found to be often incomplete 
even after years, in contrast with previous reports. The typical severe neuropathic 
initial pain often changes into a mechanical hypersensitivity of the affected nerves 
during the following months and next into persistent musculoskeletal pains from 
strain in either paretic or compensating muscles. For a summary of the phenotypi-
cal features see table 1.
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syndrome at all, and diagnosed as suffering from aspecific ‘shoulder complaints’ 
that will be self-limiting within a few months. 
III. Acute versus chronic phase: treatment and management
In addition to refining the NA phenotype the work in this thesis has tried to take 
the clinical phenomenology further towards patient management, and explore the 
sequelae of NA attacks and the best ways to manage them. This subject has hitherto 
been unexplored, and usually textbooks stop after a the remark that ‘most patients 
recover’. However, many in whom NA had been correctly diagnosed still came to 
us with persisting symptoms to ask what they should now do next. No standard 
pain management or physical therapy plan for NA patients was available, nor was 
it known what to advise with regards to going back to work or sports activities. Be-
cause of this, we have recently undertaken the writing of a Cochrane review of treat-
ments for NA, which can be the base of further systematic research in this area.
In practice we found it useful to divide an NA attack in two phases: an acute phase 
that roughly lasts for two to three months from onset, and a chronic phase after-
wards. Each phase had its own distinct symptoms and therapeutic approach, which 
are summarized below.
Acute phase
The best treatment for the acute phase neuropathic pain was found to be a combina-
tion of a long-acting NSAID and opiate. In the weeks to months following patients 
would often go on to suffer from shooting or radiating pains elicited by mechanical 
strain on the affected parts of the plexus; a mechanical hypersensitivity akin to a 
Lasègue sign of the leg. For these radiating pains co-analgesics such as gabapentin 
or carbamazepine seem to be the most reasonable treatment option, although often 
patients would decline their use because of their side effects and the intermittent, 
focal and to some extent predictable nature of this pain. 
Chronic phase
After weeks to months about two-thirds of the patients also developed an intrac-
table musculoskeletal-type pain in the periscapular, cervical and occipital regions. 
Another not uncommon complication was pain from glenohumeral joint pathol-
ogy indirectly caused by periscapular weakness.
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Clinically NA should be suspected in any patient presenting with acute severe up-
per extremity pain and can be most easily recognized and diagnosed by asking the 
following three simple questions:
 
1. Is the pain acute, very severe (NRS score ≥7) and - in case of a first episode - 
 unlike anything the patient had before? If yes: NA is likely, if not NA is possible 
 but one should consider other diagnoses.
2. Is there a limitation of passive arm exorotation or abduction? If not NA is likely; 
 if yes shoulder joint pathology is more likely.
3. Are all symptoms, i.e. pain, paresis and sensory disturbances in the same (single) 
 root distribution? If not NA is likely, if yes a cervical radiculopathy is more likely.
Attacks tend to recur in a considerable proportion of both idiopathic and hereditary 
NA patients, probably reflecting an underlying genetic structural or immunologi-
cal vulnerability in these people. The fact that the first attack occurs at a younger 
age, recurrences are more common, maximum paresis severity is worse during 
an attack and more often nerves outside the brachial plexus are involved in HNA 
stresses the effect of a genetic factor in further enhancing susceptibility.
II. Some remarks on the occurrence of NA
NA might be more common than the reported incidence of 2-3/106/year suggests. 
We know that more than 60% of our patients was first diagnosed with a different 
disorder before it became clear they suffered from NA. Since our department started 
profiling itself as a national referral centre for NA patients in the Netherlands we 
see about 2 new patients per week, and in our own university hospital we tend to 
see one of our 909 colleagues suffering from new-onset NA each year. 
There are several reasons that make it likely that the incidence of NA is underes-
timated. The diagnosis may not be considered if the typical winged scapula is not 
present or readily apparent. It is also possible that when no thorough search is 
made for signs of patchy PNS involvement and one relies heavily on the MRI find-
ings of the cervical spine (which is abnormal but not explanatory in more than half 
of NA patients) patients can easily be mistaken to suffer from a cervical radiculopa-
thy. Very mild cases with less severe or shorter duration pain and a mild paresis of 
only one or a few muscles are probably not recognized as NA or even a neurological 
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will usually be preferable as long as weakness and impairment are significant. For 
more specific help and advice we offer patients the consultation of a rehabilitation 
specialist as a part of standard care.
IV. From phenotype to pathophysiology
After refining the phenotypical features of NA this thesis explores some steps to-
wards the pathophysiology of NA. A study of histological material from HNA pa-
tients showed that the disease process during attacks can be widely distributed 
throughout the PNS, even in regions that has no clinical symptoms, and simulta-
neously affects individual nerves very focally in isolated fascicles. 
Apart from again confirming the patchiness of the disorder, this widespread sub-
clinical involvement suggest that not only or specifically brachial plexus nerve tis-
sue is susceptible to the attacks. Histology also confirmed that NA is not a pure 
or probably even predominant motor PNS disorder, making this particular feature 
less likely a discriminating factor in why certain nerves are affected. Finally nor our, 
nor other research could find evidence that NA is a particular form of PNS vasculitis, 
making it more likely that the primarily affected structure is the PNS itself.
NA as a multifactorial disorder
NA is currently thought to be immune-mediated. Support for this hypothesis was 
found in our clinical cohort study by showing that in about half of the patients an 
immunological event was present that preceded and could have luxated the onset 
of an attack. We also found anti-ganglioside antibodies in over a quarter of the 
patients tested. Although it is not known whether they are cause or consequence 
of the nerve damage they do suggest an immunological mechanism takes place 
in NA.
In a review of the sparse literature on immunological findings in NA it was shown 
that there are some lines of evidence supporting the hypothesis, but that autoim-
munity alone cannot be the only mechanism by which attacks are caused, nor does 
it explain the underlying susceptibility both INA and HNA patients have for devel-
oping the attacks. Current evidence suggests that neuralgic amyotrophy is a disor-
der with a complex pathophysiological mechanism in which autoimmune, genetic 
and external factors all seem to play an interwoven role. And while our research has 
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 Treatment of the third, musculoskeletal type of pain following an NA attack proved 
much of a challenge, as analgesics usually failed to have an effect. A first step was de-
termining which factors play a role in an individual patient. We found three com-
mon patterns: myalgia and musculotendinous pain due to strain of paretic muscles, 
similar pain in the compensating muscles, and glenohumeral joint pain. Especially 
for the first two patterns the only helpful intervention seems a re-establishment 
of an optimized biomechanical situation, by a combination of physical therapy 
to maintain fluent periscapular motion and prevent dysfunctional compensating 
strategies, and well-timed alternation between rest and activities in daily life. The 
use of a foam rubber sling to support the weight of the arm when sitting, stand-
ing or walking – relieving the scapula-stabilizing muscles of the arm weight – has 
also been a useful part of this strategy. Glenohumeral joint pathology also requires 
appropriate physical therapy, and in some more severe cases local corticosteroid / 
anaesthetic injections or even surgery can be necessary.
Some pitfalls in physical therapy management were also identified, usually as a 
consequence of increased strain on either paretic or compensating muscles by too 
strenuous exercise or weight-loading when muscle strength was still < MRC 3. 
Functionally we found that the most disturbing residual symptoms were usually 
caused by serratus anterior weakness hampering both lifting the arm and hand or 
keeping them well-positioned in front of the body. Another disabling sequel was 
a persisting paresis of the wrist and fingers extensors, preventing normal use of 
the hand. And in some cases a diaphragmatic palsy with orthopnoea and dyspnoea 
d’effort was responsible for mild to severe disability, sometimes necessitating noc-
turnal ventilation.
With regards to resuming work or leisure activities it should first be made clear 
to the patient that there is no need to be afraid that the attacks will recur or nerve 
recovery hindered by resuming physical activities. At this point in time we do not 
even know if it is possible at all to prevent a recurrence. But one should also explain 
that the work load should follow the amount of muscle strength and endurance 
capacity available, and preferably has to be adapted accordingly, or otherwise strain 
and fatigue with a deterioration of functional possibilities will very likely ensue. A 
gradual increase of activities, with spreading of the amount of time spent in certain 
postures (e.g. sitting behind a desk, working with a keyboard, lifting objects) and 
alternating these physically demanding activities with other less demanding tasks 
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ceptible to attacks. It would be interesting to explore the effects of the SEPT9 muta-
tions found in HNA, and to see if INA patients also harbour mutations in this gene. 
SEPT9 is expressed in ventral horn cells and dorsal root ganglia of mice, so a logical 
step would be to create a knockout mouse and examine the subsequent growth and 
development of the brachial plexus - and preferably the rest of the peripheral nerv-
ous system too - to see if any structural or ultrastructural anomalies occur.
Another interesting option would be to study the expression of this gene and its 
product in human brachial plexus tissue and compare it with other PNS and cra-
nial nerve structures, to see if there is a differential expression correlated with the 
clinical predilection sites in NA. Even better of course would be if material from 
a HNA patient with a known SEPT9 mutation could also be included in such a 
study.
More laboratory research
Several immunological lines of research seem promising. The first would be to take 
the host (i.e. NA patient) as a starting point, and try to find factors that could facili-
tate the occurrence of an autoimmune process in the brachial plexus. Currently we 
are investigating the statistical association with a particular immunogenetic make-
up in a large group of NA patients, both hereditary and idiopathic, in collaboration 
with colleagues from the Erasmus Medical Centre in Rotterdam. Several so-called 
immunogenetic polymorphisms and the prevalence and types of antiganglioside 
antibodies will be examined. It would be interesting to apply similar techniques 
used in GBS to elucidate the role of the immune system in NA. 
The necessity of epidemiology
It would be interesting to know if clusters of NA cases (i.e. epidemics) occur in the 
Netherlands, for this could also lead to the identification of relationships with an-
tecedent events. This would first require the accurate registration of adequately 
documented cases in a nationwide database, such as the Dutch Computer Registra-
tion of All Myopathies and Polyneuropathies (CRAMP) that has become available in 
the Netherlands in 2000.
The level of awareness for the diagnosis required for such a registration would also 
be necessary to find out if NA and especially HNA are really underdiagnosed, or vice 
versa what the true incidence of the disorder is once the different clinical mani-
festations are adequately recognized. Only when the true incidence is known the 
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focused on going from clinical findings towards the pathophysiology, other groups 
have in the meantime identified a mutation in the SEPT9 gene in some HNA fam-
ilies. This means that now from this perspective too some progress can be made 
in identifying the factors responsible for the underlying susceptibility. Hopefully, 
both ends of these research lines will meet in the near future.
A final contribution to both evidence for an immune-mediated attack mechanism 
and NA disease management was made by the results of an open-label prednisone 
treatment of patients in the acute phase of an attack. It suggested a favourable re-
sponse in some patients, mainly in those that could be treated in the first 2 weeks 
from onset.
V. Remaining questions and directions for further research
NA subtypes?
Many questions outlined in table 2 of the Introduction of this thesis could be an-
swered by the research presented here. Of course more questions will always remain. 
It seems too early to be sure of the suspicion that NA is not a single disease entity 
but rather a syndrome harbouring several different clinical subtypes or maybe even 
distinct disorders, similar to the Guillain Barré syndrome that encompasses AIDP, 
Miller-Fisher syndrome, AMAN and other subtypes.
From a clinical perspective subtypes could exist in the form of idiopathic patients 
with recurrent attacks or affection of nerves outside the brachial plexus, who may 
differ in their underlying susceptibility. Male middle-aged INA patients with se-
vere bilateral arm involvement, phrenic nerve dysfunction and disturbed liver 
enzymes could form another subtype in which a very particular antecedent infec-
tion gives rise to a fairly uniform clinical sequel. But the definite answer to these 
questions will probably come when next laboratory research is used to find discri-
minants that set certain patient groups apart. It has already shown us that some 
NA patients generate antiganglioside antibodies, which presence may constitute 
another subtype.
Genotype - phenotype correlations
We also do not yet know how much of the phenotype is explained by the genotype, 
and whether INA patients also harbour genetic defects that make them more sus-
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a priori chance of NA can be appropriately incorporated in the clinical diagnostic 
process in patients with acute upper extremity pain and deficits.
Towards treatment
Returning to the point of origin, from a patient perspective all research efforts 
should also lead to the possibility to predict individual vulnerability and outcome, 
and find therapies that lead to reassurance, relief and cure. Collaboration with oth-
ers is indispensable for reaching these goals. The cooperation with our Rotterdam 
colleagues has made it possible to initiate a randomized placebo-controlled trial 
evaluating the response to a course of oral prednisone in the acute phase of NA at-
tacks. A joint project with two Dutch physiatry departments, assessing the preva-
lence of shoulder joint pathology and the biomechanical implications of scapular 
instability, will aim to improve the rationale behind rehabilitation programs for 
NA patients suffering from these complications. And finally, for optimal patient 
management ongoing efforts should be made to improve the recognition of NA by 
physicians and other caregivers. 
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Aangekomen bij de laatste hoofdstukken wordt het duidelijk dat het onderzoek in 
dit proefschrift de interesses van de auteur als dokter, wetenschapper, en mens - tot 
uitdrukking gebracht in het oude Franse adagium dat op een van de eerste pagi-
na’s van dit proefschrift staat - nauw heeft gevolgd. Van ‘consoler toujours’ terug 
naar ‘soulager souvent’ en pas dan naar ‘guérir parfois’, ligt het zwaartepunt op 
twee sterk gerelateerde aspecten van neuralgische amyotrofie in de klinische con-
text van de patiënt: het verkennen van de uitingsvormen (het ‘fenotype’) van de 
aandoening in al haar dimensies, en het onderzoeken van de gevolgen hiervan voor 
die ene patiënt die verwachtingsvol in de spreekkamer zit op zoek naar pasklare 
antwoorden op zijn of haar vragen en problemen.
Uiteraard betekent deze voorkeur van de auteur niet dat fundamenteel onderzoek 
van minder belang zou zijn in de medische wetenschap. Vooruitgang ontstaat juist 
vaak uit een heen en weer bewegen tussen het fundamentele en het fenomeen. In 
dit onderzoek is echter de fenomenologie zowel als begin- als eindpunt genomen. 
Van hieruit wordt zowel geprobeerd het verdere beloop en de prognose van de indi-
viduele patiënt te voorspellen als het verdere onderliggende ziektemechanisme van 
NA te begrijpen. Analoog aan de ontwikkeling van de geneeskunde zelf door de eeu-
wen heen begint dit werk met een grondig onderzoek en interpretatie van de symp-
tomen om tot een afbakening te komen van wat deze aandoening is - en wat niet. 
Vervolgens worden de bevindingen bij aanvullend onderzoek gebruikt om een stap 
te maken in de richting van het ziektemechanisme op het niveau van het perifere 
zenuwweefsel. Een beschrijving van beide niveaus wordt gegeven in deel I-III hier-
onder. Vervolgens kunnen door gebruik van biochemische en fysische technieken 
verdere stappen ondernomen worden in de richting van het onderliggende molecu-
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Tabel 1. Het fenotype van NA aanvallen
Kernsymptomen
  • monofasische aanvallen
  • acuut tot subacuut begin binnen enkele uren
  • ernstige neuropathische pijn (NRS ≥ 7) in het begin
  • optreden van motore en sensibele uitval na enkele uren tot weken
  • typische vlekkige verdeling van de uitval, met een dissociatie van de symp-
   tomen qua lokalisatie
  • uitval in de distributie van de plexus brachialis
  • sensibele uitval vitaal veel meer uitgesproken dan proprioceptief
  • geleidelijk verdwijnen van de aanval zelf na enkele weken
  • gedeeltelijk tot compleet herstel van de restverschijnselen na maanden tot
   jaren
Fenotypische variaties
  • geen pijn, of initiële pijnscore < 7, of stotterend begin
  • meer of herhaalde aanvallen
  • distale vasomotore dysfunctie zonder parasympatische uitval
  • uitval in distributie lumbosacrale plexus, n. phrenicus, onderste hersen-
   zenuwen of rompzenuwen
Niet tot het fenotype behorend
  • bilateraal symmetrische uitval van de hele plexus brachialis
  • syndroom van Horner
  • progressie van de initiële pijn of symptomen gedurende meer dan 2
   maanden
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laire niveau. Een vooruitblik op hoe deze stappen er uit zouden kunnen zien wordt 
gegeven in deel IV en V.
Zoals vaak tegenwoordig bij aandoeningen waarbij ook erfelijke factoren een rol 
spelen is er ook onderzoek gaande dat zich in tegenovergestelde richting begeeft 
en vanuit het genetische cq. DNA niveau terugwerkt naar de histologie en vervol-
gens de patiënt als geheel. De resultaten hiervan zijn dankbaar gebruikt waar van 
toepassing.
I. Afbakening van het fenotype
Op het niveau van de fenomenologie worden in dit proefschrift een aantal stap-
pen genomen op weg naar een betere definitie van het fenotype van neuralgische 
amyotrofie. Het tot nu toe gebruikelijke concept van de aandoening wordt zowel 
verbreed als preciezer afgetekend. NA wordt gekenmerkt door monofasische aan-
vallen met een vlekkige beschadiging van de plexus brachialis, en minder frequent 
ook van andere perifere  zenuwstructuren zoals de n. phrenicus, plexus lumbo- 
sacralis, onderste hersenzenuwen of zenuwen van de romp. Het is erg waarschijn-
lijk dat idiopathische geïsoleerde plexus lumbosacralis neuropathie en n. phreni-
cus uitval onderdelen van het NA spectrum of syndroom zijn, in plaats van op zich 
staande aandoeningen. Het beloop en de duur tussen het optreden van symptomen 
als pijn, parese en sensibele uitval kunnen per patiënt en aanval sterk verschillen, 
maar veelal gaat de pijn aan uitval vooraf. En alhoewel de pijn en motore uitvalsver- 
schijnselen meestal klinisch op de voorgrond staan zijn sensibele axonen wel dege-
lijk vaak ook aangedaan. Ook wordt in een kleiner deel van de patiënten klinisch 
uitval van de postganglionaire sympathicusvezels van de arm gevonden.
De kernsymptomen van de aanvallen blijven echter de extreme zenuwpijn in het 
begin en de snel optredende vlekkige, multifocale uitval en atrofie, meestal in de 
bovenste extremiteiten, met een langzaam herstel in de loop van maanden tot jaren. 
Dit herstel bleek frequent zelfs na enkele jaren niet volledig, in tegenstelling tot 
wat eerder in de literatuur werd vermeld. De typische hevige neuropathische pijn 
van het begin gaat vaak in de maanden erna over in een mechanische overgevoelig-
heid van de aangedane zenuwen, en vervolgens in een hardnekkige musculoskele-
tale pijn door overbelasting van zowel de paretische als compenserende spieren. Er 
zijn echter grenzen aan het fenotype. Een volledige, symmetrische plexus brachia-
lis uitval wordt bij NA niet gezien, net zomin als een Horner syndroom of een echt 
progressief beloop over een periode van meer dan twee maanden.
Een overzicht van het fenotype van NA aanvallen wordt gegeven in tabel 1.
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vlekkige uitval, en de nadruk wordt gelegd op de radiologische bevindingen bij 
MRI onderzoek van de cervicale wervelkolom (dat bij meer dan de helft van de NA 
patiënten afwijkend is maar geen verklaring voor de symptomen vormt) per abuis 
de diagnose ‘cervicale radiculopathie’ wordt gesteld. En in hele milde gevallen met 
slechts kortdurend of minder hevige pijn en een lichte parese van slechts een paar 
spieren is het niet ondenkbaar dat de diagnose NA - of überhaupt een neurologische 
aandoening - nooit overwogen wordt, en patiënten uitgeboekt worden als ‘aspeci-
fieke schouderklachten’ die vervolgens binnen enkele maanden weer overgaan.
III. Acute versus chronische fase: behandeling en begeleiding
Naast een betere afbakening van het fenotype heeft het onderzoek in dit proef-
schrift geprobeerd om vanuit de klinische verschijnselen ook bij te dragen aan de 
begeleiding van NA patiënten, door de gevolgen van aanvallen te onderzoeken en 
een aanzet te geven voor de optimale manier om hier mee om te gaan. Tot nu toe 
was hier weinig tot niets over bekend, en de meeste leerboeken houden op na de op-
merking dat ‘herstel meestal volledig is’. In de praktijk hebben we echter gemerkt 
dat veel patiënten bij wie op zich de diagnose adequaat gesteld was toch alsnog naar 
ons verwezen (wilden) worden met de vraag hoe het nu verder moest. Een standaard 
aanpak of advies over de beste pijnbestrijding of fysiotherapeutische aanpak was 
niet beschikbaar, en weinig tot niets bekend over wat te adviseren inzake hervat-
ting van werk, sport of hobby’s. Om deze reden zijn we recent begonnen met het 
opzetten van een systematisch zgn. Cochrane review van de behandelingen toege-
past bij NA. Dit overzicht kan vervolgens een uitgangspunt bieden voor verder sys-
tematisch onderzoek van dit onderwerp.
In de praktijk bleek het nuttig om het tijdsbeloop van de aanvallen in grofweg twee 
fasen te verdelen: een acute die tot twee à drie maanden na het begin duurt, en een 
chronische daarna. Elke fase heeft z’n eigen symptomen en bijbehorend plan van 
aanpak, welke hieronder wordt weergegeven.
Acute fase
Een combinatie van een langwerkend NSAID en opiaat bleek het beste werkzaam te-
gen de hevige neuropathische pijn in het begin. Minder krachtigepijnstilling deedt 
weinig tot niets. Voor de hierop volgende schietende of stekende pijnen als gevolg 
van een mechanische overgevoeligheid van de beschadigde zenuwen – analoog aan 
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Bij elke patiënt met acute ernstige pijn in de schouder of arm zou aan NA moeten 
worden gedacht, en de aandoening kan het makkelijkst worden vastgesteld door de 
volgende drie relatief eenvoudige vragen te beantwoorden:
1. Is de pijn acuut, heel hevig (NRS score ≥ 7) en - bij een eerste episode - heeft de  
 patiënt nooit eerder zoiets gehad? Zo ja is NA waarschijnlijk, zo nee dan is NA  
 nog mogelijk maar moeten eerst andere diagnosen overwogen worden.
2. Is er een passieve beperking van de beweeglijkheid van de arm of het schouder- 
 gewricht? Zo nee dan is NA waarschijnlijk, zo ja dan is gewrichtspathologie  
 meer waarschijnlijk.
3. Worden alle symptomen zoals pijn, parese en sensibele uitval in het verzorg-
 ingsgebied van dezelfde zenuwwortel gevonden? Zo nee dan is NA waarschijn-
 lijk, zo ja dan wordt een cervicale radiculopathie meer waarschijnlijk.
Zowel bij HNA als een aanzienlijk deel van de INA patiënten treden in de loop 
der tijd meerdere aanvallen op, wat waarschijnlijk een weerspiegeling is van de 
onderliggende genetische, structurele of immunologisch bepaalde gevoeligheid bij 
deze mensen. Het feit dat bij mensen met de erfelijke vorm van NA de aanvallen 
op jongere leeftijd ontstaan, er meer recidieven optreden, de ernst van de motore 
uitval vaak erger is en er vaker ook zenuwen buiten de plexus brachialis aangedaan 
worden onderstreept nog eens het belang van een genetische factor die de individu-
ele gevoeligheid vergroot.
I. Enkele opmerkingen over het vóórkomen van NA
Het is niet onwaarschijnlijk dat NA vaker voorkomt dan de huidige incidentiecijfers 
van 2-3 per 100.000 per jaar suggereren. Zo weten we dat bij 60% van onze patiënten 
initieel een andere diagnose werd gesteld voordat het duidelijk werd dat ze aan NA 
leden. Sinds ons centrum een landelijke referentiefunctie heeft voor patiënten met 
deze aandoening zien we ongeveer 2 nieuwe patiënten per week, en ieder jaar wordt 
ook bij één van onze 909 collega’s uit het UMC St. Radboud de diagnose gesteld.
Er zijn verschillende verklaringen voor waarom de werkelijke incidentie van NA 
waarschijnlijk onderschat wordt. Het kan zijn dat de diagnose niet eens overwogen 
wordt als het typische scapula alata ontbreekt of niet duidelijk zichtbaar is. Ook is 
het mogelijk dat, als er niet gedetailleerd genoeg gezocht wordt naar de typische 
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tot het optillen en voor zich uit gestrekt werken met de arm en met name ook het 
volhouden hiervan bemoeilijkt zijn. Een ander fors beperkend restverschijnsel 
treedt op bij een ernstige parese van de pols- en vingerextensoren, wat een normaal 
gebruik van de hand verhindert. En in sommige gevallen gaf een diafragmaparese 
met orthopneu en dyspneu d’effort aanleiding tot een milde tot fors restbeperking, 
af en toe zelfs met de noodzaak tot nachtelijke beademing.
 
Als het gaat om hervatting van werk of hobby’s moet allereerst aan de patiënt 
worden uitgelegd dat er geen reden is om bang te zijn dat de aanvallen zullen te-
rugkomen of het zenuwherstel gehinderd wordt door fysieke inspanning. Op dit 
moment is het überhaupt niet mogelijk om te voorspellen of de aanvallen zullen 
terugkomen of niet, wat men ook doet of laat. Maar het is ook goed om uit te leg-
gen dat het niveau van belasting idealiter de hoeveelheid beschikbare spierkracht 
en uithoudingsvermogen moet volgen, en ook daaraan worden aangepast, omdat 
er anders een grote kans op overbelasting en vervolgens een afname van de fysieke 
mogelijkheden is. Een geleidelijk uitbreiden van de activiteiten, met het verde-
len van de tijd die men in bepaalde houdingen doorbrengt (zoals zitten voor een 
beeldscherm of bedieningspaneel, of herhaaldelijk tillen vanuit dezelfde positie), 
en het afwisselen van deze lichamelijk belastende activiteiten met andere minder 
belastende taken is meestal wenselijk zolang de spierzwakte en beperkingen nog 
duidelijk aanwezig zijn. Als onderdeel van de standaard zorg worden veel patiënten 
voor meer specifieke hulp en advies naar een revalidatiearts verwezen.
IV. Van fenotype naar pathofysiologie
Na een betere afbakening van het NA fenotype vervolgt dit proefschrift met het 
verkennen van een aantal stappen in de richting van de pathofysiologie. Uit onder-
zoek van histologisch materiaal van HNA patiënten bleek dat het ziekteproces tij-
dens de aanvallen tegelijkertijd wijdverbreid door het perifere zenuwstelsel kan 
zijn, met ook subklinische betrokkenheid, en toch zeer focale afwijkingen veroor-
zaakt in individuele fascikels binnen een perifere zenuw. Behalve dat hiermee het 
vlekkige karakter van de aandoening nog eens werd bevestigd, geeft dit onderzoek 
ook aan dat de niet alleen of specifiek de plexus brachialis gevoelig is voor de aan-
vallen. Het histologisch onderzoek bevestigde tevens dat NA geen puur of zelfs 
overwegend motore perifere zenuwaandoening is, wat het minder waarschijnlijk 
maakt dat dit klinische verschijnsel een onderscheid kan maken in waarom bepaal-
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een het Lasègue fenomeen van het been - lijken co-analgetica zoals carbamazepine 
of gabapentin de beste optie. In de praktijk blijken echter veel patiënten hier toch 
van af te zien vanwege de bijwerkingen, en de focale aard en het in enige mate voor-
spelbare optreden van deze pijnen.
Chronische fase
Ongeveer tweederde van de patiënten ontwikkelt na enkele weken tot maanden 
hardnekkige pijn in het gebied rond het schouderblad, de nek en het achterhoofd. 
Een andere niet ongebruikelijke complicatie waren klachten in het schouderge-
wricht op basis van een door de paresen veranderde biomechanische verhouding 
tussen de gewrichtsvlakken.
Behandeling van dit derde type pijn van spieren en hun aanhechting bleek niet een-
voudig, en hier hadden pijnstillers meestal nauwelijks tot geen effect. Een eerste 
stap in de aanpak was het bepalen welke factoren in de individuele patiënt pre-
cies een rol speelden bij deze pijn. Er werden drie veel voorkomende patronen ge-
vonden: spierpijn en ook vooral pijn in de aanhechting van de paretische spieren, 
soortgelijke pijnen in de spieren die voor deze paresen proberen te compenseren, 
en pijn in het glenohumerale gewricht. De enige zinvolle interventie lijkt het 
opnieuw optimaliseren van de biomechanische situatie te zijn. Dit wordt bereikt 
door een combinatie van fysiotherapie, om een zo normaal en vloeiend mogelijk 
periscapulair bewegingspatroon te herstellen en disfunctionele compensatie strate-
gieën te voorkomen, en het tijdig laten afwisselen tussen inspanning en rust van 
de aangedane extremiteit. Het gebruik van een schuimrubber sling of mitella om 
het gewicht van de arm te ondersteunen tijdens zitten, staan en lopen bleek ook een 
zinvol onderdeel van deze aanpak, met name bij een serratusparese < MRC 4. Ook 
de aanwezigheid van glenohumerale pijnklachten vergt deskundige fysiothera-
peutische begeleiding, en in ernstigere gevallen kunnen locale corticosteroïd / ane-
sthetica injecties of zelfs operatieve interventie nodig zijn.
Er werden ook enkele valkuilen in de fysiotherapeutische aanpak ontdekt. Proble-
men traden meestal op wanneer het oefenprogramma een te zware belasting gaf 
van de paretische, en soms ook compenserende spieren, met name indien hierbij ge-
bruik werd gemaakt van extra gewichten terwijl de spierkracht nog < MRC 3 was.
 
De meest hinderlijke restverschijnselen in termen van functieherstel werden ge-
zien bij patiënten met uitval van de m. serratus anterior, waarbij de mogelijkheid 
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V. Openstaande vragen en suggesties voor verder onderzoek
NA subtypes?
Veel van de vragen in tabel 2 van de introductie van dit proefschrift konden beant-
woord worden door het onderzoek dat hier gepresenteerd wordt. Uiteraard zul-
len er altijd andere en nieuwe vragen overblijven. Zo lijkt het bijvoorbeeld nog 
te vroeg om zeker te kunnen zijn van de klinische verdenking dat NA niet één 
ziekte is maar een syndroom waarbinnen verschillende klinische subtypes of zelfs 
verschillende aandoeningen vallen, vergelijkbaar met het syndroom van Guillain-
Barré dat zowel de AIDP, het Miller-Fisher syndroom, AMAN, als andere subtypes 
omvat.
 
Vanuit klinisch perspectief zouden NA subtypes kunnen bestaan in de vorm van 
idiopathische patiënten die herhaalde aanvallen krijgen of aanvallen waarbij ook 
zenuwen buiten de plexus brachialis betrokken zijn, en die daarmee dus verschil-
len in hun mate van onderliggende gevoeligheid. Mannen van middelbare leef-
tijd met INA waarbij een bilaterale ernstige uitval van de plexus brachialis en n. 
phrenicus optreedt in combinatie met leverfunctiestoornissen zouden een ander 
subtype kunnen zijn, waarbij een specifiek antecedent infect leidt tot dit vrij uni-
forme klinische patroon. Een definitief antwoord op deze vragen komt waarschijn-
lijk als aanvullend onderzoek gebruikt gaat worden om onderscheidende factoren 
te vinden waarmee deze patiëntengroepen uit elkaar kunnen worden gehaald. Dit 
type onderzoek heeft nu al laten zien dat sommige NA patiënten antiganglio-
side-antilichamen genereren, waarmee opnieuw een subtype onderscheiden kan 
worden.
Genotype - fenotype correlaties
Het is op dit moment ook nog niet bekend hoeveel van het fenotype verklaard kan 
worden door het onderliggende genotype, en of er bij INA patiënten ook genetische 
veranderingen aantoonbaar zijn die een rol spelen in de gevoeligheid voor aanval-
len. Daarom zou het interessant zijn om de gevolgen van de gevonden SEPT9 muta-
ties in HNA patiënten te onderzoeken, en na te gaan of INA patiënten ook mutaties 
in dit gen vertonen. SEPT9 wordt tot expressie gebracht in de voorhoorncellen en 
sensibele ganglionen van de muis, dus een logische stap lijkt het creëren van knock-
out-muizen waarin de effecten op de ontwikkeling van de plexus brachialis - en bij 
voorkeur ook de rest van het perifere zenuwstelsel - worden onderzocht, met name 
ook om te zien of er structurele of ultrastructurele veranderingen ontstaan.
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de zenuwstructuren gevoeliger zijn dan andere. Tot slot werd noch in ons, noch 
in eerder onderzoek bewijs gevonden dat NA een specifieke vorm van geïsoleerde 
perifere zenuwstelsel vasculitis is. Dit maakt het waarschijnlijker dat de perifere 
zenuwen zelf het doelwit zijn tijdens de aanvallen.
NA als multifactoriële aandoening
NA wordt op dit moment beschouwd als een immuun-gemedieerde aandoening. 
Enige ondersteuning voor deze hypothese werd gevonden in onze studie van een 
groot klinisch cohort waarbij in ongeveer de helft van de patiënten sprake was ge-
weest van een immunologische gebeurtenis net voorafgaand aan het ontstaan van 
de aanval. Ook werden antiganglioside antilichamen gevonden in meer dan een 
kwart van de daarop geteste patiënten. En alhoewel we op dit moment niet weten 
of deze oorzaak of gevolg zijn van de aandoening, suggereren deze in ieder geval ook 
de aanwezigheid van een immunologisch proces in NA.
Een overzicht van de spaarzame literatuur over auto-immune mechanismen in 
NA liet zien dat er inderdaad aanwijzingen zijn die een dergelijke hypothese onder- 
steunen. Maar het toonde ook dat auto-immuniteit niet het enige mechanisme kan 
zijn waardoor aanvallen ontstaan, en ook niet verklaart waarom juist HNA en INA 
patiënten een verhoogde gevoeligheid hebben om deze aanvallen te krijgen. Het op 
dit moment beschikbare bewijs suggereert derhalve dat NA een aandoening is met 
een complex pathofysiologisch mechanisme, waarin zowel auto-immuniteit als 
genetische en externe factoren een verweven rol spelen. En terwijl ons onderzoek 
poogt zich vanuit de kliniek in de richting van de pathofysiologie te begeven heb-
ben anderen ondertussen vooruitgang op genetisch gebied geboekt, door het iden-
tificeren van een mutatie in het SEPT9 gen in enkele HNA families. Dit betekent dat 
nu ook vanuit dit basale perspectief stappen kunnen gaan worden ondernomen om 
de factoren verantwoordelijk voor de onderliggende gevoeligheid te identificeren. 
Hopelijk komen beide onderzoekslijnen in de nabije toekomst bij elkaar.
 
Een laatste bijdrage aan het bewijs voor een immuun-gemedieerd ontstaan van 
de aanvallen werd gevonden in de resultaten van de open-label behandeling met 
prednison van een aantal patiënten in de acute fase. Hierbij werd bij een aantal een 
gunstige respons op het ziektebeloop gevonden, met name bij degenen bij wie de 
behandeling binnen twee weken na ontstaan kon worden gestart.
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Op weg naar behandeling
Terugkerend naar de boodschap van het begin van dit proefschrift is het noodza-
kelijk dat alle onderzoeksinspanningen uiteindelijk ook leiden tot de mogelijkheid 
voor patiënten om de individuele kwetsbaarheid en prognose te voorspellen, en 
behandelingen te vinden die leiden tot troost, verlichting en genezing. Samen-
werking met andere onderzoekers is onmisbaar om dergelijke doelen te halen. De 
samenwerking met onze Rotterdamse collega’s heeft het mogelijk gemaakt een 
gerandomiseerde, placebo-gecontroleerde trial op te zetten die het effect van een 
orale prednisonkuur in de acute fase van de aanvallen onderzoekt. Een gezamen-
lijk project met twee Nederlandse afdelingen Revalidatiegeneeskunde, waarbij 
het voorkomen van afwijkingen in het schoudergewricht en de biomechanische 
gevolgen van scapula instabiliteit zullen worden onderzocht, gaat proberen om 
de ratio achter revalidatieprogramma’s voor NA patiënten verder te onderbouwen. 
En tot slot blijft het voor een optimale patiëntenzorg noodzakelijk om voortdurend 




Ook het onderzoeken van de expressie van SEPT9 en het bijbehorende genproduct 
in menselijk plexus brachialis weefsel in vergelijking met ander perifere zenuw-
structuren zou interessant zijn, om te zien of de mate van expressie correleert met 
de klinische gevoeligheid van een bepaalde structuur voor NA. Het zou nog mooier 
zijn als ter vergelijking in een dergelijke studie ook materiaal van een HNA patiënt 
met een SEPT9 mutatie kon worden onderzocht.
Meer laboratoriumonderzoek
Ook verscheidene immunologische onderzoeksrichtingen lijken belovend. Men 
zou kunnen beginnen met de gastheer (de NA patiënt) als uitgangspunt te nemen 
om factoren te vinden die het optreden van een auto-immuun proces in de plexus 
faciliteren. In samenwerking met collega’s van het Erasmus Medisch Centrum te 
Rotterdam onderzoeken we op dit moment in een grote groep zowel erfelijke als 
idiopathische NA patiënten de statistische associatie met een bepaalde immuno-
genetische opmaak. Hierbij worden verschillende zogenaamde immunogenetische 
polymorfismen onderzocht, en ook wordt nogmaals gekeken naar de prevalentie en 
typering van antiganglioside antilichamen. Het zou interessant zijn om vervolgens 
dezelfde technieken te gebruiken als bij GBS is gedaan om de rol van het immuun-
systeem bij NA te ontrafelen.
De noodzaak van epidemiologisch onderzoek
Het onderzoeken of er clusters van NA gevallen (cq. epidemieën) optreden in Neder-
land zou een andere manier kunnen zijn om de precieze relatie met antecedente 
infecties te identificeren. Hiervoor is het eerst noodzakelijk om alle NA gevallen op 
een adequate manier te registreren in een landelijke database, zoals bijvoorbeeld 
de CRAMP (‘Computer Registration of All Myopathies and Polyneuropathies’) die 
sinds 2000 beschikbaar is in de neuromusculaire centra.
Behalve voor bovenstaande is een voldoende mate van bewustzijn voor het feit 
dat diagnose NA bestaat ook nodig om uit te zoeken of NA en vooral HNA onder- 
gediagnosticeerd zijn, of vice versa om vast te stellen wat de echte incidentie van 
de aandoening is wanneer alle klinische uitingsvormen adequaat herkend worden. 
Pas dan kan men kennis van de a priori kans op NA op de juiste manier opnemen in 
het klinisch-diagnostische proces voor patiënten met een plotselinge pijn en uitval 




Algemeen overzicht plexopathieën. 
Inleiding
Plexopathieën staan bekend als ‘lastige’ aandoeningen, zowel in algemene prak-
tijk maar ook voor de neuroloog. Dit komt vooral vanwege hun relatief zeldzame 
voorkomen, en de ingewikkelde anatomische basis die er aan ten grondslag ligt.
Toch is het in de praktijk vaak goed mogelijk om met enkele specifieke, relatief een-
voudige vuistregels op het juiste diagnostische pad te komen. Dit helpt u goed te 
zorgen voor patiënten met een aandoening die vaak langdurige en verstrekkende 
gevolgen heeft in het dagelijks functioneren.
In onderstaande worden achtereenvolgens aandoeningen van de plexus brachialis 
en plexus lumbosacralis besproken, met een kort overzicht van de anatomie, en 
aandacht voor de oorzaken, differentiaaldiagnose en bijbehorende epidemiologie. 
Extra aandacht wordt besteed aan de idiopathische plexus brachialis neuropathie of 
neuralgische amyotrofie. Er worden suggesties gegeven voor het te volgen diagnos-




De plexus brachialis bestaat uit een vlechtwerk van zenuwen naar de schouder en 
arm, gevormd door de voortzetting van de ventrale rami van de zenuwwortels C5 
t/m T1. Het vlechtwerk hangt uitgespannen achter het sleutelbeen tussen nek en 
oksel (fig. 1). Naast de motore en sensibele zenuwvezels lopen in de plexus ook au-
tonome vezels, verantwoordelijk voor o.a. de vasovegetatieve aansturing van de arm 
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Differentiaaldiagnose
De DD van een plexus brachialis neuropathie bestaat uit 3 groepen aandoeningen: 
enkele specifieke aandoeningen die het spectrum van de plexopathieën zelf vormen, 
andere perifere neurologische aandoeningen die pijn en uitval in de schouder en/of 
arm veroorzaken, en niet-neurologische, vooral orthopedische of reumatologische 
oorzaken van pijn en functieverlies in de bovenste extremiteit. Zie hiervoor tabel 1.
Het overgrote deel van de brachiale plexopathieën wordt veroorzaakt door een 
trauma (zie tabel 2). Andere relatief frequente oorzaken zijn idiopathische plexus 
brachialis neuropathie of neuralgische amyotrofie, en plexopathieën gerelateerd 
aan een tumor of na bestraling.
Tabel 1. Differentiaaldiagnose plexopathie van de arm
Aandoening die een plexopathie kunnen geven  Kenmerken
Trauma Directe relatie in tijd
Neuralgische amyotrofie Extreem pijnlijk, snel atrofie
Tumoren, o.a. Pancoast Pancoast: begint in onderste plexus / 
 T1, vaak Horner syndroom
Bestraling 5 (0.5-30) jaar na RTx, paresthesieën
Erfelijke drukneuropathie (HNPP) Vaak voorgeschiedenis CTS 
 of klapvoet
Iatrogeen (bv. na locaal anesthesie, subclavia catheter, Directe relatie in tijd
thoraxchirurgie) 
Neurogeen thoracic outlet syndroom Zeldzaam, langzaam progressief, 
 C8 / T1
 
Andere perifeer neurologische aandoeningen Kenmerken 
Cervicaal radiculair syndroom Pijn houdingsafhankelijk, 
 paresthesieën
Compressie neuropathieën Paresthesieën en pijn in hand /
  onderarm; soms atypische uitstraling
Mononeuropathia multiplex In kader autoimmuunziekte, pijnlijk
Amyotrofe lateraal sclerose Geen pijn of sensibele stoornis, 
 progressief, piramidebaansyndroom
Multifocale motore neuropathie Geen pijn of sensibele stoornis
Limb girdle myopathie of spierdystrofie Sommige vormen armen > benen,
 asymmetrie kan in begin
1
algemeen overzicht plexopatiënten
Figuur 1. Plexus brachialis
en hand. Een belangrijke bijdrage hierin wordt geleverd door takken van de halssym-
pathicus, die met wortel T1 meelopen.
Is het een plexopathie?
De klinische verdenking op een plexopathie ontstaat in 2 stappen:
• De aanwezigheid van sensibele symptomen als doofheid en tintelingen, naast 
 pijn, en een actieve bewegingsbeperking (= parese) van spieren in arm of schouder 
 zetten u op het spoor van een perifere neurologische aandoening
• Bij klinisch neurologisch onderzoek zijn de symptomen niet te herleiden tot een 
 lesie van 1 zenuwwortel of perifere zenuw
De klinische verdenking op een plexopathie is een reden om patiënt direct voor ver-
dere diagnostiek te verwijzen, bij voorkeur naar de neuroloog.
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schouder- of nekklacht en reageert niet of nauwelijks op pijnstillers (inclusief opi-
aten). In het begin is de pijn continu aanwezig en nauwelijks te beïnvloeden door 
verandering van houding o.i.d. Karakteristiek wordt de arm beschermend tegen het 
lijf gehouden, en patiënten liggen vaak nachtenlang wakker van de pijn en ellende.
Meestal ontstaat enkele uren tot dagen, maar soms ook pas na weken, een vlekkig 
verdeelde verlamming van schoudergordel- en armspieren. Ook is er vaak opval-
lend snel een forse atrofie van de aangedane spieren. Heel karakteristiek is het zgn. 
scapula alata (zie fig. 3), maar dit komt zeker niet bij elke patiënt voor. Behalve de 
klassieke ‘proximale’ vorm waarbij vaak het heffen van de arm en exoroteren van 
de schouder is aangedaan, bestaan er ook meer distale vormen waarbij het strekken 
van pols en vingers of de kleine handspieren vaak ernstig beperkt zijn (fig. 4). Bij 
goed navragen zijn er vaak wel sensibele klachten in de vorm van tintelingen of een 
lichte hypesthesie, maar deze staan meestal niet op de voorgrond.
Figuur 3. Scapula alata rechts   Figuur 4. Forse atrofie en parese distaal rechts
De pijn verloopt meestal in 3 fasen: eerst de continue extreme neuropathische pijn 
gedurende enkele dagen - weken, daarna verdwijnen van de pijn in rust maar toe-
name bij bewegen of rek aan de beschadigde plexus, en tot slot krijgen veel patiën-
ten last van een hardnekkige spierpijn door overbelasting van de paretische, maar 
ook van de compenserende gezonde spiergroepen. De parese herstelt langzaam in 
de loop van maanden tot enkele jaren. Dit trage herstel en het ontstaan van spier-
pijnklachten door surmenage geeft vaak langdurige (gedeeltelijke) arbeidsonge-




Niet-neurologische aandoeningen Kenmerken 
Impingement syndroom ‘Painful arc’, acuut (jong) of chronisch
Rotator cuff scheur en arthropathie Moeite initiëren abductie, soms pijn
Frozen shoulder / adhesive capsulitis Begin fors pijnlijk, later niet meer, 
 bewegingsbeperking passief en actief
Bicepspeesruptuur Bijna altijd proximale ruptuur lange 
 kop, initieel pijn, veranderde contour
Supraspinatus tendinitis (calcificerend) Vaak acute pijn, zwelling, roodheid
(Reumatoide) arthritis Meestal bekende RA patiënt
Schouderluxatie Veranderde contour, soms habitueel
Tenniselleboog / epicondylitis lateralis Pijn toename bij belasten, strekken
 pols
Sympathische reflex dystrofie (CRPS I) Per exclusionem, vasovegetatieve  stoor-
 nissen, functiebeperking en pijn eci
Tabel 2. Epidemiologie plexopathie van de arm.
Aandoening Hoe vaak Geschatte incidentie
 
Trauma 70% 1.2% alle traumapatiënten
Neuralgische amyotrofie 15% 4 / 100.000 / jaar (+/- 500 / jaar in NL)
Na bestraling 6% 2 - 5% locaal bestraalde patiënten
Door tumor 4% onbekend (afhankelijk type tumor)
Overige 5%
 - obstetrisch  2 / 1000 levendgeborenen
 - neurogeen thoracic outlet syndroom  0.1 / 100.000 / jaar 
Idiopathische plexus brachialis neuropathie
Deze aandoening wordt tegenwoordig meestal neuralgische amyotrofie genoemd, 
maar is ook nog bekend onder de wat oudere benamingen als ‘Parsonage en Turner 
syndroom’ en ‘plexus neuritis’. Er bestaat een idiopathische en een (zeldzame) auto-
somaal - dominant erfelijke vorm van. Hèt kenmerk van deze aandoening is het 
acute begin met extreme, zéér hevige pijn in de nek, schouder en/of arm. Als pijn-
score (VAS) geven patiënten vaak 8 - 10 uit 10 aan. Vaak zijn het mensen die nooit eer-
der schouder- of pijnklachten hadden. De pijn is veel heviger dan bij een ‘gewone’ 
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• Bij klinisch neurologisch onderzoek zijn de symptomen niet te herleiden tot een 
 lesie van 1 zenuwwortel of perifere zenuw
De klinische verdenking op een plexopathie is een reden om patiënt direct voor ver-
dere diagnostiek te verwijzen.
Differentiaaldiagnose
Ook bij de plexus lumbosacralis neuropathie valt de DD in 3 categorieën uiteen: 
specifieke aandoeningen die een lumbosacrale plexopathie geven, andere perifere 
neurologische aandoeningen die pijn en uitval in de heup, bil of been veroorzaken, 
en niet-neurologische, vooral orthopedische of reumatologische oorzaken van pijn 
en functieverlies in de onderste extremiteit. Zie hiervoor tabel 3. 
Figuur 2. Plexus lumbosacralis
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Behandeling neuralgische amyotrofie (NA) in de acute fase
De pathofysiologie van een episode of aanval is waarschijnlijk een vlekkige ontste-
king binnen de plexus brachialis op auto-immune basis. Om te proberen schade 
aan de zenuwen zoveel mogelijk te voorkomen of beperken tijdens deze ontste-
king, is recent een trial gestart waarin patiënten zo vroeg mogelijk na het ontstaan 
van klachten behandeld worden met een stootkuur prednison of placebo. Mocht 
u een patiënt hebben die hier voor in aanmerking zou komen, dan kunt u deze 
aanmelden via een speciaal telefoonnummer: 06-24741697, of via het emailadres: 
NAonderzoek@neuro.umcn.nl. Wij nemen dan zo snel mogelijk contact op met de 
patiënt. Uiteraard houden we u op de hoogte van de bevindingen.
De standaard behandeling tot nu toe is pijnstilling in de vorm van een langwer-
kend NSAID in combinatie met een opiaat (zie tabel 5), en fysiotherapie zodra de 
pijnklachten het enigszins toelaten. Co-analgetica zoals carbamazepine of gaba-
pentin zijn in theorie het meest geschikt voor de neuropathische pijn, maar in de 
praktijk laat het effect vaak te lang op zich wachten (4-6 weken) om echt van nut te 
zijn in de acute fase van een aanval van NA.
Plexus lumbosacralis
Anatomie
De plexus lumbosacralis is opgebouwd uit 2 delen: de plexus lumbalis en de plexus 
sacralis. De plexus lumbalis wordt gevormd door de ventrale rami van de wortels L2 
t/m L4, en is grotendeels paravertebraal gelegen in de m. psoas. De plexus sacralis 
wordt gevormd door de ventrale rami van de wortels L5 t/m S2, en ligt tegen de 
achterwand van het kleine bekken. De beide delen zijn met elkaar verbonden door 
de truncus lumbosacralis, die vooral bestaat uit wortel L5, en over de bekkenrand 
loopt. Waarschijnlijk door de beschermde ligging in het bekken komen lumbosa-
crale plexopathieën veel minder frequent voor dan plexus brachialis aandoeningen.
Is het een plexopathie?
Zoals hierboven reeds beschreven ontstaat de klinische verdenking op een plexopa-
thie in 2 stappen:
• De aanwezigheid van sensibele symptomen als doofheid en tintelingen, naast pijn, 
 en een actieve bewegingsbeperking (= parese) van spieren in heup, bil of been zet-




Lumbago en ischias (bij degeneratieve wervelkolom) Pijn in rug > in been, houding- en
  bewegingsafhankelijk
Arthrose heupgewricht Locale pijn, functiebeperking 
 ook passief
Collumfractuur Pijn lies, verkorting en exorotatie 
 femur
Ossale metastasen bekken of femur Diepe pijn, soms pathologische 
 fractuur
Diep veneuze trombose Pijn, zwelling, functieverlies kuit
Compartiment syndroom Na trauma of surmenage; strakke huid, 
 zwelling, paresthesieën
Omdat plexus lumbosacralis neuropathieën relatief zeldzaam zijn, ontbreken goe-
de epidemiologische gegevens. Een overzicht van de geschatte incidenties staat in 
tabel 4.
Het grootste deel van deze plexopathieën wordt veroorzaakt door (bekken-) trau-
ma’s, maligniteiten en diabetes mellitus. 
Tabel 4. Epidemiologie plexopathie van het been.
Aandoening Geschatte incidentie
Diabetische amyotrofie 0.8% type I en II diabeten 
 (waarvan in totaal zo’n 700.000 in NL)
Trauma 2 - 5% bij bekkenfractuur
Door tumor < 1% patiënten met kanker
Tijdens zwangerschap of partus 1 / 2000 - 6000 bevallingen
Iatrogeen, na operatie < 0.2% patiënten na bekkenoperatie
Na bestraling < 0.2% locaal bestraalde patiënten
Psoas hematoom onbekend
Idiopathische plexus lumbosacralis neuropathie enkele honderden casus in literatuur
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Tabel 3. Differentiaaldiagnose plexopathie van het been
Aandoening die een plexopathie kunnen geven Kenmerken
Diabetische amyotrofie Extreem pijnlijk, bovenbeen, atrofie, 
 gewichtsverlies; redelijk herstel < 1 jaar
Trauma met bekkenring fractuur Directe relatie in tijd
Laatste trimester zwangerschap of partus Vanaf 32-34 weken, bijna altijd L5-S1, 
vaak volledig herstel < 3 maanden
Tumor (kleine) bekken Vaak locale ingroei, ernstige pijn, 
 oedeem extremiteit
Psoashematoom Bij hemofilie, antistollingstherapie 
 of lekkend AAA
Na bestraling 5 (0.5-30) jaar na RTx, m.n. zwakte 
 L5-S1
Idiopathische plexus lumbosacralis  Extreem pijnlijk, redelijk herstel;
neuropathie per exclusionem
Infectieus: genitale herpes zoster, EBV en Borrelia Antecedent, huidlesies of serologie 
 nodig; behandelbaar
Abces psoas of kleine bekken M.n. na ingrepen, lage weerstand,TBC
Andere perifeer neurologische aandoeningen Kenmerken 
Lumbosacraal radiculair syndroom Acuut begin, uitstralende pijn 1 wortel, 
 m.n. S1 of L5; eerder rugklachten
Caudasyndroom Acute uitval multipele wortels 
 èn gestoorde mictie
Neurogene claudicatio Uitstralende pijn bij lopen, langzaam 
 progressief; bukken / fietsen goed 
Klapvoet (soms als uiting erfelijke  Na bedrust, rolstoel, of benen over
drukneuropathie / HNPP) elkaar geslagen zitten; prognose goed
Meralgia paresthetica Paresthesieën laterale bovenbeen, o.a. 
 na gewichtsreductie; prognose goed
Piriformis syndroom Lokale compressie n. ischiadicus, 
 per exclusionem





Uiteraard wordt eerst gezocht naar een behandelbare oorzaak van de plexopathie. Is 
deze er niet, dan wordt de aandacht gericht op pijnbestrijding, complicatiepreven-
tie, en het scheppen van de meest optimale omstandigheden voor spontaan herstel.
Pijnmedicatie
Bij acute hevige pijn werkt vaak een combinatie van een langwerkend NSAID en 
opiaat het beste. Is te verwachten dat de pijn langer dan enkele weken aanhoudt, 
dan wordt het zinvol een co-analgeticum bij te geven, om de neuropathische com-
ponent van de pijn te dempen. Wees wijs maar zeker niet te zuinig met pijnstilling: 
deze neuropathische pijnen kunnen zeer hevig en invaliderend zijn! Progressie van 
de pijn ondanks pijnstilling noopt tot zoeken naar een onderliggende progressieve 
etiologie of het ontstaan van complicerende factoren zoals gewrichtsklachten of 
tendomyogene overbelasting.
Tabel 5. Voorbeeld pijnmedicatie bij plexopathie
Soort neuropathische pijn Medicatie
acuut diclofenac retard 2 dd 100 mg +
 MS Contin 2 dd 10 mg 
 (cave: maagprotectie en laxans)
chronisch, vooral schietend / stekend bovenstaande en:
 carbamazepine 2 dd 100 - 200 mg,  
 of gabapentin 3 dd 600 - 1200 mg
chronisch, vooral brandend zie acute pijn, en:
 amitriptyline 2-3 dd 10 - 25 mg
TENS
Als medicamenteuze pijnstilling alleen onvoldoende helpt, kan soms een TENS 
(Transcutaneous Electrical Neuro-Stimulation) apparaat nog extra verlichting 
geven. Dit apparaat, een soort ‘walkman’ waaraan een aantal electroden die met 
plakkers op het pijnlijke lichaamsdeel bevestigd worden, overstemt met z’n elec-
trische prikkels als het ware de pijnsignalen die het ruggenmerg bereiken. De 
patiënt dient het apparaatje zelf met een machtiging bij de ziektekostenverzekeraar 
aan te vragen, en vervolgens zich met een nieuwe machtiging door de fysiothera-





De basis voor het diagnosticeren van een plexopathie blijft een gerichte neurolo-
gische anamnese en goed klinisch onderzoek. Verder zijn een aantal hulponder-
zoeken nuttig bij de verdenking op een plexopathie. Als bij klinisch onderzoek 
twijfel bestaat of de symptomen veroorzaakt worden door een aandoening van het 
perifere zenuwstelsel, die niet tot 1 wortel of zenuw beperkt is, kan een electro-
myografie (EMG) dit aantonen of onwaarschijnlijk maken. EMG onderzoek van de 
plexus is overigens niet gemakkelijk, en men moet goed weten waar men de lesie 
verwacht om ook gericht zenuwen of spieren te kunnen meten - anders is de kans 
op een vals-negatieve uitslag groot.
Voor het aantonen of uitsluiten van een structurele lesie is beeldvorming in de vorm 
van een CT scan of MRI noodzakelijk. Slechts zelden kan een echo-onderzoek vol-
staan. Bloedonderzoek dient vooral om onderliggende systemische aandoeningen 
die de plexopathie zouden kunnen veroorzaken aan te tonen of onwaarschijnlijk te 
maken. Zie hiervoor ook tabel 1 en 3.
Prognose
Het is lastig een uitspraak te doen over ‘de prognose van een plexopathie’ in het alge-
meen. De prognose van brachiale en lumbosacrale plexopathieën hangt namelijk 
volledig af van een combinatie van factoren zoals:
• de oorzaak (behandelbaar, reversibel versus onomkeerbaar of progressief)
• het patroon en de uitgebreidheid van de uitval (ADL- relevante spiergroepen 
 of niet)
• de mate van axonale schade (herstel enkele millimeters per week vanaf plaats bescha- 
 diging) versus ‘alleen’ neurapraxie (met herstel myelineschede in 2-3 maanden)
•  de onderliggende lichamelijke toestand van de patiënt
Sterk vereenvoudigd kan gezegd worden dat de prognose in een van de volgende 3 
categorieën zal vallen:
• herstel binnen enkele maanden (reversibele oorzaak, alleen neurapraxie, verder 
 gezonde patiënt)
• herstel na 0.5 - 3 jaar (axonale schade, oudere of sowieso minder mobiele patiënten) 
• geen herstel (progressieve uitval; m.n. tumoren of na bestraling)
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‘Wel of geen fysio?’
Veel patiënten met een plexopathie komen met de vraag of fysiotherapie verstandig 
is of juist gecontraindiceerd. In het algemeen geldt dat ‘blijven bewegen’ het beste 
advies is. Echt kracht trainen in paretische spieren is vrijwel zinloos, maar samen 
met een fysiotherapeut proberen een zo normaal en vloeiend mogelijk beweging-
spatroon te handhaven geeft zeker winst. Men start dan ook het liefst zo vroeg 
mogelijk met fysiotherapeutische begeleiding. In het begin, zeker als de bescha-
digde zenuwen nog rekpijnlijk zijn, zal het vooral gaan om het voorkómen van 
contracturen, door passief bewegen. Naarmate de zenuwen herstellen kan er steeds 
meer actief geoefend worden, en in de loop der tijd worden het aantal herhalingen 
en evt. de kracht uitgebreid. Patiënten hoeven niet bang te zijn de zenuwen door 
het oefenen extra te beschadigen. Een uitzondering hierop vormen mensen met 
een erfelijke drukneuropathie of HNPP; zij hebben in aanleg zenuwen die gevoe-
liger zijn voor rek, druk en trek. Hierbij is specialistisch advies noodzakelijk.
Specifieke pijnklachten bij een plexopathie van de schouder
In het geval van een parese van de spieren die schouderblad op de romp fixeren (m.n. 
de serratus anterior, trapezius en rhomboid) klagen patiënten vaak over een toe-
name van pijn in de arm en schouder als deze langere tijd afhangt, zoals bij lopen 
of lang staan. Bij lichamelijk onderzoek is dan meestal ook duidelijk een afglijden 
van het scapula op de romp in rust zichtbaar; vaak naar lateraal en beneden. Door 
het gewicht van de arm ontstaat tractie op de spieren die aan het scapula vast zit-
ten. Alhoewel patiënten ook in zo’n geval zeker de arm zoveel mogelijk soepel en in 
beweging dienen te houden, kan het aan te raden zijn om bij lang staan of lopen 
de arm in de jaszak of in een sling o.i.d. te hangen om zo de schouder tijdelijk te 
ontzien. Dit geeft vaak adequate verlichting.
Ook krijgt een deel van de patiënten last van een soort chronische spierpijn in de 
paretische houdingsspieren. De meeste schouder- en bekkengordelspieren zijn de 
hele dag ongemerkt actief bezig een lichaamshouding in stand te houden, en krij-
gen derhalve ‘geen rust’. Bijvoorbeeld het goed kunnen bewegen van onze armen, 
m.n. vooruit en boven de macht, is voor een belangrijk deel afhankelijk van een 
stabiel schouderblad waartegen de arm zich kan afzetten. Als de spieren die hier-
voor zorgen verzwakt zijn, moeten ze continu maximaal aanspannen om nog enige 
stabiliteit te kunnen geven. En dit de hele dag door, iedere dag weer. De chronische 
spierpijn die hierbij ontstaat reageert in onze ervaring nauwelijks op pijnstillers. 




Door een plexopathie verliezen patiënten vaak functie in een aantal spiergroepen 
gedurende maanden of jaren. Behalve de directe gevolgen hiervan, zoals het niet 
meer kunnen uitvoeren van een bepaalde beweging of handeling, kunnen hierbij 
enkele lange termijn complicaties optreden (zie tabel 6) die met de juiste begelei-
ding grotendeels te voorkomen of te behandelen zijn.
Tabel 6. Complicaties door uitval bij een plexopathie
Complicatie Praktijkvoorbeelden
‘verkeerde houding’: antalgisch arm tegen lijf houden, mankend 
 lopen, 
‘verkeerde houding’: ter compensatie uitval hooghouden schouder met m. 
 trapezius bij uitval serratus anterior of 
 deltoid, knie op slot (hyperextensie) 
 bij staan bij quadricepszwakte
 surmenage: paretische spieren pijn 
 onder schouderblad en op romp bij
 serratus anterior uitval, pijn knie bij 
 quadricepszwakte
surmenage: in compenserende spieren trapezius pijn en hypertonie bij 
 schouderzwakte
gewricht: kapselverstijving frozen shoulder na pijn / immobiliteit
gewricht: (sub-)luxatie m.n. schouder bij zwakte m. 
 supraspinatus
tendinopathie rotator cuff impingement of degene-
 ratie / ruptuur
Het is dan ook aan te raden om uw patiënt na de initiële diagnostiek en evt. thera-
pie te verwijzen naar een fysiotherapeut, of als er begeleiding op meerdere vlakken 
gewenst is, naar een revalidatiearts. Deze laatste is ook zeker belangrijk als er sprake 
is van arbeidsongeschiktheid door de pijn of uitval, vooral omdat herstel vaak lang-
er duurt dan de huidige termijn voor beoordeling van de WAO. Tevens kan deze zo 
nodig ergotherapeutisch advies of voorzieningen aansturen.
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wisselen, niet te lang achtereen te doen, en in het geval van een instabiel schouder-
blad rust te nemen door plat op de rug te gaan liggen. Vaak is locale warmte prettig; 
soms biedt een scapula-brace enige steun.
Referenties
• Brachial plexopathies (chapter 48) and Lumbosacral plexopathies (chapter 49). 
 Neuromuscular Disorders. Bashar Katirji, Henry J. Kaminski, David C. Preston, 
 Robert L. Ruff, Barbara E. Shapiro, eds. Butterworth-Heinemann; 1st edition, 2002.
• Brachial plexus lesions (chapter 48) and Lumbosacral plexus lesions (chapter 49). 
 Peripheral Neuropathy. Peter James Dyck, P.K., M.D. Thomas, Peter James, M.D. 
  Dyck, eds. W.B. Saunders Company; 3nd edition 1993.
• Peripheral Nerve Lesions: Diagnosis and Therapy. Mark Mumenthaler, Hans    
  Schliack, Marco Mumenthaler, Heinz Goerke. Thieme Medical Publishers; 1990.
• NHG Standaard Schouderklachten M08 (mei 1999).
• van Alfen N, van Engelen BGM. Wat is bekend over amyotrofische schouder-
 neuralgie? Neurologen Vademecum nr. 5, mei 2002. Bohn Stafleu van Loghum 
 Bv, Houten.
Meer informatie
• De patiënten-informatiefolder over erfelijke en niet-erfelijke neuralgische amyo-
  trofie is te vinden op de website van het UMCN www.umcn.nl/patient/patienten- 
 folders/overigen.
• Professionele informatie over neuralgische amyotrofie en lumbosacrale plexo-
 pathie is te vinden op de website www.isno.nl/sorteer/ziekten.php 
• Bij verdenking op een acute aanval van neuralgische amyotrofie kunt u voor 
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Nu weet u waarschijnlijk uit eigen ervaring dat inderdaad de spieren en het gevoel 
in schouders, armen en handen vaak aangetast zijn bij deze aandoening. Maar om-
dat bij sommige mensen ook de zenuwen van de stembanden en slokdarm, van de 
benen, en van de buikspieren zijn aangedaan, wil men het liefst een benaming die 
deze plaatsen niet uitsluit. Vandaar dat we in het vervolg de term ‘neuralgische 
amyotrofie’, of de afkorting ‘NA’ gebruiken.
2. Geschiedenis en bekendheid
De eerste patiënten met NA werden rond 1850 beschreven, en pas zo’n 30 jaar later 
viel het een Duitse arts op dat er ook een erfelijke vorm bestond. In 1948 beschreven 
de Engelse artsen Parsonage en Turner 136 patiënten met NA, en die beschrijving 
was zo treffend dat de aandoening lange tijd hun beider namen heeft gedragen. Toch 
is NA bij veel artsen een grotendeels onbekende ziekte gebleven. Hierdoor werd en 
wordt deze aandoening niet altijd herkend. Soms krijgen patiënten hierdoor als di-
agnose ‘spierzwakte’ mee, of ‘reuma’. Dit ondanks het feit dat er jaarlijks in Neder-
land zo’n 500-600 mensen de aandoening krijgen.
Een aandoening waar de erfelijke vorm van NA (HNA) op lijkt is de zogenaamde 
erfelijke drukneuropathie (in het Engels hereditary neuropathy with liability to 
pressure palsies, of ‘HNPP’). Dit laatste is een aandoening waarbij de zenuwen zo 
gevoelig zijn voor druk, dat als er een tijdje op gesteund wordt (bijvoorbeeld door 
steunen op de elleboog) er een pijnloze verlamming optreedt. Dat deze verlamming 
bijna nooit pijnlijk is, is het belangrijkste verschil met HNA. Maar we weten pas 
zeker dat het twee verschillende aandoeningen zijn sinds we HNPP door onderzoek 
van het erfelijk materiaal (DNA) kunnen aantonen of uitsluiten.
Van de HNA zijn in totaal over de hele wereld zo’n 250 mensen bekend uit 45 fami-
lies. Zo’n 30 van deze patiënten kennen we uit onderzoek binnen het Neuromuscu-
lair Centrum Nijmegen. HNA is dus een erg zeldzame aandoening, die waarschijn-




Deze folder is geschreven door N. van Alfen en B.G.M. van Engelen in aansluiting 
op het onderzoek dat sinds 1995 in het UMC St. Radboud gedaan wordt naar de erfe-
lijke en niet-erfelijke vormen van de aandoening ‘Neuralgische Amyotrofie’. In de 
folder worden een aantal kenmerken van deze aandoeningen behandeld. Het kan 
dat er dingen in staan die u al wist. Toch is er voor een uitgebreide uitleg gekozen, 
zodat u zo goed mogelijk geïnformeerd wordt. U kunt deze informatie ook aan an-
deren (familie, vrienden, of behandelend artsen) doorgeven.
De tekst bevat een aantal medische termen die bij deze aandoening horen. Deze 
woorden staan schuin gedrukt en worden zoveel mogelijk uitgelegd. Ze zijn niet 
noodzakelijk voor het begrijpen van de tekst. Als u na het lezen nog vragen heeft, 
neem dan gerust contact op met het Neuromusculair Centrum Nijmegen: 024-
3615202, of via email: NAonderzoek@neuro.umcn.nl.
 1. Naam
De aandoening waar het bij u om gaat heet officieel ‘neuralgische amyotrofie’. Dit 
wordt ook wel afgekort tot ‘NA’. De Latijnse term betekent letterlijk vertaald: ‘een 
met zenuwpijn gepaard gaande, niet meer groeien van de spieren’. Er bestaan twee 
vormen van deze aandoening: de erfelijke (‘hereditaire neuralgische amyotrofie’ of 
HNA) en de niet-erfelijke vorm (idiopathische neuralgische amyotrofie’ of INA). 
Deze laatste aandoening wordt ook wel het syndroom van Parsonage en Turner ge-
noemd.
Neuralgische amyotrofie is een beschrijvende term: er wordt mee gezegd wàt er aan 
de hand is, maar niet waarom of waardoor. De term geeft ook niet aan op welke 
plaats van het lichaam de aandoening optreedt. Maar omdat bij NA meestal de 
spieren van schouder, arm en hand aangedaan worden, werd de aandoening vroeger 
(en door sommige artsen ook nu nog ) anders genoemd. Bijvoorbeeld ‘plexus bra-
chialis neuritis’ of ‘plexus brachialis neuropathie’. Met ‘plexus brachialis’ wordt het 
vlechtwerk van zenuwen uit het ruggenmerg bedoeld, dat zich in de hals ter hoogte 
van het sleutelbeen bevindt (zie ook het plaatje op de voorpagina van deze folder). 
Deze zenuwen verzorgen de ‘aansturing’ van de spieren en het gevoel in de schou-
ders, armen en handen.
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  worden, of dat aanraken pijn doet, hoe warm of koud iets aanvoelt, en hoe onze ge- 
  wrichten staan ten opzichte van elkaar ( of we bijvoorbeeld rechtop staan of zitten). 
 In medische termen heet dit: ‘sensibele geleiding’.
• Elektrische prikkels vanuit de hersenen en het ruggenmerg naar de kleine bloed- 
 vaatjes in de huid en spieren. Hierdoor weten de bloedvaatjes hoever ze open of 
 dicht moeten gaan staan. Dit is bijvoorbeeld belangrijk als het erg warm is: de  
 vaatjes gaan dan ver open staan - de huid wordt dan rood en warm - zodat er veel 
 bloed doorstroomt dat af kan koelen ‘aan de buitenlucht’. En andersom: als het 
 koud is gaan de vaatjes juist dicht om afkoeling te voorkomen. In medische termen 
 heet dit: ‘autonome’ of ‘vasovegetatieve geleiding’.
Figuur: schema axon en myelineschede
Hoe ontstaan nu de klachten bij deze aandoening?
Bij NA wordt waarschijnlijk het axon aangedaan, en niet de isolatie eromheen. Om 
ons nog onbekende redenen (zie ook hoofdstuk 6) gaat het axon ‘ineens’ gedeeltelijk 
of helemaal kapot. Ter vergelijking: als de elektriciteitsdraad kapot gaat, geeft hij 
geen of nog maar weinig stroom meer door. Hetzelfde geldt voor de zenuw bij deze 
aandoening: hij geeft geen of nog maar weinig prikkels door.
Wat merkt iemand als een zenuw beschadigd wordt?




De klachten bij neuralgische amyotrofie verlopen in aanvallen. Eerst ontstaat een 
zeer hevige  pijn in de schouder of arm, en enkele uren tot dagen later raken een aan-
tal spieren van die arm verlamd. De pijn duurt meestal een paar dagen tot weken, 
herstel van kracht kan maanden tot jaren duren. Bij de niet-erfelijke vorm maken 
verreweg de meeste patiënten maar één aanval door. Slechts 1 op de 20 mensen krijgt 
het nog een keer terug. Mensen met de erfelijke vorm maken gemiddeld één maal 
per 6 1/2  jaar een aanval door.
Ondertussen weten we dat de plaats, ernst en duur van de pijn, en ook van de verlam-
mingen, erg kunnen verschillen per patiënt.  In de meest milde vorm kan iemand 
bijvoorbeeld een paar uur pijn in de schouder en onderarm hebben, en daarna een 
aantal maanden problemen met het buigen van het topje van duim en wijsvinger. 
Aan de andere kant kunnen de pijnklachten ook maandenlang aanhouden, heeft ie-
mand twee volledig verlamde armen en gaat ademen tijdens plat liggen nauwelijks 
meer, en is het herstel na 5 jaar nog niet volledig. En er bestaab allerlei vormen daar 
tussenin. Uw neuroloog zal bij u kunnen vaststellen of u een milde of ernstigere 
aanval heeft gehad. De persoonlijke verhalen van enkele patiënten in deze folder 
betekenen dus niet dat NA ook bij u er zo uit zal zien.
NA is op de eerste plaats een aandoening van de zenuwen. Alle klachten en symp-
tomen kunnen van hieruit verder verklaard worden. Een zenuwvezel is het best 
vergelijkbaar met een elektriciteitsdraad die stroom geleidt. Binnenin zit het axon 
(= het koperdraad). Daaromheen zit een isolerende laag (het plastic omhulsel), deze 
noemen we de myelineschede. In de onderstaande figuur zijn het axon en de mye-
lineschede getekend. Net als de meeste elektriciteitsdraden bestaan zenuwen uit 
bundels van axonen (= strengen koperdraad) die samen in een groter omhulsel 
liggen.
Zenuwen zorgen voor een aantal dingen:
• De geleiding van elektrische prikkels vanuit de hersenen, via het ruggenmerg, naar 
 de spieren. Hierdoor ‘weten’ de spieren wanneer en hoe sterk ze moeten samen- 
 trekken. In medische termen heet dit: ‘motorische geleiding’.
• De geleiding van elektrische prikkels vanuit de huid en de gewrichten, via het 
 ruggenmerg, terug naar de hersenen. Dit noemen we normaal ‘het gevoel’, en 
 het zorgt ervoor dat we ons bewust worden van of we bijvoorbeeld aangeraakt 
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in een tand die blootligt bij een gaatje; als je dan de tand aanraakt treedt er ook een 
pijnscheut op. Meestal trekt deze overgevoeligheid van de zenuwen bij NA na enkele 
maanden langzaam weg. Bij sommige mensen blijven de zenuwen echter heel lang 
gevoelig voor rek en druk. Mogelijk komt dit doordat na de ontsteking er wat lit-
tekenweefsel is ontstaan, waardoor de zenuwbundel niet meer mooi los ligt van z’n 
omgeving, maar er een beetje aan vast zit. Als de arm dan bewogen wordt trekt dat 
meer aan de zenuwbundel dan normaal, en geeft irritatie cq een pijnscheut.
Tot slot houden veel NA-patiënten heel lang een soort chronische spierpijn in het 
gebied van de deels verlamde spieren en de plekken waar deze aan het bot of een 
gewricht vastzitten. Met name spieren die eigenlijk de hele dag aangespannen 
moeten zijn - bijvoorbeeld de spieren die het schouderblad op z’n plaats houden 
op de romp - zijn hier gevoelig voor. Ook krijgen mensen pijn in niet-aangedane 
spieren die overbelast worden omdat ze al het werk van de deels verlamde spieren 
overnemen. In de praktijk levert dit vaak pijn op in het gebied tussen de nek en het 
achterhoofd, rond het schouderblad en onder de oksel op de romp. Deze chronische 
zeurende pijn is vaak erg vervelend en nauwelijks te behandelen met medicijnen of 
rust. Het beste helpt meestal het proberen samen met een goede fysiotherapeut het 
bewegingspatroon in de aangedane schouder of arm zo vloeiend,  soepel en normaal 
mogelijk te houden.
Zoals u in bovenstaande gelezen hebt is de pijn bij NA dus helaas vaak slecht met 
medicijnen te bestrijden. Daarom is pijnbestrijding bij deze aandoening vaak een 
kwestie van uitproberen, en het combineren van verschillende behandelingen zoals 
fysiotherapie medicijnen en gedoseerd bewegen. Alleen door  proberen weet u óf, en 
zo ja hoe goed iets voor u persoonlijk tegen de pijn helpt. Voor adviezen inzake pijn-
medicatie en andere therapieën: zie hoofdstuk 9.
3.2 Verlies van spierkracht
Als de beschadiging van de zenuw ernstig is, krijgt u behalve pijn ook andere 
klachten, omdat de normale functies van die zenuw niet meer goed uitgevoerd 
worden. Het meest opvallende verschijnsel hierbij is meestal het verlies van kracht 
in de spieren. De mate waarin dit gebeurt kan variëren van licht krachtverlies waar 
u nauwelijks last van heeft, tot een totale verlamming van bepaalde spieren.
Het verlies van kracht komt omdat de prikkels die de zenuw normaal doorgeeft 
nu niet of nauwelijks meer doorgegeven worden op de plaats waar de zenuw be-
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open of dicht zetten van kleine bloedvaatjes in de huid. Als een zenuw beschadigd 
wordt kunnen er klachten ontstaan doordat de bovenstaande functies niet meer 
goed uitgevoerd worden. Deze klachten bestaan uit pijn, verlies van spierkracht, 
stoornissen in het gevoel en stoornissen in de doorbloeding van de huid. Hieronder 
worden deze klachten één voor één behandeld.
3.1 Pijn
In de eerste plaats reageert ook een zenuw op een beschadiging met pijn. Zenuwen 
geven hun eigen pijn door middel van kleine vezeltjes door naar de hersenen. Deze 
pijn bij beschadiging van de zenuwen zelf verschilt van pijn bij beschadiging van 
andere weefsels. Pijn veroorzaakt door beschadiging van de zenuwen zelf heeft 
meestal een heel eigen karakter: zeer hevig, stekend of zeurend, doordringend en 
intens. Als we mensen een soort rapportcijfer laten geven aan hun pijn, waarbij 
0 geen pijn is, en 10 de meest vreselijke pijn die iemand zich voor kan stellen, dan 
geven de meeste NA patiënten hun pijn een 8 of hoger in het begin.
Het bijzondere aan pijn door beschadiging van de zenuw zelf is dat iemand de pijn 
vaak op een andere plaats voelt dan waar de zenuw beschadigd is; namelijk in dat 
deel van het lichaam waar de zenuw heen loopt. Misschien herkent u dit van bij-
voorbeeld de zenuwpijn bij een hernia in de onderrug: het probleem zit in de rug, 
maar de pijn zit vooral in het been, want daar lopen die beknelde zenuwen naar 
toe.
De pijn bij een aanval van NA lijkt in 3 fasen te verlopen. In het begin van een aanval 
is er een continue, zeer hevige zenuwpijn, die vaak ‘s avonds en ‘s nachts nog erger 
lijkt te worden. De meeste mensen kunnen nauwelijks slapen, en zitten maar wat 
met hun arm vastgehouden, of lopen rond. Pijnstillers helpen niet of nauwelijks. 
Deze pijn duurt gemiddeld 3 weken, maar de duur varieert per patiënt van een paar 
uur tot maandenlang. Meestal zakt de pijn  in een paar dagen af tot een rapportcij-
fer rond de 5 of minder. Van deze pijn in het begin denken we dat ze komt doordat 
de zenuwen ontstoken zijn (zie ook hoofdstuk 6; oorzaken).
Na de periode van continue pijn in het begin is er meestal een fase waarin de schouder 
 of arm in rust geen pijn meer doet, maar er bij bepaalde beweginen of houdingen in-
eens felle pijnsteken inschieten. Deze pijn zakt dan in de loop van een paar uur weer 
wat af. Waarschijnlijk is deze pijn het gevolg van een overgevoeligheid van de be-
schadigde zenuwen voor rek of druk. Het is een beetje vergelijkbaar met een zenuw 
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3.4 Stoornissen in de doorbloeding van de huid
Dit zijn meestal de minder opvallende verschijnselen bij beschadiging van een 
zenuw. Heel plaatselijk (bijvoorbeeld handen of  bovenarmen) kan de huid ) roder 
worden, en kunnen huid, haren en nagels sneller gaan groeien. Dit komt doordat 
de huidvaatjes alleen nog maar open staan en er dus te veel bloed dat voedingsstof-
fen voor weefsels bevat door de huid stroomt.
U kunt ook merken dat de doorbloeding veranderd is, doordat koud en warm an-
ders gaan aanvoelen aan het aangedane lichaamsdeel. Meestal voelt alleen koud 
kouder aan dan normaal; het openzetten van de vaatjes bij teveel warmte is name-
lijk niet aangetast bij NA. Het lichaam kan dus op bepaalde plaatsen niet meer goed 
reageren op een afkoeling door middel van het dichter zetten van de huidvaatjes, 
waardoor de warmte binnen gehouden zou worden. Hierdoor koelen met name 
handen en voeten sterker af dan eigenlijk zou moeten, en dit voelt u als ‘te koud’. 
Het sneller groeien van huid, haren en nagels, en het anders aanvoelen van koud en 
warm heten samen in medische termen vasovegetatieve of autonome stoornissen 
van de huid. Deze stoornissen zitten bij NA alleen in die delen van het lichaam waar 
ook de zenuwen naar spieren en huid zijn aangedaan, niet overal.
3.5 Herstel
Beschadigde zenuwen herstellen zich maar langzaam. Een zenuw groeit ongeveer 
0,5 tot 3 millimeter per dag. Als bijvoorbeeld de zenuw die de spieren van de duim 
verzorgt kapotgaat ter hoogte van de oksel, kan het tussen de 8 maanden en vier jaar 
duren voor de nieuwe zenuwvezels vanuit het plaats van de schade in de plexus de 
duimspieren weer bereikt hebben. Dit is de reden waarom het herstel van de ge-
deeltelijk verlamde spieren bij NA zo lang duurt en zo langzaam gaat. Aan de andere 
kant wil het ook zeggen dat er na twee jaar nog steeds verbetering van de spierkracht 
op zou kunnen treden; vooral als het om spieren gaat die het verst weg zitten.
Aan het bovenstaande verhaal zit wel een ‘maar’: als een zenuw meerdere malen 
getroffen wordt, dan neemt de kans op herstel erg af. Ook zenuwen kunnen niet 
alles verdragen; als ze nog meer beschadigd worden gaan ze voorgoed kapot. In de 
praktijk betekent dit dat de functie van bijvoorbeeld de arm na een eerste periode 
van pijnlijke uitval nog wel voor een groot deel zal herstellen, maar dat na een 
tweede of derde keer herstel niet goed en tenslotte helemaal niet meer mogelijk is. 
Het krachtverlies, maar ook de stoornissen in het gevoel en in de bloedvoorziening 
van de huid blijven dan vanaf dat moment onveranderd aanwezig.
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schadigd is. Met de spier op zich is niets mis, alleen is er geen signaal om hem te 
vertellen wanneer en hoe sterk hij zich moet samentrekken. In medische termen 
heet dit denervatie (‘ontzenuwing’). En als spieren een tijdje niet hebben hoeven 
samentrekken, dan nemen ze in omvang en gewicht af. U merkt dit als het afne-
men van de omvang van armen of benen, en soms lijkt het zelfs alsof er een spier 
helemaal verdwenen is. Dit heet in medische termen atrofie van de spieren.
In het dagelijks leven merken mensen vaak pas dat ze kracht in een spier kwijt zijn 
als ze al zo’n 30% van hun maximale kracht hebben ingeleverd.  De kracht tussen 
70% en 100% van maixmaal heb je als het ware als ‘extra’, voor als er onverwacht een 
zware inspanning verricht moet worden.
Bij neuralgische amyotrofie neemt de kracht in aangedane spieren vaak af tot (veel) 
minder dan de 50% van maximaal. Het lukt dan vaak niet eens meer om het gewicht 
van de arm zelf te dragen of helemaal op te tillen, laat staan dat extra gewicht (bijv. 
een tas tillen) nog lukt. Ook volhouden van bewegingen wordt lastig. Soms lukt het 
wel om een bepaalde beweging één keer te maken (zoals de arm uitstrekken of iets 
boven je in de kast zetten), maar niet om dat een aantal keer of bepaalde tijd achter-
een vol te houden. Zowel het verlies van de kracht als de moeite met bewegingen 
volhouden belemmeren NA patiënten vaak fors in hun dagelijkse werk, sport, of 
activiteiten thuis.
3.3  Stoornissen in het gevoel
Ook de prikkels die terugkomen van de huid en de gewrichten worden niet meer 
goed doorgegeven. Hierdoor ontstaan er gebieden op de huid die doof of ‘anders’ 
aanvoelen. ‘Anders’ kan betekenen dat er tintelingen ontstaan, maar ook dat een 
huidgebied heel onaangenaam of pijnlijk aanvoelt als het aangeraakt wordt. Soms 
voelt het alsof de aangedane arm of hand dik en opgezet, of koud is, terwijl er aan de 
buitenkant niets te zien of merken valt. Dit komt doordat de aangedane zenuwen 
de signalen van het gevoel als het ware verkeerd doorgeven aan de hersenen. Iets dat 
normaal als ‘gewoon’ zou voelen, wordt nu doorgegeven als ‘pijn’ of ‘koud’.
De medische termen voor ‘doof’, ‘tintelingen’ en ‘onaangenaam aanvoelen bij aan-
raken’ van de huid zijn (in dezelfde volgorde) hypesthesie, paresthesie, en dysesthe-




Het meest voorkomend is pijn en uitval van de schouder, arm en/of hand. Daar-
naast kunnen aangedaan zijn de zenuwen naar:
• de bovenbenen, onderbenen en voeten
• de spieren van de stembanden en slokdarm
• de huid en spieren van de buik
• de spieren van een helft van het middenrif (hier merkt u meestal niets van, behalve 
 als beide helften zijn aangedaan; hier kunt u benauwd van worden, met name als 
 u ligt)
• de spieren van het gezicht (dit geeft een acute verlamming van één gezichtshelft; 
 komt zelden voor)
• het oor en evenwichtsorgaan (geeft acute doofheid aan één oor of zeer hevige draai 
 duizeligheid; komt zelden voor)
• één helft van de tong (komt zelden voor)
Met ‘aangedaan zijn’ wordt zowel krachtverlies in de spier, als pijn en stoornissen in 
het gevoel of de doorbloeding van de huid bedoeld. Deze kunnen samen voorkomen, 
maar ook los van elkaar.
5. Andere lichamelijke kenmerken
Onderzoekers hebben al in 1961 opgemerkt dat mensen die aan de erfelijke vorm 
van NA (HNA) lijden soms een opvallend uiterlijk hebben. Die veranderingen 
in het uiterlijk worden met een medische term ‘milde dysmorfe kenmerken’ ge-
noemd. Hieronder vallen lichamelijke kenmerken zoals, in het gezicht: dicht bijeen 
staande en diepliggende ogen, een ‘Chinese’ vorm van de ogen, ongewone vorm van 
de oorschelp, een smal of niet symmetrisch (beide helften niet hetzelfde) gezicht, 
een smalle mond, een gespleten gehemelte of huig, en wijd uiteen staande tanden. 
In de rest van het lichaam kunnen als kenmerken voorkomen: bij de geboorte aan 
elkaar zittende vingers of tenen, of aan elkaar zittende botten van de onderarm, 
hamertenen, en een klein postuur (klein van stuk).
Niet alle patiënten hebben deze uiterlijke kenmerken. Ook binnen één familie kan 
hierin verschil zitten. En er zijn ook familieleden beschreven die wel deze uiterlij-
ke kenmerken hebben maar geen HNA. Over de betekenis van deze uiterlijke ken-
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Naast het herstel van de zenuwen zelf, is in de loop der tijd ook duidelijk geworden 
dat er andere factoren meespelen in hoe snel en hoeveel functie patiënten terugkrij-
gen. Voor de meeste spieren geldt dat je er in het dagelijks leven weer goed mee kunt 
functioneren als ze weer 70% van hun oude kracht terughebben. Maar sommige 
spieren moeten echt weer bijna 100% hersteld zijn voordat ze in het dagelijks leven 
weer normaal functioneren. De spier die bij uitval een afstaand schouderblad geeft 
(de serratus anterior) is hier het belangrijkste voorbeeld van. Dit verschijnsel maakt 
dat het soms lijkt alsof herstel van de zenuw naar deze spier toe veel langer duurt 
dan de andere zenuwen, maar dat is dus waarschijnlijk niet zo. Het duurt alleen 
langer voordat je er iets aan hebt.
3.6  Complicaties
De uitval in, of gedeeltelijke verlamming van een aantal spieren in de schouder, 
arm en / of hand heeft niet alleen gevolgen voor de kracht. Ook de stand van de 
schouder, arm, pols of vingers kan er fors door veranderen. Bij uitval in de spieren 
die het schouderblad op z’n plaats moeten houden is het vaak zo dat door het ge-
wicht van de arm in staande houding, de schouder een stuk naar opzij en beneden 
zakt. Dit levert dan weer problemen op als de arm opgetild wordt, omdat de ruimte 
in het schoudergewricht, tussen de kop van de bovenarm en de schouder, kleiner is. 
Hierdoor kunnen de pezen rondom het schoudergewricht bij bepaalde bewegingen 
knel komen te zitten, en dat is pijnlijk. Als het schouderblad afhangt, worden ook 
de spieren die er vanaf de nek en rug aan vast zitten uitgerekt. Ook dit is vaak pijn-
lijk, zeker op de lange termijn, vooral omdat spieren er niet goed tegen kunnen als 
ze uitgerekt zijn en toch moeten aanspannen.
Als bepaalde spieren op het schouderblad fors verlamd zijn, kan het zelfs voorkomen 
dat de kop van de bovenarm helemaal niet meer goed op zijn plek kan worden ge-
houden in het schoudergewricht. Dan ontstaat een gedeeltelijke ontwrichting (‘uit 
de kom zijn’) van de schouder; in medische termen een subluxatie. Om verdere 




klachten voorafgegaan is. Overigens is het lijstje niet volledig. Misschien heeft u 
zelf al gemerkt dat de klachten ook door andere gebeurtenissen kunnen worden 
uitgelokt. Als dat zo is dan horen we graag van u welke gebeurtenissen dat zijn. 
Of er ook nog andere factoren een rol spelen in het krijgen van klachten bij deze 
aandoening is onbekend. We weten ook niet waarom meestal de zenuwen naar de 
schouder en arm getroffen worden.
7. Erfelijkheid bij HNA
Per definitie komt de erfelijke vorm van NA bij meerdere personen in één familie 
voor, en wordt van de ene generatie naar de volgende doorgegeven. Als er bij u in 
de familie verder niemand is die klachten of verschijnselen heeft die bij NA passen, 
dan mag u er van uitgaan dat u deze erfelijke vorm niet heeft. U kunt dit hoofdstuk 
dan in principe ook overslaan.
Als NA wel bij u in de familie voorkomt, is het misschien goed om eerst wat meer 
over erfelijkheid uit te leggen. Erfelijkheid wil zeggen dat eigenschappen van 
mensen van de ene generatie op de andere worden overgedragen. Eigenschappen 
kunnen zowel lichamelijk zijn (bijvoorbeeld de kleur van de ogen) als psychisch 
(het karakter).
Het overdragen van eigenschappen gebeurt door middel van het erfelijk materiaal 
in de cellen. Dit erfelijk materiaal heet ook wel ‘DNA’. Het DNA zit in de cellen 
opgerold en verpakt in de chromosomen, oftewel celkernlichaampjes. Een stukje 
erfelijk materiaal dat één eigenschap overdraagt wordt een gen (meervoud: genen) 
genoemd.
Ieder kind krijgt bij de bevruchting twee versies van ieder gen, één van vader en één 
van moeder. Vader en moeder hebben op hun beurt ook weer twee versies van hun 
vader en moeder gekregen. Nu kunnen eigenschappen, en ook erfelijke aandoening- 
en, op twee manieren doorgegeven worden. Voor de ene manier is het gen van maar 
één ouder nodig. Wat het gen van de andere ouder doet is dan niet belangrijk. Dit 
soort erfelijkheid noemen we met een medische term dominant. Voor de andere 
manier zijn de twee genen van beide ouders nodig. Als die niet allebei aanwezig zijn, 
wordt de eigenschap niet doorgegeven. Deze vorm van erfelijkheid heet recessief. 
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merken zijn onderzoekers het nog niet eens. Vermoedelijk erven ze op een bepaalde 
manier met de aandoening mee over naar de volgende generatie. Helaas zijn de 
kenmerken te verschillend bij de verschillende patiënten en families om in de rich-
ting van één bepaalde plaats in het erfelijk materiaal te wijzen.
6. Oorzaken
De precieze oorzaak van NA is nog niet goed opgehelderd. Waarschijnlijk gaat het
Het enige dat we op dit moment weten is dat het om een samenspel van een aan-
tal factoren gaat. Waarschijnlijk zijn de zenuwen van mensen met een vorm van 
NA al in aanleg gevoeliger voor een bepaald soort beschadiging. Bij mensen met 
de erfelijke vorm is dit heel uitgesproken. Zij krijgen ook vaker in hun leven een 
aanval. Waar die verhoogde gevoeligheid precies uit bestaat is nog onbekend. We 
weten wel dat een verandering in het erfelijk materiaal alléén niet voldoende is om 
deze klachten te krijgen. Er zijn namelijk een aantal gebeurtenissen bekend die de 
pijn en het krachtverlies kunnen uitlokken. Ook hier weten we niet precies waarom 
dat gebeurt, maar men vermoedt dat het met het afweersysteem te maken heeft. 
Hieronder staan die gebeurtenissen op een rijtje gezet:
Gebeurtenissen die een aanval kunnen uitlokken:
• infecties (met name infecties van de neus en keel; bijvoorbeeld een verkoudheid 
 of griep)
• zwangerschap en bevalling (met name enkele uren tot dagen na een bevalling 
 kunnen pijn en uitval optreden)
• zware inspanning of belasting van de schouders en armen
• stress, zowel lichamelijk als psychisch
• inentingen en behandelingen met bloedproducten (serumtherapie)
• operatie en narcose
• een ongeluk of verwonding van de schouder of arm
• weersomslag, meestal van warm naar koud of nat weer
Bij dit lijstje hoort een aantal kanttekeningen. Op de eerste plaats is het niet zo dat 
elke gebeurtenis die hierboven beschreven staat bij iedere patiënt pijn en krachtver-
lies zal veroorzaken. Per persoon kan dit heel erg verschillen. Verder is het niet zo 
dat zo’n gebeurtenis iedere keer pijn en krachtverlies zal uitlokken. Heel vaak kan 
men ook pas achteraf zeggen of er een opvallende of ongewone gebeurtenis aan de 
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dat u de verandering hebt), dan hebt u 80% kans om ook daadwerkelijk klachten te 
krijgen. Maar u hebt ook 20% kans om ze niet te krijgen. Het is dus maar de vraag 
of u bij die 8 van de 10 mensen hoort die wel klachten krijgen, of bij die 2 van de 10 
die nergens last van zullen hebben. Er is op dit moment geen enkele manier om 
te voorspellen tot welke groep u behoort. De enige zekerheid die u heeft is, dat als 
de test negatief is (dat betekent dat u niet de verandering in het erfelijk materiaal 
heeft), u geen klachten krijgt en de aandoening ook niet door kunt geven aan uw 
kinderen. Dit betekent ook dat de aandoening niet ‘een generatie overslaat’, zoals 
dat heet.
Recent zijn bij een aantal HNA families veranderingen gevonden in het zgn. SEPT9 
gen op het 17e chromosoom (17q24-25). Daarnaast waren er ook families die deze ver- 
anderingen niet hadden, dus waarschijnlijk zijn er meer chromosomen die bij een 
verandering HNA kunnen geven. Het is op dit moment nog niet mogelijk om op 
routine basis mensen te testen voor deze veranderingen, maar we hopen dat deze 
tests snel wel beschikbaar komen. 
8. Wetenschappelijk onderzoek
In het Neuromusculair Centrum Nijmegen zijn tot nu toe twee vormen van neur-
algische amyotrofie onderzocht: de erfelijke vorm (HNA) en de niet-erfelijke vorm 
bij kinderen. In de afgelopen 10 jaar hebben we bijna 250 patiënten gezien en ge-
sproken. Hieronder geven we u een overzicht van de resultaten van die onderzoeken. 
Daarna wordt iets verteld over een studie die op dit moment plaatsvindt, en zich 
bezig houdt met de acute fase van aanvallen van NA. Mocht u meer willen weten 
dan kunt u zich wenden tot het telefoonnummer voorin deze folder.
8.1 HNA - klachten, symptomen en erfelijkheid bij Nederlandse families
De leeftijd waarop bij de 24 door ons onderzochte patiënten de eerste klachten 
ontstonden varieerde van 3 tot 59 jaar. Gemiddeld ontstonden de eerste klachten 
rond het 21e jaar. Meer dan driekwart van de klachten (80%) traden op in de boven- 
arm en schouder, meestal aan de rechterkant. In 13% (iets meer dan een tiende deel) 
waren de benen (ook) aangedaan. Verder betrof een tiende deel van de klachten 
(mede) de stembanden of slokdarm.
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HNA is een dominante aandoening. U heeft dus van één van uw ouders een stukje 
erfelijk materiaal gekregen waar een verandering inzat die andere mensen niet 
hebben. Deze verandering zorgt waarschijnlijk voor de verhoogde gevoeligheid van 
de zenuwen voor beschadiging. We weten dat HNA dominant is, door de manier 
waarop de aandoening in families wordt doorgegeven. In geen enkele familie die we 
kennen zijn bijvoorbeeld beide ouders van een patiënt aangedaan.
Het dominant zijn van een aandoening heeft ook gevolgen voor de kans van uw 
kinderen om dezelfde aandoening te krijgen. Statistisch gezien is die kans 50%. Dit 
wil zeggen dat in theorie de helft van de kinderen de aandoening erven van hun 
ouders. Hierbij moet u goed onthouden dat dit alleen in theorie precies de helft 
zal zijn. Theorie over dit soort kansen is altijd gebaseerd op grote groepen mensen. 
Voor u en uw gezin kan het in de praktijk heel anders uitvallen. Soms zal geen van 
de kinderen klachten krijgen, soms krijgen ze het allemaal. Het is ook niet zo dat als 
het eerste kind de aandoening niet heeft, het volgende kind meer kans zou hebben 
om het wel te krijgen of andersom. U kunt de kans op overerven vergelijken met het 
gooien van kop of munt. Als u kop gooit krijgt uw kind de aandoening niet, als het 
munt is, heeft hij of zij wel kans om de aandoening te krijgen. En voor ieder kind 
moet u als het ware opnieuw gooien. Samengevat valt er over de kans op deze aan-
doening in uw persoonlijke geval dus geen enkele zinnige voorspelling te doen.
Het laatste punt in verband met de erfelijkheid van deze aandoening is de penetran-
tie. Dit is de medische term voor hoeveel procent van de mensen die de verandering 
in hun erfelijk materiaal hebben ook daadwerkelijk klachten krijgen. De penetran-
tie van HNA is niet volledig (geen 100%). Niet iedereen die de verandering in het 
erfelijk materiaal heeft krijgt dus ook klachten. De schatting is dat gemiddeld 8 
van de 10 mensen (80%) met de verandering in het erfelijk materiaal ook klachten 
zal krijgen.
Dat de penetrantie niet volledig is, kan in de toekomst belangrijk worden voor u 
en uw familie. Als we namelijk eenmaal weten waar de verandering in het erfelijk 
materiaal ligt bij HNA, kunnen deze ook bij u en uw kinderen aangetoond worden. 
Maar omdat de penetrantie niet volledig is, zegt het nog niet alles als we inderdaad 
zo’n verandering vinden. Een voorbeeld: stel dat uw ouders deze aandoening had-
den, en u wilt op uw 18e weten of u ook de kans loopt klachten te krijgen. En stel 
dat we op dat moment in het bloed de verandering in het erfelijk materiaal kunnen 
aantonen. Als u zich nu laat testen en de test is positief (dat wil in dit geval zeggen 
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dat meestal binnen een half jaar, terwijl het bij volwassen meer dan 2 jaar kan du-
ren. Bij kinderen kan je dus al eerder voorspellen hoe het uiteindelijk herstel zal 
worden.
8.3 Lopend onderzoek: de acute fase van aanvallen
In 2004 is gestart met een uitgebreid onderzoek naar de acute fase van aanvallen van 
NA. Met de acute fase bedoelen we de periode tot 8 weken na het ontstaan van de 
klachten, maar het liefst willen we patiënten zo snel mogelijk zien. Er zijn name-
lijk aanwijzingen dat als je er maar vroeg genoeg bij bent, d.w.z. binnen 1 of uiter-
lijk 2 weken na ontstaan van de klachten, je de aanvallen kan behandelen met een 
krachtige ontstekingsremmer zoals prednison. Daarnaast willen we in de acute fase 
bloed afnemen om te zien hoe het afweersysteem functioneert, en enkele andere 
onderzoeken doen, zoals een EMG (spier-zenuw geleidingsonderzoek), om te kijken 
hoe uitgebreid de aanval nu werkelijk is.
Tot slot is een belangrijk deel van het onderzoek gericht op het in kaart brengen 
van de invloed van NA op je kwaliteit van leven: wat doet het met je, zo’n aanval? 
Hoe lang ben je echt uit de roulatie? Hoe goed is het herstel eigenlijk? Het is erg 
belangrijk om dit een keer netjes vast te stellen bij een grote groep patiënten, zeker 
omdat we de afgelopen jaren de indruk hebben gekregen dat het herstel vaak niet 
zo gunstig is als werd verwacht. 
De bedoeling is dat het hele onderzoek minstens de komende 3 jaar gaat lopen, in 
ieder geval in Nijmegen, maar waarschijnlijk in samenwerking met andere neur-
ologische centra in het land. Als u vragen hierover hebt, of u krijgt opnieuw een 




In hoofdstuk 3 werd duidelijk dat de behandeling van HNA heel moeilijk is. Aan de 
verlammingen op zich is niets te doen. Fysiotherapie is echter wel nuttig bij deze 
aandoening, maar dan als ondersteunende behandeling. Bijvoorbeeld om om ver-
groeiingen of verstijvingen in de gewrichten te voorkomen. Vergroeiingen kunnen 
ontstaan als het gewricht (bijvoorbeeld de ellebogen of de knokkels van de vingers) 
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Het bekendste patroon van klachten bij HNA is het verloop in ‘aanvallen’: pijn 
gevolgd door uitval en vervolgens door langzaam herstel; dan een tiijd geen klachten 
en dan ineens weer pijn en uitval, enzovoorts. Maar toen men de klachtenpatronen 
in dit onderzoek nader ging bekijken, zag men dat iets meer dan de helft van de 
patiënten een ander beloop van de aandoening heeft. Namelijk: al een hele tijd last 
hebben van snel vermoeide of pijnlijke spieren, dan ineens veel pijn en uitval, en 
daarna langzaam een beetje herstel maar met telkens terugkerende periodes van 
(meer) pijn. En hier overheen kon dan weer een periode van hevige acute pijn en 
uitval optreden. Dit laatste patroon was al wel bekend, maar men dacht dat het 
eerder uitzondering dan regel was. Volgens ons onderzoek is het juist andersom: 
eerder regel dan uitzondering.
Slechts een kwart van alle ‘aanvallen’ werd gevolgd door volledig herstel. En hoe 
meer klachten mensen gehad hadden, hoe slechter het herstel was. Op dit moment 
heeft iedereen die aan het onderzoek heeft meegewerkt nog ‘restklachten’. Sommige 
mensen daarvan hebben een nauwelijks opvallend verlies van spierkracht, anderen 
hebben zeer storende verlammingen en/of nog de hele tijd pijn. Eenderde van de 
mensen die onderzocht zijn is door deze aandoening geheel arbeidsongeschikt ge-
worden. Onze mening is dan ook dat het herstel zeker niet zo gunstig is als in ‘de 
literatuur’  wordt aangenomen. De resultaten van het onderzoek zijn gepubliceerd 
in het neurologische tijdschrift Brain (Brain 2000;123:718-723).
8.2  Niet-erfelijke neuralgische amyotrofie bij kinderen
Hiervoor hebben we de gegevens van alle bekende gevallen van neuralgische amyo-
trofie bij kinderen (tot 16 jaar), inclusief twee patiëntjes uit Nijmegen, op een rijtje 
gezet. In totaal waren dit zo’n 35 kinderen. Het blijkt dat bij kinderen de aanvallen 
niet altijd beginnen met pijn, maar slechts bij 66% van de patiënten. Dit terwijl 
bij volwassen bijna iedereen in het begin van een aanval pijn heeft (meer dan 95%). 
Omdat de pijn juist hetgene is dat artsen vaak op het spoor van de diagnose NA zet, 
zal het bij kinderen dus nog lastiger zijn om de diagnose te stellen, zeker in het 
begin.
Opvallend was dat kinderen onder de 8 weken oud die een aanval van NA kregen, 
bijna altijd een infectie van het bot van de bovenarm of schouder bleken te heb-
ben. Iets om op te letten dus bij zulke jonge patiëntjes. Tot slot bleek dat kinderen 
minder vaak volledig herstellen als volwassenen: slechts in de helft van de geval-




Pijnbestrijding met medicijnen gaat altijd in een aantal stappen (meestal drie), van 
lichte naar sterkere medicatie. Afhankelijk van het effect wordt hierbij van de ene 
naar de andere groep overgestapt.
Hieronder staat  een tabel met de verschillende stappen op de pijnmedicatie-
ladder.
 Soort Merknaam
Groep 1a - paracetamol Paracetamol, Panadol, Finimal
   (met coffeïne) 
 - acetylsalicylzuur Aspirine, Aspro, Alka-Seltzer
Groep 1b - ibuprofen Ibuprofen, Brufen, Advil
 - naproxen Naprosyne, Femex,
  Aleve
 - diclofenac Voltaren, Cataflam
Groep 2 - paracetamol+codeïne (idem)
 - tramadol Tramal
Groep 3 Opiaten zoals:
 - morfine MS-Contin, Kapanol
 - buprenorfine Temgesic
 Samen met een middel 
 uit groep Ib gebruiken 
“Groep 4” - carbamazepine Tegretol, Carbymal
 - gabapentine Neurontin
 - amitriptyline Tryptizol, Sarotex 
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door de verlamming lang niet meer bewogen wordt. Met fysiotherapie kan het ge-
wricht ondanks de verlamming toch in beweging worden gehouden, bijvoorbeeld 
door de arm of schouder door de fysiotherapeut te laten bewegen.
Bij uitval van de schouderspieren is het heel belangrijk om samen met de fysiother-
apeut te oefenen dat het bewegingspatroon van de arm en schouder vloeiend blijft. 
In medische termen heet dit het trainen van het scapulothoracaal ritme. Ook kan 
een fysiotherapeut u leren hoe u voorkomt dat de nog wel werkende spieren over-
belast en pijnlijk worden. Het streven is door te oefenen een zo normaal mogelijk 
bewegingspatroon te krijgen, ondanks het verstoorde evenwicht tussen deels ver-
lamde en nog normale spieren. Daarnaast kan het prettig zijn om te proberen de 
kracht door versterkende oefeningen zoveel mogelijk op peil te houden. De enige 
leidraad hierbij is tot hoever ú kunt en wilt gaan. Forceren, zoals ‘door de pijn heen 
oefenen’ heeft geen zin.
Ook heeft echt krachttrainen voor de verlamde spieren geen zin. Dit kunt u zich 
waarschijnlijk wel voorstellen als u bedenkt dat de kracht vaak niet eens toereikend 
is om het gewicht van de arm zelf op te tillen. En als de zenuw naar zo’n spier be-
schadigd is, dan kunt u willen trainen al u wilt, het signaal kan de spier toch niet 
(volledig) bereiken. De zenuwen op zich herstellen ook niet sneller door wel of niet 
trainen. Wel leert u door te oefenen de kracht en mogelijkheden die u nog hebt zo 
goed mogelijk te benutten.
Als de verlammingen u erg storen bij uw dagelijkse bezigheden, kunt u eventueel 
door middel van ergotherapie andere manieren leren om deze dingen te doen (bij-
voorbeeld door middel van het gebruik van andere spieren of een andere houding, 
of door gebruik van hulpmiddelen). Als u zowel ergotherapie als fysiotherapie 
nodig hebt, of er hulpmiddelen aangemeten moeten worden, dan is het meestal 
verstandig om u naar een revalidatiearts te verwijzen. Deze dokter kan alle boven-
staande therapieën aansturen en coördineren. Ook kan deze u advies geven als er 
door de NA problemen onstaan in uw werksituatie, bijvoorbeeld met keuringen 
voor de Ziektewet of WAO. Als u door de NA dergelijke problemen tegenkomt, is het 
sowieso verstandig dit zelf met uw bedrijfsarts te gaan bespreken. Vaak helpt het 
om informatie over NA mee te nemen, zoals deze folder en eventueel een kopie van 
de brief die uw neuroloog voor de huisarts heeft gemaakt.
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Behalve met medicijnen kan voor de pijn ook nog een zogenaamde TENS-behan-
deling geprobeerd worden. TENS staat voor het Engelse Transcutaneous Electri-
cal Nerve Stimulation, oftewel het stimuleren van zenuwen door de huid heen. 
Daarvoor worden electroden op de huid aangebracht die zijn verbonden met een 
apparaatje dat stroompjes opwekt. Dat apparaatje moet u een aantal uren per dag 
bij u dragen. TENS is overigens iets anders dan elektrostimulatie van de spieren 
(‘elektriseren’). De werking van TENS is een beetje vergelijkbaar met wrijven over 
een pijnlijke plek (bijvoorbeeld als u zich net ergens aan gestoten heeft) waardoor 
de pijn minder wordt. Het is een behandeling die door de fysiotherapeut wordt in-
gesteld. Om een TENS behandeling te krijgen heeft u twee machtigingen van uw 
arts nodig: een waarmee u het apparaat kan aanvragen bij uw ziektekostenverze-
keraar, en een voor de fysiotherapeut die u het apparaatje leert bedienen.
10. Persoonlijke ervaringen van een NA en twee HNA patiënten
Een ‘luxe pijn’, ervaringen van een vrouw met NA
“Ik ben nu 54 jaar. Drie jaar geleden kreeg ik voor het eerst het gevoel een ‘hete plek’ in mijn 
linkerschouder te hebben, die aanvankelijk goed te verdragen was, maar gaandeweg steeds 
meer problemen ging geven. De pijn werd zodanig dat ik bij mijn huisarts aan de bel trok, 
die i.v.m. mijn al jaren slepende nekpijn, mij de zoveelste pijnstiller voorschreef en het daar-
bij liet. Ikzelf liet het daar ook bij, omdat ook ik dacht dat de pijn wel vanuit mijn nek zou 
komen. Door de pijnstillers werd het gevoel tijdelijk onderdrukt, maar ging zeker niet weg.
Het hele daaropvolgende jaar bleef ik de pijn voelen. Ik kreeg mijn normale fysiotherapie 
voor mijn nek en alles ging gewoon door, maar soms kreeg ik kramp in mijn linkerarm en 
begonnen mijn vingers, duim en handpalm van mijn linkerhand te prikkelen. Ondertussen 
sukkelde ik maar door.
Een jaar later kwam ik na een hevige pijnaanval weer bij de huisarts terecht, waarop ik 
foto’s mocht laten maken bij de neuroloog in het ziekenhuis . De uitslag van de foto’s heb 
ik toen besproken met een vervangende neuroloog. De foto’s wezen op slijtage van de nek-
wervels, maar niet zodanig dat dat die vreselijke pijn kon veroorzaken. De vervangende 
neuroloog deed het af als een ‘luxe’ pijn in deze luxe tijd. Volgens hem kwam dit vroeger ook 
wel voor, maar piepten mensen niet zo!
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Medicijnen uit groep 1 kunt u gewoon bij de drogist kopen. Overleg met uw arts en 
lees voor gebruik goed de bijsluiter over hoe veel en hoe vaak u ze in mag nemen! 
Gebruik de medicijnen niet door elkaar, tenzij dat zo staat aangegeven. Een tip: als 
de medicijnen wel iets helpen, zorg dan dat u ze niet pas inneemt als de pijn op 
komt zetten of weer terugkomt. Houdt een vast schema aan. Dit wil zeggen dat u 
om de zoveel tijd (meestal 3 of 4 uur) een tablet inneemt. Zo kunt u zorgen dat u 
continu minder of geen pijn voelt. Lees voor gebruik eerst de bijsluiter en gebruik 
niet meer tabletten per dag dan is toegestaan!
Medicijnen uit groep 2, 3 en 4 zijn alleen op recept verkrijgbaar. De stof uit groep 
2 en 3 hebben als nadeel dat ze vaak obstipatie (darmverstopping) veroorzaken als 
bijwerking. Dit kunt u voorkomen door veel te drinken en vezelrijke voeding te 
gebruiken. Meestal is het verstandig om ook een extra medicijn te gebruiken, een 
zogenaamd laxans (zoals bijvoorbeeld Importal of lactulose). De stoffen uit groep 3, 
de morfine-achtige middelen, zijn de sterkste pijnstillers die we kennen. Ze worden 
alleen voorgeschreven bij hele hevige pijn, die nergens anders mee te bestrijden is. 
Ook in uw geval kan de pijn bij NA zo hevig zijn dat een morfine-achtig middel 
nodig is.
De zogenaamde co-analgetica uit groep 4 vormen een aparte categorie. Het zijn 
middelen die van oorsprong òf tegen epilepsie, òf tegen depressies zijn. Ze dempen 
als het ware zenuwprikkels in het  hoofd, maar dat doen ze ook in de beschadigde 
zenuwen in uw arm of been. Daarom werken ze tegen de zenuwpijn bij NA. Deze 
middelen zijn geen gewone pijnstillers, je kan ze niet nemen op het moment dat 
de pijn ineens op komt zetten, maar ze moeten continu gebruikt worden om een 
bepaalde hoeveelheid medicijn in het bloed op te bouwen. De eerste weken geven 
ze vaak bijwerkingen in de vorm van duizeligheid of een gestoorde concentratie; dit 
gaat meestal over. Daanaast beginnen ze pas na een aantal weken te werken. U moet 
ze minstens 6 weken geprobeerd hebben voordat bepaald kan worden of ze wel of 
niet helpen. U krijgt dus als het ware eerst de lasten (de bijwerkingen) en dan pas 
het effect (pijndemping).
Uit ons onderzoek is gebleken dat een combinatie van diclofenac (2 maal daags 100 
mg ‘Retard’ vorm, d.w.z. met vertraagde afgifte) en een langwerkende morfineta-
blet (MS-Contin,  2 maal daags 30 mg) vaak de beste - maar niet volledige - pijnstil-
ling geeft in het begin. Het effect van een stootkuur prednison in de acute fase van 




Ik maak me soms veel zorgen over de toekomst. Als het zo blijft dat ik aanval op aanval 
krijg, moet ik dus medicijnen blijven slikken. Als de verlammingen vaker voorkomen en 
erger worden wat dan?
Ik probeer zo lang mogelijk alles te blijven doen wat ik kan, mag en wat mogelijk is. Ik 
probeer ook zo veel mogelijk positief in het leven te staan, voor mezelf en naar en voor an-
deren.
Ik ben niet sterk, maar wel héél taai!”
Hereditaire neuralgische amyotrofie (HNA), (ervaring van een patient, 
geboren in 1964)
De ervaring die ik heb met HNA is de volgende:
Algemeen
Hoe en waardoor HNA precies begint is mij niet geheel duidelijk. Wel kan ik zeggen in de 
4 ervaringen tot nu toe dat de spieren die aangetast raken een aantal weken (ongeveer 2 tot 
4) moe aanvoelen zoals bij een vermoeidheid na intensief sporten. Deze vermoeidheid neemt 
geleidelijk toe tot een zeurende, steeds aanwezig zijnde pijn.
Na 2 tot 4 weken begin je te bemerken dat de pijn niet normaal (te constant en te hevig) 
is en komt het vermoeden dat het wel eens HNA kan zijn. Na ongeveer 4 tot 6 weken is de 
pijn zo aanwezig en hevig dat normaal functioneren (werken, privé) niet of nauwelijks meer 
mogelijk is. Je wordt prikkelbaar en futloos, je hebt nergens zin in. Totdat de pijn van het 
ene op het andere moment weg is, tenminste zo lijkt het. Ik denk dat dit een periode van een 
aantal dagen is waarin de pijn wegvalt en een spierverlamming optreed.
Naast de spierverlamming heb ik veel last gehad van een gevoelloze huid. Altijd daar waar 
ook de verlamming was. Het herstel na een verlamming in de armen duurde ongeveer een 
jaar (90%). De laatste 10 procent komt gedurende een aantal jaren en is afhankelijk van de 
mate van gebruik van de verlamde spieren. 
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Weer een jaar later was de pijn zo hevig witheet en ijskoud dat ik in het ziekenhuis werd 
opgenomen en zelfs verlammingsverschijnselen in mijn linkerarm kreeg.
In het ziekenhuis heb ik kennisgemaakt met dokter van Alfen uit het UMC St. Radboud in 
Nijmegen. Zij herkende de aandoening en schreef mij medicijnen voor, een kuur prednison 
en gabapentin, om me van die vreselijke pijn af te helpen. Uiteindelijk ben ik uit het zieken-
huis ontslagen met gabapentin, dat ik nu nog steeds gebruik.
Het is nu mei 2001 en ik heb sinds de aanval in september vorig jaar nog een aanval gehad 
in februari van dit jaar. Deze was minder erg, maar die heb ik ook aan voelen komen, zodat 
ik snel weer met een kuur medicijnen kon beginnen, waardoor me meer narigheid bespaard 
is gebleven.
Hoe beleef ik dit?
Ik heb hulp in huis gekregen, iets waar ik veel moeite mee heb, omdat ik een ‘doe-het-zelf 
figuur’ ben. Echter als ik veel pijn heb kan ik alles makkelijker over me heen laten komen. 
De pijn schommelt ook. Soms sta ik ‘s ochtends op en dan voel ik dat ik een ‘offday’ heb. Dan 
kan ik dus niet te veel doen en moet ik me rustig houden. Maar er zijn ook dagen dat ik best 
wat kan: was ophangen, tillen van zware dingen zoals een volle pan, koffie- of theepot, of 
een vaas met bloemen. Zulk soort dingen zijn echter wel heel moeilijk geworden.
De zorg voor mezelf is ook anders geworden. Panty’s en ondergoed, schoenen, haren wassen 
en kammen zijn lastig. Ik betrap me erop dat ik jassen en blouses anders aantrek, kortom, 
het heeft veel beperkingen met zich meegebracht. Slapen is ook zoiets. Het kussen gaat wel 
tien keer per nacht in en uit bed, en ik kan niet zo goed op mijn linkerkant slapen. Zitten 
vind ik pas prettig als mijn linkerschouder voldoende gesteund wordt, en druk op mijn arm 
of hoofd of een vreemde houding kan ik absoluut niet hebben.
Hoe beleeft mijn omgeving dit?
Het beheerst een deel van ons leven. De zorg die mijn man en kinderen naar mij toe hebben 
is anders geworden. Er wordt veel meer opgeruimd door henzelf, en er wordt bedacht hoe het 
voor mij makkelijker kan. Ze helpen waar ze kunnen als er tijd voor is.
In familieverband wordt er altijd en overal naar mijn gezondheid geïnformeerd. Logisch en 






Ermee omgaan is voor mij niet zo moeilijk. Ik heb HNA vrij snel geaccepteerd. Volgens mij 
helpt het niet om opstandig te zijn, ondanks al m’n beperkingen.
 Informatie 
Voor meer informatie en vragen op allerlei gebied die met idiopathische of erfelijke 
neuralgische amyotrofie te maken hebben kunt u terecht bij het Neuromusculair 
Centrum Nijmegen.
Bezoekadres en telefoon NCN:
Postadres: Bezoekadres:
Neuromusculair Centrum Nijmegen Radboud Oost
UMC St Radboud Reinier Postlaan 4
Postbus 9101 6500 HB  Nijmegen
Nijmegen
Telefoon: 024-3615202 / fax: 024-3541122  (secretariaat NCN)
Of via de speciale NA-studietelefoon: 06-24741697
Email: NAonderzoek@neuro.umcn.nl
Ook kunt u voor aanvullende informatie terecht bij de Vereniging Spierziekten 
Nederland (VSN).
VSN







Waar uit zich HNA
In mijn geval heb ik 3 maal een aandoening in één arm gehad en 1 maal in de stemband-
streek.
Jaar: Waar: Herstel:
1977 Rechter arm volledig incl. gevoelloze huid onderarm en hand 1 jaar
1985 Linker arm volledig incl. gevoelloze huid onderarm en hand 1 jaar
2000 Linkerarm gedeelte incl. gevoelloze onderarm binnenkant 3 maanden
2000 Beide stembanden (6 mnd niet kunnen praten) en gedeelte slokdarm 6 maanden
Hoe verder
Met HNA is te leven. Ik merk elke keer wel dat het herstel minder wordt. Mijn linker arm, 
waar ik 2 aanvallen heb gehad, is er het slechtst aan toe. Sommige armbewegingen blijven 
 moeilijk. Fysiotherapie kan je helpen zo goed mogelijk te herstellen na een aanval. Doorzet-
tingsvermogen en (verantwoord) blijven sporten zijn in mijn geval van groot belang ge-
weest. Verder heb ik tijdens de aanvallen veel gehad aan pijnbestrijding met TENS. Ik bezit 
privé nu een TENS.
‘HNA in mijn geval’
Ik ben een man van nu 50 jaar en maakte op 8-jarige leeftijd mijn eerste aanval door. Voor-
zover ik me kan herinneren deed het geen pijn, maar had ik wel fors krachtsverlies aan de 
armen. Vanaf mijn 15e ben ik al gaan werken als constructiebankwerker. In de periode dat 
ik werkte was ik regelmatig enkele maanden thuis met aanvallen van pijn en krachtsverlies. 
Op 27-jarige leeftijd kwam ik in de WAO terecht, voor 80-100% afgekeurd.
Tussen mijn 30e en 50e jaar heb ik telkens weer verschillende aanvallen in de armen. Mijn 
laatste aanval is van zeer recente datum.
Verloop van een aanval
Eerst komt de pijn. Die scoort 8-10 uit 10 op de pijntabel. ‘S nachts kan ik er niet van slapen. 
Dan de spieruitval. Het geheel duurt zo’n 6 tot 10 weken. Ik gebruik gaan medicijnen be-
halve soms 2 paracetamols van 500 mg. Waarom niet? Omdat er eigenlijk geen medicijnen 




Figuur 1. Scapula alata rechts   Figuur 2. Atrofie en parese distaal rechts
   
Behandeling neuralgische amyotrofie (NA) in de acute fase
De pathofysiologie van een episode of aanval is waarschijnlijk een vlekkige ontste-
king binnen de plexus brachialis op auto-immune basis. Om te proberen schade 
aan de zenuwen zoveel mogelijk te voorkomen of beperken tijdens deze ontste-
king, is recent een trial gestart waarin patiënten zo vroeg mogelijk na het ontstaan 
van klachten behandeld worden met een stootkuur prednison of placebo. Mocht 
u een patiënt hebben die hier voor in aanmerking zou komen, dan kunt u deze 
aanmelden via een speciaal telefoonnummer: 06-24741697, of via het emailadres: 
NAonderzoek@neuro.umcn.nl. Wij nemen dan zo snel mogelijk contact op met de 
patiënt. Uiteraard houden we u op de hoogte van de bevindingen.
De standaard behandeling tot nu toe is pijnstilling in de vorm van een langwerk-
end NSAID in combinatie met een opiaat (zie tabel 4), en fysiotherapie zodra de pijn-
klachten het enigszins toelaten. Co-analgetica zoals carbamazepine of gabapentin 
zijn in theorie het meest geschikt voor de neuropathische pijn, maar in de praktijk 
laat het effect vaak te lang op zich wachten (4-6 weken) om echt van nut te zijn in de 
acute fase van een aanval van NA.
Beleid
Uiteraard wordt eerst gezocht naar een behandelbare oorzaak van de plexopathie. Is 
deze er niet, dan wordt de aandacht gericht op pijnbestrijding, complicatiepreven-
tie, en het scheppen van de meest optimale omstandigheden voor spontaan herstel.
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 Bijlage: Neuralgische amyotrofie 
- informatie voor huisarts en fysiotherapeut
Deze aandoening wordt tegenwoordig meestal neuralgische amyotrofie genoemd, 
maar is ook nog bekend onder de wat oudere benamingen als ‘Parsonage en Turner 
syndroom’ en ‘plexus neuritis’. Er bestaat een idiopathische en een (zeldzame) au-
tosomaal - dominant erfelijke vorm van.
Hèt kenmerk van deze aandoening is het acute begin met extreme, zéér hevige pijn 
in de nek, schouder en/of arm. Als pijnscore (VAS) geven patiënten vaak 8 - 10 uit 10 
aan. Vaak zijn het mensen die nooit eerder schouder- of pijnklachten hadden. De 
pijn is veel heviger dan bij een ‘gewone’ schouder- of nekklacht en reageert niet of 
nauwelijks op pijnstillers (inclusief opiaten). In het begin is de pijn continu aan-
wezig en nauwelijks te beïnvloeden door verandering van houding o.i.d. Karakte-
ristiek wordt de arm beschermend tegen het lijf gehouden, en patiënten liggen 
vaak nachtenlang wakker van de pijn en ellende.
Meestal ontstaat enkele uren tot dagen, maar soms ook pas na weken, een vlekkig 
verdeelde verlamming van schoudergordel- en armspieren. Ook is er vaak opval-
lend snel een forse atrofie van de aangedane spieren. Heel karakteristiek is het zgn. 
scapula alata (zie fig. 1), maar dit komt zeker niet bij elke patiënt voor. Behalve de 
klassieke ‘proximale’ vorm waarbij vaak het heffen van de arm en exoroteren van 
de schouder is aangedaan, bestaan er ook meer distale vormen waarbij het strekken 
van pols en vingers of de kleine handspieren vaak ernstig beperkt zijn (fig. 2). Bij 
goed navragen zijn er vaak wel sensibele klachten in de vorm van tintelingen of een 
lichte hypesthesie, maar deze staan meestal niet op de voorgrond.
De pijn verloopt meestal in 3 fasen: eerst de continue extreme neuropathische pijn 
gedurende enkele dagen - weken, daarna verdwijnen van de pijn in rust maar toe-
name bij bewegen of rek aan de beschadigde plexus, en tot slot krijgen veel patiën-
ten last van een hardnekkige spierpijn door overbelasting van de paretische, maar 
ook van de compenserende gezonde spiergroepen.
De parese herstelt langzaam in de loop van maanden tot enkele jaren. Dit trage her-
stel en het ontstaan van spierpijnklachten door surmenage geeft vaak langdurige 
(gedeeltelijke) arbeidsongeschiktheid, en noopt tot een goede begeleiding van deze 
patiënten in revalidatie en arbeidsproces.
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enkele lange termijn complicaties optreden (zie tabel 5) die met de juiste begelei-
ding grotendeels te voorkomen of te behandelen zijn.
Het is dan ook aan te raden om uw patiënt na de initiële diagnostiek en evt. thera-
pie te verwijzen naar een fysiotherapeut, of als begeleiding op meerdere vlakken ge-
wenst is naar een revalidatiearts. Deze laatste is ook zeker belangrijk als er sprake is 
van arbeidsongeschiktheid door de pijn of uitval, vooral omdat herstel vaak langer 
duurt dan de huidige termijn voor beoordeling van de WAO. Tevens kan deze zo 
nodig ergotherapeutisch advies of voorzieningen aansturen.
Tabel 5. Complicaties door uitval bij een plexopathie
Complicatie Praktijkvoorbeelden
‘verkeerde houding’: antalgisch arm tegen lijf houden, mankend lopen, 
‘verkeerde houding’: ter compensatie uitval hooghouden schouder met m. trapezius bij 
 uitval serratus anterior of deltoid
surmenage: paretische spieren pijn onder schouderblad en op romp bij 
 serratus anterior uitval
surmenage: in compenserende spieren trapezius pijn en hypertonie bij 
 schouderzwakte
gewricht: kapselverstijving frozen shoulder na pijn / immobiliteit
gewricht: (sub-)luxatie humeruskop bij zwakte m. supraspinatus
tendinopathie rotator cuff impingement of degeneratie /
 ruptuur
‘Wel of geen fysio?’
Veel patiënten met een plexopathie komen met de vraag of fysiotherapie verstandig 
is of juist gecontraindiceerd. In het algemeen geldt dat ‘blijven bewegen’ het beste 
advies is. Echt kracht trainen in paretische spieren is vrijwel zinloos, maar samen 
met een fysiotherapeut proberen een zo normaal en vloeiend mogelijk bewegings- 
patroon te handhaven geeft zeker winst. Men start dan ook het liefst zo vroeg 
mogelijk met fysiotherapeutische begeleiding. In het begin, zeker als de bescha-
digde zenuwen nog rekpijnlijk zijn, zal het vooral gaan om het voorkomen van 
contracturen, door passief bewegen. Naarmate de zenuwen herstellen kan er steeds 
meer actief geoefend worden, en in de loop der tijd worden het aantal herhalingen 
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Tabel 4. Voorbeeld pijnmedicatie bij plexopathie
Soort neuropathische pijn Medicatie
acuut diclofenac retard 2 dd 100 mg +
 MS Contin 2 dd 10 mg 
 (cave: maagprotectie en laxans)
chronisch, vooral schietend / stekend bovenstaande en:
 carbamazepine 2 dd 100 - 200 mg,  
 of gabapentin 3 dd 600 - 1200 mg
chronisch, vooral brandend zie acute pijn, en:
 amitriptyline 2-3 dd 10 - 25 mg
Pijnmedicatie
Bij acute hevige pijn werkt vaak een combinatie van een langwerkend NSAID en 
opiaat het beste. Is te verwachten dat de pijn langer dan enkele weken aanhoudt, 
dan wordt het zinvol een co-analgeticum bij te geven, om de neuropathische com-
ponent van de pijn te dempen. Wees wijs maar zeker niet te zuinig met pijnstilling: 
deze neuropathische pijnen kunnen zeer hevig en invaliderend zijn! Progressie van 
de pijn ondanks pijnstilling noopt tot zoeken naar een onderliggende progressieve 
etiologie of het ontstaan van complicerende factoren zoals gewrichtsklachten of 
tendomyogene overbelasting.
TENS
Als medicamenteuze pijnstilling alleen onvoldoende helpt, kan soms een TENS 
(Transcutaneous Electrical Neuro-Stimulation) apparaat nog extra verlichting 
geven. Dit apparaat, een soort ‘walkman’ waaraan een aantal electroden die met 
plakkers op het pijnlijke lichaamsdeel bevestigd worden, overstemt met z’n elec-
trische prikkels als het ware de pijnsignalen die het ruggenmerg bereiken. De 
patiënt dient het apparaatje zelf met een machtiging bij de ziektekostenverzekeraar 
aan te vragen, en vervolgens zich met een nieuwe machtiging door de fysiothera-
peut te laten instrueren in het gebruik.
Paramedische begeleiding
Door een plexopathie verliezen patiënten vaak functie in een aantal spiergroepen 
gedurende maanden of jaren. Behalve de directe gevolgen hiervan, zoals het niet 
meer kunnen uitvoeren van een bepaalde beweging of handeling, kunnen hierbij 
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en evt. de kracht uitgebreid. Patiënten hoeven niet bang te zijn de zenuwen door 
het oefenen extra te beschadigen. Een uitzondering hierop vormen mensen met 
een erfelijke drukneuropathie of HNPP; zij hebben in aanleg zenuwen die gevoe-
liger zijn voor rek, druk en trek. Hierbij is specialistisch advies noodzakelijk.
Specifieke pijnklachten bij een plexopathie van de schouder
In het geval van een parese van de spieren die schouderblad op de romp fixeren (m.n. 
de serratus anterior, trapezius en rhomboid) klagen patiënten vaak over een toe-
name van pijn in de arm en schouder als deze langere tijd afhangt, zoals bij lopen 
of lang staan. Bij lichamelijk onderzoek is dan meestal ook duidelijk een afglijden 
van het scapula op de romp in rust zichtbaar; vaak naar lateraal en beneden. Door 
het gewicht van de arm ontstaat tractie op de spieren die aan het scapula vast zit-
ten. Alhoewel patiënten ook in zo’n geval zeker de arm zoveel mogelijk soepel en in 
beweging dienen te houden, kan het aan te raden zijn om bij lang staan of lopen 
de arm in de jaszak of in een sling o.i.d. te hangen om zo de schouder tijdelijk te 
ontzien. Dit geeft vaak adequate verlichting.
Ook krijgt een deel van de patiënten last van een soort chronische spierpijn in de 
paretische houdingsspieren. De meeste schouder- en bekkengordelspieren zijn de 
hele dag ongemerkt actief bezig een lichaamshouding in stand te houden, en krij-
gen derhalve ‘geen rust’. Bijvoorbeeld het goed kunnen bewegen van onze armen, 
m.n. vooruit en boven de macht, is voor een belangrijk deel afhankelijk van een 
stabiel schouderblad waartegen de arm zich kan afzetten. Als de spieren die hier-
voor zorgen verzwakt zijn, moeten ze continu maximaal aanspannen om nog enige 
stabiliteit te kunnen geven. En dit de hele dag door, iedere dag weer. De chronische 
spierpijn die hierbij ontstaat reageert in onze ervaring nauwelijks op pijnstillers. 
De beste oplossing is vaak proberen de houdingen en bewegingen frequent af te 
wisselen, niet te lang achtereen te doen, en in het geval van een instabiel schouder-
blad rust te nemen door plat op de rug te gaan liggen. Vaak is locale warmte prettig; 




jaren. En heerlijk dat je me ook nu weer wil helpen met deze mijlpaal. Alide, soms 
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heel veel dank voor alle tijd die we samen met plezier hebben doorgebracht mijn 
vriendje. Je verdient alle goeds in dit leven; ik hoop dat ik er nog wat aan bij kan 
blijven dragen. Een dikke kus.
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